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Summary
The aims of this project w ere to investigate the effect of immune complexes 
on mononuclear phagocytes in the presence or absence of infection with the 
human immunodeficiency virus (H IV). Mono M ac 6(M M 6) cells and human 
monocyte-derived m acrophages (M DM ) w ere used to compare the effect of 
chemical stimulants, cytokines and immune complexes on surface antigen 
expression. The sam e experiments w ere performed using HIV-infected cells to 
determine the effect of H IV  infection on these parameters. Som e of the stimulants 
especially IL-6, IL-10, T N F -a  and HIV increased C D 80  expressions, the effect 
being greater in MDM than M M 6 cells. This has implications for antigen  
presentation. Cytokines caused the differentiation of M M 6 cells and significantly 
increased or decreased surface antigen expressions. The M M 6 cells express 
surface antigens at lower levels then M D M  this indicates that M M 6 cells need to 
differentiate before expressing surface antigens. The high standard deviations 
obtained m eant that no significant change in surface antigen expression was seen  
in all H IV non-infected and infected M DM  incubated with various immune 
complexes and HIV-sera.
Comparing whole blood incubated with KLH and rabbit anti-human IgG 
showed that both seem ed to produce IL-10 and IL-6 early. Only rabbit complexes 
stimulated TN F-a  release. M DM  incubated with IL-6, IL-10, and TN F-a  showed  
increased expression of C D 16  and C D 80  only at day 3. However, H IV  proteins 
(C H O ) incubated in whole blood caused a significantly release of IL-6 at 8 hours 
with no detection of IL-10 and TNF-a.
MM 6 infected with HIV-1 Ba-L for 5 days showed increased expression of 
C D 16  and CD 11c, but reduced expression of the other antigens examined. 
Significant levels of IL-10 w ere released at 8 and 12 hours with a slight increase in 
IL-6, and TN F -a. HIV  protein-containing (C H O ) immune complexes slightly 
increased IL-6 secretion at 8 hours at which point, IL-10 production w as high. H IV- 
infected cells incubated with H IV-sera showed a lack of TN F-a  release but IL-6 and  
IL-10 w as detected at 12 and 8  hours respectively. The detection of high levels of 
IL-10 and the inhibition of TN F-a  production may stimulate progression to full 
blown A IDS.
ABBREVIATIONS
cAMP - Cyclic adenosine monophosphate
ADCC - Antibody-dependent cellular cytotoxicity
AIDS - Acquired Immunodeficiency Syndrome
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HLA-DR - Hum an leukocyte antigens-DR
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IFN-y - Interferon gam m a
IL- - Interleukin
IN - Integrase
ITAMs - Im munoreceptor tyrosine-base activation motifs
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KS - Kaposi’s Sarcom a
LAS - Lymphadenopathy
LFA-1 - Lymphocyte function associated m olecule-1
LTR - Long terminal repeat
LTNP - Long-term, non-progresso’s
MA - Protein matrix
MACS - M agnetic cell sorter
M-CSF - M acrophage colony-stimulating factor
MIP - Macrophage-inhibiting protein
MHC - Major histocompatibility complex
MM6 - Mono M ac 6 cells
MPS - Mononuclear phagocyte system
MTT -3-[4,5-dim ethylthiazol-2-yl]-2,5-D iphenyltetrazolium  bromide
NC - Nucleocapsid
NK cells - Natural killer cells
NF-k B - Nuclear factor-icB
PBL - Peripheral blood lymphocytes
PBMC - Peripheral blood mononuclear cells
PBS - Phosphate buffered saline
PCP - Pneumocystis carinii pneumonia
PPD - Adjuvant peptide
p g e 2 - Prostaglandin E2
PHA - Phytohemagglutinin A
PI - Propidium iodide
PLA2 - Phospholipase A2
PMA - Phorbol 12-myristate 13-acetate
PMNs - Polymorphonuclear neutrophils
RPMI-1640 - Roswell Park Memorial Institute 1640 Medium
RT - Reverse transcriptase
SIV - Simian immunodeficiency virus
SU - Surface glycoprotein
TCR - T  cell receptor
7TM - Seven-transm em brane-dom ain receptors
TNF-a - Tum our necrosis factor-alpha
TPA - T  etradecanoylphorbol-13-acetate
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Vit D3 - 1 ,25-dihydroxyvitamin D3 (1,25-[O H] 2D 3)
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1.0. INTRODUCTION
1.1. GENERAL INTRODUCTION
At the end of 1979, a large num ber of cases of mononucleosis-like 
syndrome accom panied with high fever, w eight loss, and swollen lymph nodes 
w ere reported in the G ay community of California. This community also exhibited a 
high incidence of other unusual diseases including infection caused by 
Cytomegalovirus (C M V), Pneumocystis carinii pneumonia (PCP), Toxoplasm a  
gondii and the cancer, Kaposi’s sarcom a (Grmek, 1990). These opportunistic 
disorders indicated suppression of the immune system and the condition become 
known as the Acquired Immunodeficiency Syndrome (AIDS; Siegal et al., 1981).
In 1983, Barre-Sinoussi et al., isolated a reverse transcriptase containing 
virus from the lymph node of a patient with persistent Lym phadenopathy syndrome 
(LAS). Since viral infections are often accom pained by enlarged lymph nodes, it 
was presumed that LAS resulted from a hum an virus such as Epstein-Barr virus 
(EBV) or cytomegalovirus (C M V). The virus isolated from the LAS patient (known 
as the lym phadenopathy-associated virus or LAV) demonstrated characteristics 
similar to those of the hum an T-cell leukaem ia virus (HTLV). However, Montagnier 
and co-workers (1983) pointed out that the LAS agent, although similar to H TLV in 
infecting C D 4+ lymphocytes, destroyed the cells rather than immortalising them. 
Around the sam e time, a team  in the United States of America (USA) led by Robert 
Gallo isolated a  human retrovirus from the peripheral blood m ononuclear cells 
(PBM C) of adult and paediatric A ID S  patients which was distinct from HTLV (Gallo 
et al., 1984). It was called HTLV-III. This virus exhibited lymphotropic and 
cytopathic properties showed cross reactivity with some of the proteins found in 
HTLV-i and HTLV-II, especially the p24 core proteins. Later it w as confirmed that 
LAV and HTLV-III w ere effectively the sam e virus.
In 1986, the International Com m ittee on the Taxonom y of Viruses  
recom m ended giving the A ID S  virus the nam e “Human Immunodeficiency Virus” or 
HIV. Since it had been shown that the A ID S  virus showed greater genetic 
homology with equine infectious anaem ia virus and other lentivirus, rather then the 
hum an T  cell leukaem ia virus. Subsequently another subtype of H IV  w as isolated
1
in W estern Africa and the viruses becam e known as HIV-1 and H IV -2  respectively. 
Although H IV-2 can cause A ID S, the developm ent of overt disease may be very 
protracted compared to that caused by HIV-1 (Levy, 1993).
The W orld Health Organisation (W H O ) estimated that 13 million people 
would be infected with H IV by the end of 1993, representing an increase of 1 
million new infections since 1992 (W H O , 1993; Hughes and Rutherford, 1995). The  
rural regions in sub- Saharan Africa and South and Southeast Asia, remain 
vulnerable to new H IV  infections because by the year 2000, an estimated 40  
million people will be infected with H IV  and 10 million will have died of A ID S  (W H O , 
1991; Murray, 1996).
HIV infection is initially established in lymphoid organs that serve as major 
reservoirs for HIV. Indeed, lymphoid organs may exhibit active and progressive HIV  
disease during clinically latent periods. Destruction of the lymphoid tissue and the 
loss of the patient’s ability to respond to H IV  and/or other pathogens are caused by 
chronic stimulation of the immune system due to persistence of the virus in 
lymphoid organs. Som e patients with primary H IV  infection show expansions of 
restricted VJ3 subsets of C D 8+ T-cells that represent HIV-specific cytolytic T  cells 
(Pantaleo and Fauci, review, 1995). Patients who are long-term, non-Progresso’s 
(LTNP) and who have been HIV-infected for about 10 years have normal lymph 
nodes, HIV-specific humoral and cell m ediated responses and high, stable C D 4+ T  
cell counts over a num ber of years. These patients express only a low-level 
viremia, although virus derived from the m ononuclear cells of such patients are 
found to be replication com petent and infectious (Pantaleo and Fauci, review,
1995).
The depletion of C D 4+T-lymphocytes in an A IDS patient with 
lymphadenopathy (Barre-Sinoussi et al., 1983) and the ability of monoclonal anti- 
C D 4 antibodies to block H IV  infection of C D 4*T - lymphocytes in vitro (Dalgleish et 
al., 1984; Klatzman et al., 1984b), indicated that C D 4 is a natural receptor for HIV  
(Klatzman e ta l., 1984a; Popovic et al., 1984a). However, conclusive evidence  
cam e from Maddon et al (1986) and Evans et al (1988) that the receptor for HIV-1 
and H IV-2 is C D 4. H IV infects cells with higher expression of C D 4 such as a sub­
population of T-lymphocytes, m acrophages and, to a lesser extent, blood 
monocytes (Asjo et al., 1987; Sattentau and W eiss, 1988).
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In vitro isolation of H IV  from infected T-lymphocytes was demonstrated  
using m itogen-generated syncytia (multinucleated giant cells) which died releasing 
viral progeny (Lifson et a lM 1986; Yoffe et al., 1987). In vitro, cytopathic changes  
are shown to be minimal in H IV  infected mononuclear phagocytes, with a low level 
of virus released into the supernatant (Lifson et al., 1986; Yoffe et al., 1987; 
Gendelm an et al., 1988). It is assum ed that cells of the m ononuclear phagocyte  
lineage are involved in the continuous production and transmission of virus to a 
new  host (Pearce-Pratt and Phillips, 1993).
HIV  only infects activated and proliferating T-lymphocytes that express the 
nuclear factor-icB (N F-kB) responsible for the up-regulation of transcription of 
certain genes by binding to distinct sequences in gene promoters (Stevenson et 
al., 1990). The replication of HIV-1 in T-lymphocytes is dependent upon the viral 
long terminal repeat (LTR) which binds NF-kB (Nabel and Baltimore, 1987, Duh et 
al., 1989. By contrast, hum an monocytes (either activated, quiescent o ry- 
irradiated) and in vitro differentiated human m acrophages do not need to express 
NF-icB for HIV-1 to replicate (Bernstein et al., 1991; W einbery et al., 1991; 
Schuitem aker et al., 1990).
Host proteins m ay play a role in the viral life cycle e.g. by incorporating into 
the virion during virus assem bly or by playing a role in early infection (Ott, 1997). 
Briant et a!., 1996 showed that the binding of gp120-anti-gp120 immune 
complexes to infected, resting, PBM Cs stimulated viral replication.
1.2. CLINICAL FEATURES OF HUMAN IMMUNODEFICIENCY 
VIRUS INFECTION
1.2.1. Infections and tumours associated with AIDS
Opportunistic infections associated with late stages of A ID S  which include 
Candida albicans, Cryptococcus, Salmonella typhimurium, Mycobacterium 
tuberculosis, Pneumocystis carinii, Mycobacterium avium intracellular, Herpes 
Simplex virus (HSV) and Cytomegalovirus (CMV) begin to em erge as a  patient 
condition worsens (Horsburgh, 1991). Typically, HIV-infected adults who develop  
Pneumocystis carinii pneumonia (P C P ) have C D 4 counts<200/m m 3 indicating a
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severe immune deficiency. The type of infection involved may vary geographically. 
For example, PenicHlium marneffei is found in-patients in Northern Thailand and 
visceral leishmaniasis is seen in various parts of the Mediterranean and Latin 
America (Beiser, 1997). Mycobacterium avium infection occurs in half of all people 
who develop A ID S  in North America. In addition, cytomegalovirus disease affects 
45%  of patients with H IV  infection (Hoover et al., 1993). Cytomegalovirus retinitis is 
a typical manifestation of infection which often results in blindness (Beiser, 1997).
Tuberculosis is the commonest opportunistic infection globally and the 
leading cause of death in H IV  infection. Although treatm ent with the drugs such as 
isoniazid and rifampin has been found to be effective in patients with HIV, (Beiser, 
1997; Murray, 1996) multidrug resistant tuberculosis affects about 19%  of H IV  
patients (Beiser, 1997).
Kaposi’s Sarcom a (KS) w as formerly found predominantly in elderly males 
but is now frequently associated with H IV  infection (Hymes et al., 1981). Recent 
studies have shown that KS is caused by a new herpesvirus which was detected in 
the peripheral blood m ononuclear cells of patients with HIV, its presence  
correlating with low C D 4 counts (Beiser, 1997). H IV patients who lacked clinical 
evidence of KS but had detectable KS-associated herpesvirus in peripheral blood 
cells showed a higher chance of developing the disease. The virus may be 
sexually transmitted and is commonly found in the genital tissues of healthy adults 
especially in semen (Beiser, 1997). Although KS is associated with HIV, its 
incidence in homosexual males has decreased sharply due to safe sex practice but 
has increased among intravenous drug abusers and heterosexuals of both 
genders (Murray, 1996).
HIV has been shown to cause neurological dysfunction and the incidence 
of A IDS-related dem entia has increased (Sharer, 1992).
1.2.1.1. Epidemiology of HIV infection
Epidemiological studies have demonstrated that the route of transmission 
of H IV  is by blood or blood products (Am m ann et al., 1983). High-risk groups were  
identified which included homosexuals, intravenous drug abusers and blood 
product recipients, especially haemophiliacs, (Stoneburner et al., 1990). In
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homosexuals, it has been demonstrated that HIV-1 is present in the sem en during 
and immediately after primary infection (Tindall et al., 1992). Infected, heterosexual 
wom en produce HIV-1 in cervico-vaginal secretions in both cell-associated and 
cell-free forms. This shedding of infectious virus is more likely in HIV-infected  
wom en with genital inflammation. In addition, seronegative w om en with genital 
tract inflammation are susceptible to HIV-1 infection via intercourse because  
lymphocytes and macrophages are found a t the site of inflammation (M ayer and  
Anderson, 1995).
In Africa and Asia, the high transmission of HIV in adults is largely 
heterosexual due to frequent, unprotected sexual contact (W .H .O . report, 1993; 
Fischl e ta l., 1987; Mastro e ta l., 1994). Epidemiological studies suggest 
susceptibility to H IV infection per sexual contact is higher in wom en than men. 
However, the long incubation period complicates the estimation of the rate of 
sexual transmission, as m any persons do not know they are infected until years  
after exposure (M ayer and Anderson, 1995).
Infants can be infected via breast-feeding from infected mothers (Kimball et 
al., 1995). Between 15 and 35%  of infants born to seropositive mothers are  
infected but factors influencing transmission are uncertain (R yder et al., 1989).
The introduction of preventative programmes has reduced the risk of 
infection from infected blood products, needle sharing (among intravenous drug 
users), needle-stick injury and exposure to open wounds or mucous m em branes  
(Ammann et al., 1983).
1.2.1.2. Clinical features of HIV infection
Persons infected with H IV  may be asymptomatic or may exhibit a range of 
clinical signs and symptoms including lymphodenopathy, opportunistic infections 
and cancers (M etroka et al., 1983). A t the time of infection, about 30%  to 60%  of 
people exhibit a syndrome resembling infectious mononucleosis (Cohn, 1997). 
Acute infection appears 2 -6  w eeks after exposure to the virus. Typical symptoms 
include fever, myalgia, arthralgia, lethargy, lymphadenopathy, pharyngitis, nausea, 
headaches, photophobia and rashes. H IV  infected persons enter a latent 
asymptomatic phase that m ay last as long as 14 years before the em ergence of
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full-blown AIDS. A person with full-blown A ID S  has a poor prognosis of m aybe 1-2  
years (Schuitem aker et ai., 1992b).
A large decline in C D 4 cells in the first six month after seroconversion is 
associated with rapid progression to A ID S  or death (Cohn, 1997). Similarly, plasma 
levels of 10 ,000  copies or more of H iV -R N A  within one year of seroconversion  
indicates a similar prognosis (Mellors e t a!., 1995; Saag et al., 1996). Infected  
patients with a low viral load and plasma HIV RNA levels < 4 5 30  copies/ml have an 
8%  probability of developing A ID S  in five years whilst patients with > 36 ,270  RNA  
copies/ml have a 62%  probability of doing so (Mellors et al., 1996).
1.3. The human immunodeficiency virus
HIV is a  retrovirus that belongs to the lentivirus family. It is typically 
associated with a long period of latency betw een infection and onset of clinical 
symptoms (Gelderblom et al., 1987). Studies on the structure of the isolated virus 
showed a cone-shaped core and a viral capside. The latter being composed of 
identical subunits arranged with an icosahedral symmetry, that provide protection 
for the viral nucleic acid and enzym es required for replication (Figure 1.1; 
Gelderblom et al., 1987). The virus comprises two identical strands of RNA that are  
surrounded by a nucleocapsid (p7) and associated with reverse transcriptase. This 
is enclosed by the polypeptides that comprise the capsid (p24) of the mature virion. 
The  outer structure of the virus is glycoprotein (gp160) arranged as 72, knob-like 
structures (Ozel et al., 1988; Pinter et al., 1989; Earl et al., 1990; M cCune et al.,
1988). The gp160 comprises gp120 (responsible for HIV-1 binding to C D 4 on the 
host cells) that noncovalently interacts with gp41 (Ott, 1997).
The RNA-dependent, DNA polymerase (reverse transcriptase, RT), 
converts the virus RNA into DNA. Reverse transcriptase is cleaved by the Pol gene  
products (enzym es which are vital for infectivity) which also cleave the protease 
and integrase enzym es (Haseltine, 1991; Cullen, 1991).
The HIV-1 genom e encodes four accessory proteins (Figure 1.2) Nef, Vif, 
Vpr and Vpu (see Section 1.3.1, Ott, 1997). It has been suggested that Vif 
encodes regulatory proteins that play a role in the final stages of packing the viral
6
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MA (p i
Phospholipid bilayer
RNA
Figure 1.1. Structure of human immunodeficiency virus-1 (HIV-1)
The structure of the human immunodeficiency virus (H IV), using the nomenclature 
adopted by Leis et al., (1988). The spikes of the transm em brane glycoprotein (TM, 
gp41) and surface glycoprotein (SU, gp120) project through the lipid envelope. 
These surface spikes initiate the viral infection cycle by binding to specific 
receptors on the surface of host cells. A protein matrix (MA, p17) surrounds the 
capsid, which in turn is covered with a lipid bilayer (derived from the host cells 
during budding). The viral RNA (in association with nucleocapsid, NC, p7), viral 
reverse transcriptase (RT) and integrase (IN) enzym es are present inside the viral 
capsid (CA). The CA consists of repeating subunits of p24 and is responsible for 
the cone-shaped core of virions.
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nucleoprotein core and can influence infectivity of progeny virions (Hoglund et al., 1994).
1.3.1. Binding of HIV to CD4
The gp120 knobs projecting from H IV  virions bind to the C D 4 molecule (Figure 1.3) 
on host T-lymphocytes and m ononuclear phagocytes (Klatzman et al., 1984b; Sattentau  
and W eiss, 1988). Peripheral blood monocytes that express a higher level of C D 4 decline at 
the sam e rate as T-cells during disease progression (Lucey et al., 1991). W hilst gp120 is  
responsible for C D 4 recognition, gp41 (which is noncovalently linked to gp120) anchors H IV  
to the host cell m em brane (Geleziunas et al., 1994).
C D 4 is a m em ber of the immunoglobulin (Ig) supergene family and consists of four 
external Ig-like domains, (D 1-D 4  or V 1-V 4), a transm em brane region and a cytoplasmic tail 
linked to p56 lck protein tyrosine kinase. The  binding of HIV-1 gp120 occurs at the V1 region 
(Geleziunas et al., 1994). The V1 and a non-contiguous region on C D 4 bind to the fourth 
conserved portion of gp120 near the C terminal (Arthos e ta l., 1989; C ordonnieret al., 1989; 
Maddon et al., 1986). Alterations in the conformation of gp120 allows the virus to 
demonstrate different cell tropism’s (Koito et al., 1994). Interaction of gp120 with C D 4  
exposes a fusion domain in gp41 that m ay be the first step of H IV  entry (Sattentau and 
Moore, 1991). Studies indicate that gp41 alone can mediate H IV  entry and syncytium  
formation between C D 4+ and C D 4' cells (Marcon and Sodroski, 1994; P erez et al., 1992).
Once infected with HIV, C D 4 surface expression is down regulated (Hoxie et al.,
1986; Poulin et al., 1991; Geleziunas et al., 1994). This is associated with expression of 
HIV-1 auxiliary proteins A /efand Vpu which respectively are expressed during the early 
regulatory and structural phases of HIV-1 gene expression (Cullen, 1991). The Vpu gene  
encodes a 16-K D a protein whilst Nef encodes a 27-K D a myristilated, m em brane-associated  
phosphoprotein vital for HIV-1 replication in vitro (Geleziunas et ai., 1994). Down-regulation  
of C D 4 surface expression on thymocytes of transgenic mice or C D 4+ cell lines has been  
shown to be due to the expression of Nef which does not however affect the levels of C D 4  
m RNA or protein. Nef also affects C D 8 expression on murine but not human cells (Garcia et 
al., 1993, Skowronski e ta l., 1993).
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Figure 1.3. The CD4 receptor binding to gp120
The virus replication cycle is initiated when viral glycoprotein spikes bind to a specific 
receptor on the host cell surface. C D 4 is the main receptor, and binding of gp120 to C D 4 is 
thought to cause a conformational change that exposes gp41. The mechanisms by which 
the virus enters the cells and uncoats are still unclear, but probably involve fusion of the 
viral and host cell m embranes. Once inside the cell, the virus forms pre-integration  
complexes and reverse transcribes its RNA genome. The DNA copies of the viral genom e  
move to the nucleus w here they integrate randomly into the host chromosomes. W hen the 
cell is activated, viral proteins are transcribed and progeny virions are produced. Virions 
mature by budding either through the host cell membrane, or in myeloid cells, into 
intracellular vesicles (adapted from Cook, 1994).
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Lymphocytes and monocytes both transfected with g p 160w ere  shown to contain 
C D 4-gp160 complexes. In the absence of syncytium formation, the expression of gp160  
causes cytopathic effects in C D 4+ but not C D 4' cells. This is associated with CD4, P56 lck 
PTK found in gp160-C D 4 complexes which inhibit maturation and transport of g p160an d  
C D 4 molecules. The complexes are form ed and retained in the endoplasmic reticulum (ER) 
(Geleziunas et al., 1994).
1.3.1.1. Co-receptors for HIV
For over a decade researchers have looked for other receptors that facilitate H IV  
infection. In 1996 several groups showed that the chemokine receptors C C R 5 and C X C R 4  
fulfilled these roles. The  co-receptors w ere identified as members of seven-transm em brane- 
domain (7TM ) receptors that form a group of structurally related proteins. The chemokine  
receptors have two cysteines, one in the N H 2-terminal domain and the second in the third 
extracellular loop, that form a disulphide bond important for ligand binding (Baggiolini et al., 
1997). These molecules act as co-receptors for both non-syncytium-inducing and  
syncytium-inducing HIV-1 strains. O ther chemokine receptors (e.g. C C R 3 and C C R 2b) can 
be used by some HIV-1 strains but only in association with C C R 5 and C X C R 4 (Clapham , 
1997). The C C R 5 is for ‘ m acrophage-tropic’ (M- tropic) HIV-1 strains and C X C R 4 for ‘T-cell 
tropic’ (T-tropic) HIV-1 strains. The  M-tropic strains replicate in macrophages and in C D 4+ T  
cells but do not form syncytia in T  cell lines (Moore et al., 1997).
The V 3  loop region of gp120 is vital for interaction with C C R 5  or C X C R 4 although  
the nature of the C C R 5 and C X C R 4 binding sites on gp120 are not yet understood (Paxton  
et al., 1996; Choe et al., 1996; Cocchi et al., 1996). Mutant gp120 in which the V 3  loop has 
been deleted is unable to bind to C C R 5 but it has been suggested that V 3  might not be the 
only binding site (W u et al., 1996, Trkola et al., 1996). However, deletion of the V 1 -V 2  loop 
structure from gp120does  not prevent gp120-C C R 5 interaction (W u et al., 1996). It is 
feasible that C C R 5 and/or C X C R 4 can bind at multiple points on conserved structures in the 
V 3  loop. Also, C D 4 residues may be involved in the gp120-C C R 5 interaction since M IP -ip  
binding to C C R 5 on CC R5-transfected cells can be inhibited by the amino-terminal domains 
(D1, D2) of C D 4 (W u et al., 1996). Adapted strains of H IV-2 and S IV , when used to infect 
C D 4' human cells in vitro w ere able to replicate, indicating that these strains m ay use 
C X C R 4 for entry, in the absence of C D 4. Indeed, it has been shown that a mAb against
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C X C R 4 inhibited C D 4-dependent and C D 4-independent C XC R 4-m ediated infection (Endres  
et al., 1996).
1.3.1.2. Entry and uncoating of HIV
The initial stage of infection depends upon virus glycoprotein binding to specific 
cellular receptors as described in previous sections. Following this, the virus envelop fuses  
with the cell m em brane and uncoating is encouraged by the acidic environment of 
intracellular endocytic vesicles which causes the release of viral nucleic acid (M addon et al., 
1986). O ther studies have suggested that cellular entry of H IV  is unaffected by pH both in T  
cells (Stein et al., 1987; McClure e t al., 1988) and C D 4' cells (Tateno et al., 1989). O ther 
factors have been suggested as instrumental in H IV infection of myeloid cells. These  
include antiviral antibodies and specific Fc receptors (Robinson et al., 1991; Haubrich et al.,
1992) and the binding of com plem ent-coated virions to C R 3 and C D 11b /C D 18  (Reisinger et 
al., 1990).
1.3.1.3. Formation of syncytia
In 1955, Black and Melnick recognised that a virus could spread from one cell to 
another. Early blocking experiments using cocultures of peripheral blood lymphocytes (PBL) 
from HIV seropositive patients and mitogen-stimulated PBL from uninfected people showed  
that azidothymidine and virus-neutralizing antibodies had no effect on cell-to-cell 
transmission of HIV. However, antibodies to the C D 4 receptor H IV  prevented fusion 
between infected and uninfected cells. This suggested the importance of C D 4 receptor in 
HIV  entry into uninfected cells (G upta et al., 1989). Later experiments, by Sato et a!., (1992) 
demonstrated that within hours of incubating HIV-infected H9 cells with T-cells, synthesis of 
new viral protein and unintegrated DNA w ere detected. Observations using light 
microscopy indicate that one hour after infection numerous small syncytia w ere observed  
followed by large syncytia at 2 -4  hours and giant syncytia by 8 hours (Sato et al., 1992). In 
HIV infection, the induction of syncytium formation is caused by surface expressed gp120  
binding C D 4 on ceils. This has been confirmed since syncytium formation and viral 
spreading is blocked by antibody to the viral gp120 (Phillips, 1994).
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1.3.1.4. Cell to cell transmission of HIV
The transmission of virus from one mononuclear cell to another involves cell 
adhesion molecules that m ediate adherence between infected and virgin cells. Adherence  
is followed by shedding of the virus into the space between the two cells and its subsequent 
attachm ent to the virgin cell. The cytokines produced by these cells may influence the  
secretion of H IV  (Kupfer et al., 1986; Young and Cohn, 1986). Additionally, cell-to-cell 
transmission may occur through uninfected dendritic cells passively transferring HIV to 
C D 4+ lymphocytes. The infected lymphocytes form syncytia and undergo cytolysis releasing 
H IV  (Cam eron et al., 1992). Epithelial cells that line organ systems allow the passage of 
some pathogens by transcytosis. Infected epithelial cells do not serve as reservoirs of H IV  
but are infected and die even though the cells do not express C D 4. Anti-CD4 antibodies did 
not block infection of these cells (Tateno et al., 1989). Culture supernatants from HIV- 
infected, transformed T-cells was less successful in infecting epithelial cell lines than those 
from chronically infected T  cell or monocyte lines infect (Phillips and Tan, 1992; Tan  et ai.,
1993). It was found that 15 minutes after adding infected cells, H IV  budding could be 
observed at the point of contact with the epithelium. T-cells w ere also observed to adhere to 
epithelium for a few  minutes then detach and bind to another site on the epithelium  
(Pearce-Pratt and Phillips, 1993). It has been shown that the integrin molecule protein 
complex C D 11a-c /C D 18  is involved in the infection and cytopathic effect of HIV-1 in vitro in 
addition to CD4.
1.3.1.5. Reverse transcription and integration of viral nucleic acid
Following entry, the viral RNA is released in the cytoplasm and is reverse transcribed 
to give double-stranded, linear, DNA (cDNA) provirai intermediates. The association of 
virion gag proteins facilitates the migration of this viral nucleoprotein into the cell nucleus. 
Long terminal repeat (LTR) elem ents generated by reverse transcription are important for 
regulating viral expression (Bukrinsky et al., 1992). Integrase, a  single, viral, 32 KDa protein 
helps the DNA integrate into the host chromosomes (Farnet and Haseltine, 1991). This 
integration is a random process and is vital for productive infection (Hong et al., 1993).
Productive infection has been shown to be associated with cellular activation. In 
quiescent cells, only a small portion of the virai genom e is transcribed and there is no 
production of viral protein. Infection is aborted after 3 to 5 days if the cells are not activated
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and expressing HLA-DR. Peripheral blood monocytes express >90%  HLA-DR but are not 
as susceptible to H IV  infection as are m acrophages. Differentiated m acrophages have less 
C D 4 expression than non-differentiated monocytes. Peripheral blood, C D 4+ monocytes 
maintained in suspension and inoculated with HIV, produces a continuous, low level of virus 
as they differentiate into macrophages. H IV  remains quiescent in non-differentiated cells, 
replication occurring after differentiation in the tissues (Levy, 1993)
1.3.1.6. Late stages of the viral replication cycle
Translated as polypeptides, which are cleaved by a viral protease, retroviral proteins 
undergo myristolation or phosphorylation and glycosylation by host enzymes. Precursor 
proteins and the m ature gp160 are heavily glycosylated (Mizouchi et al., 1988), 
deglycosylation resulting in reduced infectivity and capacity to form syncytia (Kozarsky et 
al., 1989). During release of the virus by budding, the host cell m em brane is incorporated in 
the envelope. Phosphorylation regulates H IV  -1 specific Vpu which enhances viral 
detachm ent from the cell m em brane and degradation of C D 4 in the endoplasmic reticulum  
(Schubert and Strebel, 1994).
Infection of human cells by H IV  varies depending on the strain of the virus. 
Successful entry may be accom panied by a latent phase due to failure of integration of viral 
nucleic acids into the host chromosome, or to lack of transcription of the viral proteins. Once  
integrated, viral DNA can remain in a latent state for long periods. However, once activated, 
replicating C D 4+ T-lymphocytes are a major source of H IV  (Zack et al., 1990). Production of 
HIV by cells of the mononuclear phagocyte system is quite distinct from that seen in T  ceils. 
M ononuclear phagocytes form a reservoir of virus, low levels of which are constantly 
released. In contrast to this, follicular dendritic cells of the lymph nodes are associated with 
high levels of virus production (Pantaleo et al., 1993). The mechanism of release of mature 
virus from myeloid cells differs to that seen in T-lymphocytes since H iV  is found in large 
intracellular vacuoles that restricts their release (Popovic and Gartner, 1987; Schuitem aker 
et al., 1991).
In the early stages of infection, asymptomatic individuals produce non-syncytium- 
inducing virus that is tropic for primary cells but not for transformed T  cell lines (Popovic and 
Gartner, 1987; Schuitem aker et ai., 1991). In the later stages of the disease, viruses are  
produced that show a high rate of replication and the capacity to induce syncytia (Fenyo et 
al., 1988). This may be because in the early stages of infection the immune response
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suppresses the highly virulent strains of H IV  whilst the less virulent escape immune 
surveillance. Also, the persistent infection in macrophages goes unnoticed during the 
asymptomatic period of the disease (Fenyo et al., 1988).
1.3.1.7. Host proteins in HIV
The complicated life cycle of H IV  is carried out by a limited set of proteins. Thus the 
virus depends on host proteins for survival. These m ay play a role in the viral life cycle 
either by incorporation into the virion during virion assembly or in early infection (Ott, 1997).
Studies have shown that budding HIV-1 contains components from the host cell 
plasma m em brane in its envelope (Zavada, 1982). Neutralisation studies showed the 
presence of HLA-DR antigen on all virions produced from an H LA -DR+ cell line (Arthur et 
al., 1992). O ther studies have dem onstrated the presence of this antigen on viruses isolated 
in vivo (Bastiani et al., 1997; Saarloos et al., 1997). Recently it has been shown that HLA- 
DR increases viral infectivity in vitro and in vivo. However, it is not vital to infection since 
host cells can be infected in vitro by HIV-1 produced from H LA -D R 'cells  (Arthur et al., 1992; 
Cantin et al., 1997). In T  cell activation, H LA -DR -dependent intracellular signals are  
required to ensure cell division. W ithout such signals, activation results in programmed cell 
death (apoptosis). Earlier studies indicated that the interaction between free virus and C D 4+ 
provided this signal. It has been suggested that the observed decline in virus specific C D 4 +
T  cells could be due to HLA -DR on the surface of virions inducing apoptosis. Recent work 
demonstrated that H LA -DR on virions interacts with T  cells and presents superantigen to 
resting T  cells in vitro (Ott, 1997). HLA class I is present at low levels on HIV and does not 
affect its infectivity (Benkirane et al., 1994).
Cell adhesion proteins also have been detected on HIV-1. C D 44, a receptor for 
hyaluronic acid increases in vivo infectivity. LFA-1 (C D 11a) and it counter receptor ICAM-1 
has been found on the surface of HIV. These adhesion molecules can bind to C D 4'ce lls  
allowing infection. O ther surface proteins found on H IV  are two-com plem ent cytolysis 
inhibiting proteins, C D 55  and C D 59. O ther host cell components associated with H IV  
include Cyclophilin A, an abundant cellular protein produced from epithelial cells and 
involved in T  cell activation. It has been demonstrated bound to G ag a t a site in the centre 
of p24(Luban , 1996; Franke et al., 1994). Also, actin and cytoskeleton components which 
play an active role during budding are found incorporated into the virion (Ott, 1997). Another
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com ponent found in H IV  is ubiquitin, a  protein which is implicated in protein turnover, cell 
cycle control, antigen presentation, DNA repair, and the heat shock response (Finley and  
Chau, 1991). A single ubiquitin molecule is conjugated to a small am ount of the p6 protein 
in mature HIV-1 suggesting a role in H iV  budding. The host and virus interaction offers 
potential targets for therapeutic intervention (Ott, 1997).
1.3.1.8. HIV infection of mononuclear phagocytes
As mentioned earlier, replication of H IV  in cells of the m ononuclear phagocyte series 
is quite distinct to that seen in T  cells. The  stage of maturation and differentiation is vital for 
HIV-1 replication in these cells (G azzolo and Mace, 1990). Studies have shown that, owing 
to their heterogeneity, the use of hum an mononuclear phagocytes in studying viral 
replication poses some difficulties. Therefore monocytic cell lines such as THP-1 and U 937  
have been instead (Kitano et al., 1990). O ther studies have shown that human monocytes 
infected with HIV-1 in vitro for 2 days show enough virus production to measure reverse  
transcriptase (RT) activity in culture supernatants whilst infected, differentiated, 
m acrophages yield only low levels of extracellular virus as detected by a p24 assay  
(Valentin et ai., 1991).
Biologically active chemicals such as vitamin D3) Dimethyl suiphoxide (D M SO ), 
dibutyryl, cyclic adenosine m onophosphate (cAMP), and Tetradecanoylphorbol-13-acetate  
(TPA) induce differentiation of both monocytic cell lines and human peripheral blood 
monocytes (Kitano et al., 1990). These chemicals are thought to enhance replication of both 
monocytotropic and lymphotropic variants of HIV-1 (Skolnik et al., 1991).
Mononuclear phagocytes (which include tissue m acrophages and blood monocytes) 
are primary targets for H IV  infection. They act as a reservoir for viral replication and are  
resistant to virus-induced apoptosis. Blood monocytes aid in the dissemination of H IV  into 
various tissues such as the brain (M eltzer et al., 1990). Macrophages are the predominant 
cell type infected with H iV and play a vita! role in the pathogenesis of HIV-related  
encephalopathy (A IDS dem entia complex). The resident m acrophages of the brain, 
microglia, are able to support productive H IV  infection and may possess between 500  and 
1500 copies of H IV  RNA per cell; about 10 times more than in blood leukocytes 
(Bornemann et al., 1997).
The interaction between HIV and the C D 4 receptor on mononuclear phagocytes 
requires an appropriate H IV strain tropic for C D 4+  cells (O ’Brien, 1995). Conformational
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changes take place in the gp120 when monocyte C D 4 binds, thus exposing V 3  
determinants and allowing the entry of m acrophage tropic strains (Koka et al., 1995). The  
entry of viral DNA into the nucleus is similar in both T  cellls and macrophages although the 
rate of reverse transcription varies. The  lack of division and a limitation in intracellular 
nucleotide pools may cause a slow rate of reverse transcription in macrophages (O, Brien, 
1994).
The high H IV  copy num ber in m acrophages may be attributed to the non-cytopathic 
character of H IV  in these cells and the budding of large amounts of virus into intracellular 
vacuoles. The latter are derived from the Golgi complex and provide an environment for 
virus assembly. H IV  produced in m acrophages may disseminate throughout the body. This 
process is aided by cytokines that regulate and modulate m acrophage activity and virus 
replication (Bornemann et al., 1997).
1.4. The mononuclear phagocyte system
In order to understand the unique role of the cells of the m ononuclear phagocytes  
system in the spread of HIV, it is necessary to have a detailed understanding of the cells 
themselves. Mononuclear phagocytes are capable of synthesising over 100 products, 
processing and presenting antigens and communicating with other cells via the secretion of 
cytokines. They originate from granulocyte-m acrophage colony forming units (G M -C S F) that 
are stem cells present in the bone marrow. These go through a num ber of divisions, 
differentiating into fully mature monocytes in the bone marrow (Figure 1.4). A fter 24hrs, 
these mature cells are released to the circulation (Metcalf, 1971). In response to 
inflammation, injury, allograft or tum our rejection cytokines are released that encourage the  
production of monocytes from the bone marrow (van Furth et al., 1973).
Surface antigens expressed on monocytes include the lymphocyte function 
associated mo!ecu!e-1 (LFA-1, C D 11 a /C D 1 8 ) that binds to the intracellular adhesion  
molecule-1 (ICAM -1, C D 54) on endothelial cells allowing migration of monocytes. The  
monocytes migrate from the blood vessel between the endothelial cells into the 
subendothelial space by a process term ed diapedsis (Rothlein e t al., 1986). This process 
allows monocyte migration to a particular site of inflammation in response to interleukin-1 
(IL-1) and interferon -y (IFN-y) that upregulate expression of ICAM-1 (Dustin et a!., 1986). 
W hen monocytes migrate into the tissues they mature into m acrophages. The latter can
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remain in the tissues for days or even years and show distinct phenotypic characteristics 
depending on the tissue in which they are found e.g. alveolar macrophages in the lungs and 
Kupffer cells in the liver (van Furth, 1989; Lasser, 1983).
1.4.1. Monocyte/macrophage characteristics
Cells of the M P S  are a functionally and phenotypically diverse group.
Monocytes are small (10-12um ) uniformly rounded cells, in vitro, blood monocytes will 
adhere, flatten and spread in the presence of serum. They will develop a heterogeneous  
appearance after 6-8 days. Activation of monocytes/macrophages by the addition of IFN-y 
or 1 ,25-dihydroxyvitamin D3 in culture causes an increase in cell size which is accompanied  
by an increase in the cytoplasmic to nuclear ratio and, increased numbers of cytoplasmic 
granules and lipid inclusions (Andreesen et al., 1990).
1.4.1.1. Enzyme activity
Certain ceil types can be identified by their enzym es such as a-naphthyl acetate esterase  
(a - NAE) and a-naphthyl butyrate esterase found in mononuclear phagocytes (Kaplow, 
1975). Blood monocytes have peroxidase activity in their primary lysosomes that is lost as 
they mature but reappears in association with the nuclear envelope and rough endoplasmic 
reticulum, as exhibited in tissue m acrophages (Bos et al., 1988). Lysosomal 
myeloperoxidase activity (which m akes up 5%  of the total cellular protein in monocytes) 
decreases as they mature. This enzym e cans catalyse the oxidation of hydrogen peroxide, 
in the presence of chloride ions to give hypochlorous acid that is toxic to microorganisms 
(Edwards and Swan, 1986). Myeloperoxidase also plays a role in the metabolism of 
leucotriene C 4 (LTC4) (Neille e t al., 1985).
1.4.1.2. Respiratory burst activity
The  respiratory burst occurs as a result of increased oxygen uptake during which 
glucose is metabolised by the hexose m onophosphate shunt. This is associated with the 
production of superoxide ( 0 2‘) and hydrogen peroxide (H 20 2), which are toxic to pathogenic  
bacteria and fungi (Figure1.5; Babior, 1984). Superoxide is converted to H20 2 by the cellular
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Figure 1.4. The  path of m onocytes differentiating to tissue m acrophages
Based on information from Van Furth et al., (1973; 1979) and W hitelaw  (1966).
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Halide ions 
e.g.C I'
Hypohalous acid 
(microbicidal)
Figure 1.5. Respiratory Burst
This occurs as the result of stimulated phagocytes that produces oxygen metabolites and 
other microbicidal compounds. Diagram is adapted from that of Eales, 1997.
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enzym e superoxide dismutase (SO D ). H20 2 reacts with halide ions to produce hypohalous 
acid, a reaction catalysed by myeloperoxidase metabolites (N akagaw ara et al., 1981).
Free radicals are effective microbicidal agents due to their instability but their 
production is regulated to prevent adverse toxicity to host cells (N akagaw ara et al., 1981).
1.4.1.3. Non-oxidative microbial killing
M acrophages contain granule-associated proteins such as collagenases, 
deoxyribonucleases, sulphatases, lipases, and elastase, phosphatases and 
polysaccharidases that have antimicrobial activity. Also, exposure of M P S  to IFN-y causes  
the degradation of cellular reserves of tryptophan that are vital for microbial growth (Mintz et 
al., 1988; Ozaki e ta l., 1987).
1.4.1.4. Secretory activity
Mononuclear phagocytes (M NPs) can generate prostaglandins, leucotrienes and 
hydroxyeicosatetraenoic acid (H E T E ) through the oxidative metabolism of arachidonic acid 
in response to a variety of stimuli. Synthesis of cyclooxygenase and the production of 
prostaglandin by M NPs have been shown to be stimulated by endotoxin (Fu et al., 1990). 
However, quiescent human peritoneal macrophages have been shown to synthesise and  
release P G E 2 and throm boxane B2 (M ackenzie et al., 1992). M NPs, without stimulation, can 
synthesise large amounts of cytokines, in particular IL-1. Secretion of this cytokine may be 
stimulated by a num ber of factors including bacterial endotoxin. IL-1 is detected in 
lysosomal fractions and exists in two forms; IL-1 a  that is associated with the plasma  
m em brane and IL-1p, the secreted form (Bakouche et al., 1987). IL-1 induces inflammation  
and activates T - and B-cells (Manetti et al., 1996).
Tum our necrosis factor-a is also produced by m acrophages. It is involved in the  
regulation of the immune system and acts as an effector molecule in m acrophage-m ediated  
tumour cell cytotoxicity (Carswell et al., 1975; Urban et al., 1986). Hum an peripheral blood 
monocytes isolated by adherence to plastic release m acrophage colony-stimulating factor 
(M -C SF) and granulocyte m acrophage colony-stimulating factor (G M -C S F, Bennett et al., 
1992).
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M NPs are one of the chief sources of IL-12. It is produced by neutrophils, dendritic 
and Langerhans’ ceils. Phagocytic cells produce IL-12 in response to various bacteria, 
bacterial products, other intracellular pathogens and viruses. The production of IL-12 during 
infection is followed by the production of IFN-y resulting in activation of phagocytic cells, 
which in response, produce higher levels of IL-12 (Trinchieri, 1997).
IL-10 that is produced by m acrophages and other cells, inhibits the production of IL- 
12. It has been suggested that the delayed expression of IL-10 compared to IL-12 and other 
proinflammatory cytokines, both in vivo and in vitro, makes IL-10 an effective downregulator 
of the IL-12 response (Trinchieri, 1997).
1.4.1.5. Chemotaxis, chemokines and their receptors
Monocytes use their receptors to sam ple the environment and use a process called 
chemotaxis to allow them to move along concentration gradients of stimulatory molecules. 
Chemicals called chemokines (Synderm an et ai., 1986) enhance this process. The  
chemokines are composed of a large family of small cytokines with four cysteines linked by 
disulphide bonds. There are two subfamilies of chemokines C X C  and CC that differ by one  
amino acid. Both groups of chemokines are important because of their actions on 
leukocytes and their involvement in inflammation and immunity (Baggiolini et al., 1997). In 
humans, the genes coding for C X C  chemokines are on chromosome 4 and those for CC  
chemokines coded for by genes on chromosome 17 (Baggiolini et al., 1997). Table 1 shows 
chemokines and their selective chem okine receptors.
Chem okines act through a group of structurally related protein receptors which have  
a characteristic seven-transm em brane-dom ain (7TM , Baggiolini et al., 1994; Murphy, 1994). 
Two receptors for IL-8, CXCR 1 and C X C R 2 are expressed on all neutrophils and 
monocytes and at low levels on C D 8+ T  cells and natural killer cells (NK). The receptors are  
not present on C D 4+ T  cells and B cells. CXCR 1 is specific for IL-8 whilst C X C R 2 shows 
affinity for IL-8 and other C X C  chemokines. C X C R 3  is expressed on IL-2-activated T  
lymphocytes but not on resting T  lymphocytes, B-lymphocytes, monocytes, or granulocytes. 
C X C R 4 is distributed on leukocytes and a variety of tissue cells (Baggiolini et al., 1997). It 
has been identified as a co-receptor, (with CD 4), for the infection of cell lines or blood 
lymphocytes by lymphocyte-tropic, syncytium inducing, HIV-1 strains (Feng et al., 1996).
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Chemokin Receptors Ligands
CXC CXCR1 IL-8
CXCR2 IL-8, GRO<x,p,y, NAP-2, ENA78, GCP-2
CXCR3 IP10, Mig
CXCR4 SDF-1
CC CCR1 RANTES, MIP-1a, MCP-2, MCP-3
CCR2a/b MCP-1, MCP-2, MCP-3, MCP-4
CCR3 Eotaxin, RA NTES, MCP-3, MCP-4
CCR4 RANTES, MIP-1a, MCP-1
CCR5 RANTERS, MIP-1a, MIP-ip
Table 1. The Ligand selectivity of chemokine receptors (adapted from Baggiolini et al., 
1997)
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Two receptors for CC  chemokines, CCR1 and C C R 2 (originally designated M IP- 
1a /R A N TE S  and MCP-1 receptor) are expressed on monocytes, their genes being located  
on chromosome 3p21. They recognise the chemokines M C P-2, M C P -3  and M C P-4  
(Baggioiini et al., 1997). C C R 3  (or eotaxin receptor) recruits cells in allergy and is mostly 
expressed on eosinophils (Daugherty et al., 1996). The C C R 4 and C C R 5 chemokine 
receptors bind R A N TES  and M IP -1a . C C R 4 is expressed on basophils, T  and B- 
lymphocytes, and monocytes (Pow er et al., 1995). The gene for C C R 5 is located on 
chromosome 5 and has been shown to be a co-receptor for cellular entry of 
monocyte/macrophage-tropic HIV-1 strains (Baggioiini et al., 1997).
1.4.1.6. Surface antigen expression
Surface antigen expression on monocytes may change during maturation to 
m acrophages and thus may be used as an indicator of cellular activation and differentiation  
(W right et al., 1990). Blood monocytes express C D 4, C D 54  (ICA M -1) C D 64  (FcyRI) but not 
C D 16 (FcyRlll) which is found on monocyte-derived m acrophages (Ravetch and Kinet,
1991).
CD14
Monocytes characteristically express C D 14, a receptor that binds complexes of 
lipopolysaccharide (LPS) and LPS-binding protein (W right et al., 1990). It is a phospholipid- 
linked protein w hose expression is modulated by bacterial LPS, IFN-y, and ph'orbol 12- 
myristate 13-acetate (PM A), calcium ionophore A 23187  and anti-C D 14 monoclonal 
antibody. Monocytes in vitro shed soluble CD 14 that may play a role in regulating C D 14  
surface expression (Bazil and Strominger, 1991). Hum an monocytes cultured in-vitro for 5 
days with 10%  human serum showed a decrease in CD  14 expression (Ziegier-Heitbrock et 
al., 1993).
Adhesion molecules
Hum an monocytes express C D 1 1 a / 11b / 18 and C D 32  (Valentin et al., 1991). The  
integrin molecule C D 11c /C D 18  (C R 4, p150, 95) is found on activated myeloid cells and T  
cell subsets. Studies showed that incubating these cells with PMA increased the expression 
of CD 11c. Hum an peripheral blood monocytes incubated for 15 days in a cytokine and
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serum -free system showed reduced expression of C D 11c compared to fresh monocytes 
(Bennett et al., 1992).
Major histocompatibility complex class M (MHC classll)
Monocytes and m acrophages have been shown to express products of the Major 
histocompatibility complex class II genes (M HC Class II) that are important in antigen  
presentation to T  cells (Andreesen et al., 1990). Human monocytes cultured for 5 days 
express high levels of HLA-DR, one of the M H C class II gene products (Tokuda and Levy,
1996). IL-4 induces HLA-DR expression on human monocytes via a G protein-dependent 
system (Vassiliadis and Papam atheakis, 1992). Antigen presentation to T-lymphocytes 
requires the direct interaction of T  cell C D 4 with M HC Class II molecules on m acrophages  
(G ay et al., 1987) and the interaction of C D 28  and C D 80, one of the dominant costimulatory 
pathways (Lenschow et al., 1996).
CD80
T-cell activation requires costimulatory signals from C D 28  that are dependent upon 
the binding of C D 80  (B 7-1/B 7, Matulonis et al., 1995). C D 80  was first identified as a B cell 
activation molecule and the ligand for C D 28  and later for C TLA -4 (Yokochi et al., 1982). 
Subsequently, this molecule has been detected on antigen presenting cells including 
dendritic cells, Langerhans cells, activated monocytes, activated T  ceils and a variety of 
tumour lines. The hum an and murine C D 80  genes have been cloned and found to be 
m embers of the immunoglobulin supergene family (Tivol et al., 1997). C D 80  expression on 
B cells can be increased by cytokines such as IL-2 and IL-4 whilst IFN-y treatm ent increases 
its expression on monocytes (Hathcock and Hodes, 1995). A second B7 family member, 
C D 86 (B7-2), w as identified and found to be structurally similar to C D 80. C D 86  has an  
extracellular domain containing two Ig-like domains, a transm em brane domain, and a 
cytoplasmic tail that contains three sites for protein kinase C phosphorylation. Resting B 
cells express low levels of C D 86  and no C D 80  but both are upregulated following B cell 
activation with agents such as lipopolysaccharide (LPS), the mitogen Concanavalin A (Con 
A), or cyclic adenosine m onophosphate (cAMP). The induction of C D 86  on B cells with IL-4 
occurs within 6hrs of stimulation, with maximal expression occurring between 18 and 24h.
By contrast, C D 80  expression on B-cells is only detected 24h post stimulation and reaches  
a maximum 48  to 72h later (Stack et al., 1994; Lenschow et al., 1996). Also, IFN-y
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increases the expression of C D 86  on B cells, peritoneal m acrophages and peripheral blood 
monocytes. By contrast, IL-10 blocks the upregulation of C D 80  and C D 86  on human  
peritoneal m acrophages (Bulens et al., 1995, W illems et al., 1994).
The binding of its ligand by C D 80  expressed on antigen-presenting cells is thought 
to promote the developm ent of T  helper 1 (Th1)- rather than a Th2- type responses. IL-4 
and IL-10, which cause the developm ent of Th2 immune responses, down regulate C D 80  
expression on resting C D 14+  human monocytes. IFN-y, responsible for the developm ent of 
a Th1-type immune response, enhances the expression of C D 80  and C D 86  isoforms 
(Creery e ta l., 1996). O ther cytokines tested including IL-1a, IL-1{3, IL-2, IL-5, IL-6, IL-12, 
granulocyte- m acrophage colony-stimulating factor (G M -CSF), and transforming growth 
factor (TG F)- a  have not been shown to modulate C D 80 expression on resting human 
monocytes or B cells. The expression of C D 80  on resting B cells is higher (2 1 .1± 2 .5% ) than  
that on resting human monocytes (4 .8±  0 .35% ; Creery et al., 1996).
The affinity of the C D 80 /C D 86  molecules for C D 28  and C TLA -4 may influence which 
interaction will predominate during an immune response. If these molecules w ere expressed  
at low levels, the high-affinity, inhibitory receptor, CTLA-4 may be engaged. CTLA-4  
expression is up regulated following T  cell activation and the inhibitory nature of the 
C D 80/C D 86-C TLA -4  interaction will term inate T  cell activation (Tivol et al., 1997).
C D 23
C D 23, a low affinity receptor for IgE (FcsRII) is found on a variety of hematopoietic  
cell types including the hum an monocytic cell line U 937 (after stimulation with IL-4), human  
monocytes and Langerhans cells (Conrad, 1990, Alderson et al., 1992). The FceRII is 
involved in IgE-dependent cytotoxicity and in promoting phagocytosis of IgE-coated  
particles by m acrophages and eosinophils (Conrad, 1990). IL-3 and G M -C S F have been  
shown to enhance the expression of C D 23  on monocytes and to increase the level of 
soluble C D 23  (sC D 23) in monocyte-culture supernatants. G M -C S F  and IFN-y enhance  
surface and soluble C D 23  production by the monocytic cell line U 937 (Alderson et al.,
1992). Treatm ent of the human monocytic cell line Mono M ac 6 for up to 3 days with 
prostaglandin E2 enhanced the expression of C D 23 whilst iipopolysaccharid (LPS) and 
tetradecanoylphorbol-13-acetate (TPA ) treatm ent did not (Ziegler-Heitbrock et al., 1994).
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1.4.1.7. CD16, CD32, and CD64
There are three major classes of receptor for immunoglobulin G which have been  
identified as CD 16, C D 32, and C D 64. Most human and murine FcR are members of the 
immunoglobulin superfamily (IgSF). The biological properties of m em brane FcR are 
dependent upon the presence or absence of one or several intracytopiasmic activation 
motifs similar to the BCR and T C R  signal transduction subunits (Daeron, 1997; Reth, 1989). 
The presence of these motifs m ean that FcRs are able to trigger cell activation (Reth,
1989). There are three classes of FcyR - FcyRIII (C D 16), FcyRII (C D 32), and FcyRI (C D 64) 
all of, which m ediate phagocytosis of IgG -opsonized materials (Jones et al., 1996).
CD16
FcyRIII (C D  16) is a low affinity receptor with a Mr between 50 -80  KDa. It exists in two 
forms -FcyRIIIA and FcyRlllB. The  latter is encoded by a single gene with two alleles located  
on chromosome 1 (1q23-24, Qiu et al., 1990). The receptor FcyRIIIA is expressed on 
natural killer (NK) cells (where it regulates their cytotoxic and non-cytotoxic functions), 
monocytes cultured in vitro, and tissue macrophages. The FcyRlllB is expressed in 
neutrophils (M asuda and Roos, 1993). FcyRIIIA activates the src and syk tyrosine kinases 
(Daeron, 1997).
CD32
FcyRII (C D  32) is a 40 -K D a  glycoprotein with low affinity for ligands and interacts with 
complexed IgG. In humans, C D 32  is encoded by a minimum of three genes FcyRIIA, B, and  
C. The FcyRIIA, and FcyRIIC m RNA is expressed in monocytes, m acrophages and 
neutrophils. FcyRIIB m RNA is expressed in monocytes, macrophages, and B-lymphocytes 
(M asuda and Roos, 1993). Cell activation resulting from FcyRIIA engagem ent is mediated  
by ITAMs (immunoreceptor tyrosine-base activation motifs) located in the cytoplasmic 
region which is capable of interacting with the FcR y-chain resulting in a change in its 
signalling behaviour (M asuda and Roos, 1993; van den Herik-Oudijk et al., 1995).
In monocytic cell lines, ITAMs phosphorylation is induced by aggregation of FcyRIIA  
(G hazizadeh et al., 1994). Engagem ent of C D 32  also activates the protein tyrosine kinases 
belonging to the src and syk family of kinases. In infected cells, HIV-1 transcription may be 
induced via FcyRIIA engagem ent (Tsitsikov et al., 1995). FcyRIIB have no ITAMs and
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belong to a family of single-chain, low-affinity IgG receptors encoded by a single gene  
located on chromosome one (1q23-24; Hogarth et al., 1991). Alternative splicing generates  
several isoforms including FcyRIIB I and FcyRIIB2. Cells of hematopoietic origin express 
FcyRIIB with FcyRIIB I on lymphoid and FcyRIIB2 on myeloid cells. FcyRIIB do not activate 
cells but, when aggregated by multivalent ligands, are involved in capping, endocytosis and 
phagocytosis (Daeron, 1997).
CD64
The high affinity FcyRI (C D 64) is a 72-K D a glycoprotein receptor which is expressed  
on neutrophils, monocytes and m acrophages and which binds to monomeric IgG. 
Interferon-gam m a (IFN-y) increases the expression of C D 64  on hum an neutrophils, 
monocytes and some monocytic cell lines by up to 20-fold (Perussi et al., 1983, Looney et 
al., 1986). It has been shown using the myeloid cell line U937, that the receptor is 
associated with actin (M asuda and Roos, 1993).
In humans, the three genes that encode the a subunits of FcyRi are clustered, on the 
long arm of chromosome 1 (1q21.1; Daeron, 1997; Morton et al., 1995). In order to bind IgG  
with high affinity, FcyRi must associate with the y chain (Miller et al., 1996). It has been  
shown (using m acrophage cell lines) that the aggregation of C D 64  occurs after the ITAMs 
of the receptor molecules are phosphorylated (Duchemin et al., 1994). This phosphorylation 
coincides with the activation of several sets of cytoplasmic protein tyrosine kinases that 
belong to the src and sky family of kinases. To prevent FcyR from activating human  
monocytes and hum an neutrophils, C D 45  co-aggregates with C D 64  (Daeron, 1997).
Macrophages and monocytes m ediate A D C C  via C D 64  which triggers superoxide 
production and the secretion of inflammatory cytokines (Daeron, 1997). In human  
monocytes, NF-tcB is induced by FcyRi aggregation which, in H IV infection, activates 
transcription of the virus (Tsitsikov et al., 1995).
1.4.1.8. FcyR-mediated signalling
The Fc domain of IgG simulates phosphorylation of tyrosine residues within ITAMs 
located in the cytoplasmic domain of FcyRi I or in the y-chains associated with FcyRi or 
FcyRlllA. This induces receptor clustering causing FcyR activation. The  src- and syk-family 
kinases cause phosphorylation of conserved tyrosine residues.
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The activation of FcyRs involves other phosphotyrosine containing proteins such as 
paxillin which co-localises with F-actin beneath nascent phagosomes and is phosphorylated  
by syk (a PI 3-kinase-associated protein that links the FcyR pathway to PI 3-kinase; 
Greenberg e ta l., 1994; Nada e ta l., 1994; Ninomiya e ta l., 1994). O ther tyrosine 
phosphorylated proteins, phosphatidyl-inositol specific phospholipase Cyi and PI-PLCy2, 
upon FcyR activation, caused phosphatidyl-inositol-4, 5-bisphosphate hydrolysis and, 
intracellular C a2+ mobilisation (K iener et al., 1993, Liao et al., 1992).
1.5. Phagocytosis
The term "professional phagocyte” refers to polymorphonuclear neutrophils (PM Ns), 
monocytes and m acrophages (Rabinovitch, 1995). These cells ingest and clear large 
particles (>0 .5  pm) including infectious agents, senescent cells and cellular debris by 
phagocytosis (Allen and Aderem , 1996). Tw o models of this process have been proposed. 
These are the zipper and trigger models (F igure1.6). The zipper model originated from  
studies involving the phagocytosis of erythrocytes and bacteria m ediated by m acrophage Fc 
and com plem ent receptors. For phagocytosis to occur a particle must initiate a response  
that involves the Fc-dependent cross-linking of FcRs (Griffin and Silverstein, 1974). Studies 
on phagocytosis have indicated that the process requires receptors other than those initially 
involved in particle binding. It w as shown that m acrophages could phagocytose opsonised  
erythrocytes but the removal of the opsonin or the occupied receptor adjacent to the initial 
binding site prevented particle ingestion (Griffin et al., 1975). Further studies showed that 
lymphocytes uniformly coated with IgG w ere completely ingested by m acrophages whilst 
those opsonized over only one hem isphere of their surface w ere incompletely ingested as 
the m acrophage pseudopodia extended no further than the IgG cap on the lymphocytes. 
These studies indicate that the zipper model is under local control due to the close contact 
between the phagocyte and particle. This encourages pseudopodia to form tight-fitting 
phagosomes through the continuous ligation of new receptors (Swanson and Baer, 1995).
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Figure 1.6. The zippering and triggering models
Initial binding is enough for complete ingestion of the particle by the trigger model while the 
zipper model, requires additional interactions between opsonins and receptors, (a) Particles 
attached to the cell surface; (b) Ligands outside the attachm ent zone removed 
experimentally; (c) ‘Triggering’ mechanism; (d) ‘Zippering’ mechanism. Diagram adapted  
from Swanson and Baer, 1995.
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In the trigger model, bacteria indiscriminately enter epithelial cells and m acrophages via 
macropinosomes. The release of growth factors such as m onocyte-m acrophage colony- 
stimulating factor increases surface ruffling and the formation of macropinosomes in these  
cells (Racoosin and Swanson, 1989). A fter trapping bacteria, ruffles form with the aid of 
actin microfilaments and fold back against the cell surface thus forming macropinosomes 
that are large endocytic vesicles that trap extracellular fluid. Ruffles are unguided 
pseudopodia and are larger than the bacteria they trap. Thus, the response is 
disproportionate to the size of the particle. A study showed that the attachm ent of S. 
typhimurium to epithelial cells and m acrophages stimulated ruffling and macropincytosis 
thus aiding invasion by S. typhimurium (Swanson and Baer, 1995). The surfaces of 
macrophages exhibit ruffling in m any places. Since it is not restricted to the site of binding, 
phagosomes are formed that are not closely adjacent to the bacteria. The latter enter by 
random capture (Swanson and Baer, 1995).
1.5.1.1. The role of the complement receptor 3 (CR3)
Adhesion and phagocytosis of particles opsonized with com plem ent is mediated by 
CRs on leukocytes. CR1 mediates adhesion to C3b on com plement-opsonized particles 
causing Factor-I to initiate CR1 conversion of C3b to iC3b. This process reduces the affinity 
of the opsonised particles for CR1 and increases their affinity for C R 3. The C R 3 is a 
heterodimer whose engagem ent initiates a transient increase in cytosolic C a2+ (Schmitz et 
al., 1997; Janconi e ta l., 1991).
Monocytes, macrophages and polymorphonuclear cells express CR1 (C D 35) and 
C R 3 (a M/p2 integrin, C D H b /1 8 , M A C-1) (Schm itz et al., 1997). Differences exist between  
complement- and FcR-m ediated phagocytosis. CR 3-m ediated phagocytosis happens in 
cells activated by inflammatory mediators or extracellular matrix proteins while FcyR- 
mediated phagocytosis occurs constitutively (Greenberg, 1995).
1.5.1.2. The role of phagocytosis in antigen processing and presentation
Major histocompatibility complex (M HC) molecules associate with small peptides to 
produce peptide-M HC complexes that are presented to T  cells. The  recognition of peptide- 
M H C complexes stimulates T  cells to m ediate cellular immune reactions and/or to regulate
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B cell production of antibody (Harding, 1995). Two distinct classes of molecules present 
antigens, M HC class I (M HC-I) and M H C  class II (M HC-II; Germain, 1994). M HC-ll is 
associated with an invariant chain that blocks the binding of peptides in the endoplasmic  
reticulum (ER). The cytoplasmic tail of the invariant chain directs the M HC-Il-invariant 
complex from the Trans Golgi network to the endocytic compartments. The invariant chain 
is proteolytically cleaved as it reaches the endosom e and M HC-II molecules bind antigenic  
peptides (Germain, 1994). It has been shown that a minimum of 2 0 -3 0  min is required for 
phagosome-lysosome fusion and phagolysosomal degradation of bacteria and presentation  
of peptide- MHC-II complexes at the cell surface (Pfeifer et al., 1992).
M H C-I molecules are free to bind peptides in the ER and are not associated with an 
invariant chain. Also they do not move to the endocytic compartment. Peptides which have  
been cleaved from antigens in the cytosol by proteasomes are transported into the lumen of 
the ER where they bind to the M HC-I molecules (Germain, 1994). Som e pathogens not 
detected by the vacuolar system reside in the cytosol w here they escape by lysing vacuolar 
m em branes (Pam er, 1993, Brunt et al., 1990). Endogenous antigens or antigens that 
escape into the cytosol are primarily presented by MHC-I molecules (Collins et al., 1992, 
Zhou e ta l., 1992; Harding, 1995).
An alternative to the conventional pathway for M HC-I associated antigen processing 
and presentation is thought to exist primarily in macrophages (Collins et al., 1992, Zhou et 
al., 1992). It w as shown that in the alternative MHC-I pathway, Brefeldin A, which inhibits 
transport through the Golgi complex to the cell surface in the conventional pathway, did not 
inhibit processing of antigen. This indicates that the alternative pathway does not involve a 
transporter for loading of peptides onto M HC-I molecules in the ER (Harding and Song, 
1994). This m eans that peptides released from phagocytic compartments in the cytoplasm  
may associate with M H C-I on the cell surface (Pfeifer et al., 1993; Harding and Song,
1994). Alternatively, peptides may bind to M HC-I molecules in post-Golgi compartments or 
M HC-I molecules may be internalised in phagosomes from the plasma m em brane where  
they may bind peptides produced in the phagolysosomes.
1.5.1.3. Initiation of an antigen-specific response
The recognition of antigen associated with M HC by the T C R  along with the co­
stimulatory signal derived from the interaction between C D 80 /86  and their ligands 
C D 28/C TLA 4 is vital for T  cell activation. An initial signal is received from the T  cell receptor
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(TCR) complex and its co-receptors C D 4 or C D 8 interacting with antigen presented by 
MHC-class II or I antigens respectively. A  second signal is derived from the interaction of 
C D 28 with C D 80 /86  and is essential for initiating antigen-specific T  cell responses, 
upregulating cytokine expression and promoting T  cell proliferation and differentiation  
(Lenschow et al., 1996).
1.5.1.3.1. CD28/CTLA4
C D 28, a  glycoprotein, is expressed on the surface of 80%  of human T  cells. It is 
present at high levels on developing thymocytes and its expression increases following T  
cell activation (Lenschow et al., 1996). C D 28  is a disulphide-linked homodimeric 
glycoprotein that can exist as a monomeric protein (W alunas et al., 1994). As a  result of 
ligation, the production of various cytokines is induced including IL-1, IL-2, IL-4, IL-5, TNF, 
and IFN-y. C D 28  plays an early role in the developm ent and differentiation of Th1 and Th2  
subsets and the absence of this signal causes naive T  cells to differentiate toward the Th1 
phenotype (Lenschow e t al., 1996). By contrast, CTLA-4 is not constitutively expressed on 
T  cells, its expression only occurs following T  cell activation, peaking 48  h after activation 
and returning to background levels by 96 h. Expression of C TLA -4 is maximal when C D 28  
expression is down regulated or impaired (Lenschow et al., 1996). Regulation of expression 
is a complex process as evidenced by the fact that anti-TCR antibody stimulation of human  
T  cells did not upregulate C TLA -4 but soluble ICAM-1 (a ligand for LFA-1) did so to a slight 
extent (Linsley et al., 1992; Dam ie et al., 1994). It has been suggested that CTLA-4  
expression is post-transcriptionally regulated or CTLA-4-associated proteins are required for 
transport and cell surface expression (Lenschow et al., 1996).
C TLA -4 is a disulphide-linked homodimeric glycoprotein that can exist as a 
monomeric protein (W alunas et al., 1994). Antibodies to hum an C TLA -4 block the  
interaction of C D 28 /C D 80  and prevent the production of IL-4 (S eder et al., 1994).
1.6. Human monocytic cell lines
Monocytic cell lines provide a  relatively hom ogeneous group of cells to enable  
examination of the effect of external agents on m onocytes/macrophage characteristics.
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O ne of the problems with these cell lines is that they are relatively immature and may 
require treatm ent with various agents to promote maturation.
1.6.1. Mono Mac 6 cell line
The Mono M ac 6 (M M 6) cell line w as first established by culturing cells isolated from  
the blood of a patient with monoblastic leukaem ia (Ziegler-Heitbrock et al., 1988). M M 6 was  
isolated and assigned to the monocyte lineage according to morphology, cytochemical and 
immunological criteria. The  cells express NaF-sensitive non-specific-esterase, produce 
reactive oxygen intermediates, express C D 14  and are capable of phagocytosing antibody- 
coated erythrocytes. The expression of certain surface antigens has been enhanced by 
treatm ent of MM 6 with IFN-y. (Ziegler-Heitbrock et al., 1988).
As mentioned above, the M M 6 cell line is CD 14*, that a m arker characteristic of 
mature peripheral blood monocytes and tissue macrophages (Ziegler-Heitbrock et al.,
1994). The cells also produce cytokines such as IL-1a, IL-1 p, T N F  and lL-6 after stimulation 
with lipopolysaccharide (Ziegler-Heitbrock et al., 1994, Q uentm eier et al., 1995).
Prostaglandin E2 (PG  E2), lipopolysaccharide (LPS) and tetradecanoylphorbol-13- 
acetate (TPA) cause M M 6 cells to differentiate as evidenced by reduced cellular 
proliferation and expression of C D 33  and increased phagocytosis of Staphylococcus sp. 
and M -C S F m RNA expression. M M 6 cells constitutively express C D 23  but it can be up 
regulated by PG E2, rlL-4 and rlL-6 (Ziegler-Heitbrock et al., 1994).
The human Mono M ac 6-cell line has many of the characteristics of mature blood 
monocytes and expresses the C D 14  molecule. Treating Mono M ac 6 cells with LPS and  
P G E 2 increased surface C D 14  expression twofold and was accom panied by a rise in 
soluble C D 14  and enhancem ent of C D 14  m RNA. In contrast, Tetradecanoylphorbol-13- 
acetate (TPA) decreased surface C D 14  expression twofold and C D 14  m RNA while sC D 14  
remained the sam e (Ziegler-Heitbrock et al., 1994). Studies involving the blockade of C D 14  
or inhibition of protein kinase C indicate that both are involved in signal transduction 
pathways which results in T N F -a  secretion from Mono M ac 6  cells (Steube and Drexler,
1995). MM 6 cells have been shown to adhere to human umbilical vein endothelial cells 
(H U V E C ) which are unstimuiated or stimulated with T N F -a  (Erl et al., 1995). A maximum of 
6.2  M M 6 cells bind per H U VE C , a similar level to freshly isolated human blood monocytes
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but 34%  less than the level observed with U 937 cells. To investigate this interaction further, 
monoclonal antibodies (mAb) directed against E-selectin, VCAM -1 and ICAM-1 on H U V E C  
and C D 11b  or C D 14  on M M 6 cells w ere used. The decrease in cellular adhesion after 24h  
correlated with a reduction in E-selectin expression on H U V E C  (Erl et al., 1995).
Differentiation of M M 6 cells induced can be by the active metabolite of vitamin D3 
(1 ,25  (O H) vitamin D3) as evidenced by the enhanced the activity of phospholipase A2  
(PLA2), which is important in the differentiation and growth of monocytic cells (Aepfelbacher 
e ta l.,  1995).
1.6.1.1. THP-1 cell line
The THP-1 cell line w as derived from cells isolated from the blood of a 1-year-old  
boy suffering from acute monocytic leukaem ia (Tsuchiya et al., 1980). The ceils retain the  
appearance of leukaem ic cells and grow in suspension as loose clumps. They show  
lysosyme and NaF-inhabitable a-naphthyl butyrate esterase activity. THP-1 express C D 64, 
C D 32 and C3b receptors also M H C  antigens HLA-A2, -A9, -B5, -D R 1, -D R 2. They do not 
express surface or cytoplasmic immunoglobulins. THP-1 cells have a diploid (46 + X, Y ) 
num ber of chromosomes (Tsuchiya et al., 1980).
Phorbol esters induce maturation in THP-1 cells resulting in the expression of 
phenotypic and functional characteristics associated with m acrophages (Tsuchiya et al., 
1982). PMA (Phorbol 12- myristate 13-acetate) causes cells to adhere, stop proliferating 
and show increased phagocytosis (Auxerx et al., 1992). These differentiated cells revert to 
a de-differentiated phenotype after three to four w eeks of treatm ent (Hass et al., 1993).
PMA decreases the expression of c-myc and c-myb integrin oncogenes whilst retinoic acid 
treatm ent decreases c-myc expression alone. Retinoic acid also induces differentiation in 
THP-1 cells, causing the acquisition of m acrophage-like characteristics after treatment. The  
expression of the /22~integrin genes, C D 11a  and CD 11b, was found to be increased after 
treating THP-1 with both reagents (Matikainen and Hurme, 1994). PM A treatm ent 
decreases both gene and m em brane expression of C D 64  (FcyRl) in THP1 cells, but only 
reduces m em brane expression of C D 32  (FcyRII). This indicates different regulatory 
mechanisms at work (Auxwerx et al., 1992).
Cytokines are produced by THP-1 cell lines during differentiation, maturation and the 
response to physiological concentrations of chemicals. THP-1 cells do not produce
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detectable levels of T N F - a  or IL-1(3 or of the m RNA coding for them (Molina et al., 1989). 
However, stimulation of THP-1 cells with LPS (incubated with or without IFN-y or G M -C S F) 
resulted in the secretion of both T N F - a  and 1L-1 p  (Chantry et al., 1990).
Phagocytosis of latex beads or organisms such as Toxoplasm a gondii has been  
shown to induce the release of TN F, IL-6 and IL-8 by THP-1 cells (Friedland et al., 1993). 
The surface expression of H LA -DR and C D 54  and the production of TN F - a ,  iL-1 p and IL-6 
are induced by IFN-y treatment. However, 1 ,25(O H ) 2D 3  fails to stimulate cytokine 
production from THP-1 cells but does induce surface expression of C D 11b and C D 14  
(Lozanski et al., 1992).
1.7. Immunology of HIV infection
HIV  disease is divided into three phases, firstly primary infection in which 50 -70%  
infected individuals exhibit a mononucleosis-like clinical syndrome. Secondly, an 
asymptomatic phase indicating a period of clinical latency and thirdly a phase during which 
the acquisition of opportunistic infections leads to AIDS.
The earliest response to H IV  infection is antibodies against a variety of viral proteins 
and the production of HIV-specific cytotoxic T  cells (Pantaleo et al., 1993). During the period 
of clinical latency and in the early stage of disease, HIV-infected individuals exhibit C D 4+ T  
cell counts between 2 0 0  and 500  per pi and the lymphoid tissue is progressively replaced  
by fibrotic tissue. In the later stages of disease, the C D 4+T  cell count drops below 2 0 0  per 
ptl and the lymphoid tissue undergoes extensive fibrosis and fatty infiltration (Pantaleo et al.,
1993). Thus, the patients’ immune mechanisms becom e impaired, since infected cells are 
no longer com petent to respond to other pathogens (Pantaleo et al., 1994). A percentage of 
HIV-infected individuals designated as long-term non-progressors (LTNP) do not experience  
progression of HIV disease. Their C D 4+ T  cell count remains in the normal range (greater 
than 6 0 0  cells per pil) and the C D 8+ T  lymphocyte count is increased (between 500  and  
2 5 00  cells per pi, Salk and Salk, 1993). The continued detection of HIV-specific cytotoxicity 
in LTNP suggests that H IV disease is the result of virus-specific, T  cell-mediated  
immunopathoiogy (reviewed by Pantaleo and Fauci, 1995).
Studies using the simian immunodeficiency virus (S IV) experimental animal model 
showed that H IV is carried to lymphoid organs where it is processed to generate a specific 
immune response (Parrott and Wilkinson, 1981). S IV  was detected in lymph nodes as early
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as day 7 after infection, indicating that lymphoid tissues are a site for the establishment of 
infection and are ideal for virus replication and spreading (depending upon the state of 
activation of the target cells).
Antigen-specific immune responses require the aid of activated effector cells (T  
cells, B cells, and m acrophages) which m ay support virus replication and release cytokines 
such as T N F -a , IL-6 and IL-10 that can induce virus expression. Also these responses may 
modulate certain components of the HIV-specific immune response which paradoxically 
may favour the initial establishment of H IV  infection (reviewed in Pantaleo and Fauci, 1995).
Dissemination of H IV throughout the lymphoid tissue occurs once infection is 
established. This process precedes the developm ent of a fully com petent HIV-specific 
immune response (Pantaleo et al., 1994). The  process of dissemination is associated with 
high levels of plasma viremia, p24 antigenem ia, and circulating mononuclear cells that 
contain HIV proviral DNA (reviewed by Pantaleo and Fauci, 1995). Virus replication reaches 
a peak and is suddenly down- regulated. Safrit et al., (1994) have suggested that this may 
be caused by HIV-specific cytotoxic T  lymphocytes (CTL) prior to the appearance of 
neutralising antibodies. This is supported by Reimann et al., (1994) whose studies using the 
S IV  model suggested that the down-regulation of viremia indicate that HIV-specific C TL play 
a major role in killing virus-expressing cells thus controlling virus replication and spread. 
Virus-expressing cells complexed with immunoglobulin (Ig) and com plem ent are trapped by 
follicular dendritic cell (FD C ) in the germinal centre of lymph nodes. Koup et al., (1994) 
suggested that this indicated that an HIV-specific humoral immune response contributes to 
the downregulation of viremia through complement activation.
The lack of complete elimination of H IV  by the primary immune (Fauci et al., 1991) 
response has led to the suggestion that important components of the immune response are  
not present during this critical stage of infection. However the presence of virus-specific 
C TL and the dramatic decrease of virus-expressing cells in lymph nodes contradicts the 
suggestion that the cell-mediated immune response is inadequate (Reim ann et al., 1994; 
Safrit et al., 1994). Another possibility is that the virus is able to evade the primary immune 
response. Indeed, neutralising antibodies are not detected during the primary immune 
response to H IV  that may allow the virus to exist in a latent from in a large proportion of 
infected cells. Despite the down-regulation of replication, some individuals experience a 
different clinical outcome, progressing to A ID S  within 12 months of sero-conversion with
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very low viremia after primary infection, and strong HIV-specific cytotoxic activity 
(Schnittman e ta l., 1989, Embretson e ta l.,  1993).
This diversity of the clinical outcomes of infection prompted studies of the cell- 
mediated immune response. Particular interest was shown in changes in the T  cell receptor 
(TC R ) repertoire during primary HIV infection (Pantaleo et al., 1994). Oligonucleotides that 
encompass all known V/3 sequences w ere used to exam ine the T C R  repertoire on 
peripheral blood mononuclear cells obtained at different stages of infection. Using a 
combination of PCR and cytofluorometry the results indicated that during the first 8 weeks  
following primary infection, cells expressed a restricted num ber of \f/3 domains (Pantaleo et 
al., 1994).
Studies have shown that the H IV  envelope and M HC class II molecules share 
homologous sequences. Anti-Class II antibodies had an inhibitory effect on C D 4+ T  
lymphocyte activation which contributes to the progression o f H IV  disease (Golding et al., 
1988, Golding e ta l., 1989; Pantaleo and Fauci, 1995). Another two mechanisms associated  
with disease progression have been suggested which involve apoptosis or the abnormal 
activation of programmed cell death, and a switch from a Th1 to a Th2 pattern of cytokine 
production. Additionally, it has been proposed that H IV may cause immunosuppression and 
disease by inducing anergy in C D 4+ T  cells following abnormal antigen presentation by 
other C D 4+ T  cells and costimulatory molecule C D 80 on tissue m acrophages (reviewed in 
Pantaleo and Fauci, 1995). A significant depletion of C D 4+ T  cells from HIV-infected  
patients caused an increase in delayed type hypersensitivity (D TH) reactions this leads to 
allergies (Emery and Lane, 1997).
1.8. Genera! Biology of Immune complexes
In 1911, Von Pirquet suggested that the toxic effects of antigen-antibody  
interactions caused serum sickness. This w as confirmed in the 1950s and 1960s with 
animal models of acute and chronic serum sickness. Antibodies react with antigen that is 
fixed in the tissue or free in the circulation. O nce in the circulation, the immune complexes 
may fix com plem ent and be eliminated from the circulation by the m ononuclear phagocytic 
system. Persistence as soluble complexes in the circulation allows the immune complexes 
to escape mononuclear phagocyte clearance and to deposit in endothelial or vascular
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structures causing an inflammatory response which could lead to immune complex disease  
(Spiegel, 1985).
The classical com plem ent pathway is activated by immune complexes and helps to 
protect the body against the developm ent of immune complex disease. Com plem ent reacts 
with immune complexes and binds to erythrocyte CR1 thus inhibiting immune precipitation 
and dissolving immune aggregates; these reactions prevent the accumulation of soluble 
complexes in local tissues. CR1 acts as a cofactor to Factor I, which catabolises the 
conversion of C3b to iC3b and subsequently to C3dg (Davies et al., 1994).
The precipitation of antigen-antibody at equivalence or in antibody excess requires 
intact IgG molecules for Fc-Fc interactions that promote precipitation (Davies et al., 1994). 
Gavin et al., (1995) demonstrated in vitro that recombinant soluble FcyRII (rsFcyRII) is 
effective in modifying immune complex formation and delays immune precipitation in a 
dose-dependent manner. This effect can be inhibited by anti- FcyRII MoAb Fab’ fragments. 
This process may inhibit immune complex-induced inflammation in the Arthus reaction in 
vivo (Fries et al., 1984).
The solubilisation of immune precipitates is caused by covalently binding C3b to 
immune complexes thus reducing the various forces that hold the aggregate together. This 
process is inefficient, as large amounts of complement are required (Fries et al., 1984). The  
transfer of immune complexes from red cells to human monocytes is C R 1-dependent, as 
monocytes possess more binding sites. This facilitates transferring of complexes to fixed 
m acrophages from red cells in the sinusoidal circulation of the liver and spleen (Em len et 
al., 1992).
Inflammation and tissue injury with the release of autoantigens may be due to 
immune complexes that escape the m ononuclear phagocytic system and deposit in the 
tissues. These autoantigens cause further tissue injury as they stimulate an autoimm une 
response with the formation of more immune complexes and the consequent release of 
more autoantigens. Mononuclear phagocytes of the liver and spleen clear immune 
complexes as tissue m acrophages bear both Fc and com plem ent receptors (C R 3 and C R 4) 
which allow opsonised complexes to interact with both groups of receptors. A defect in 
mononuclear phagocytic function, defective immune complex delivery to the m ononuclear 
phagocytic system or low levels of erythrocyte CR1 lead to the developm ent of disease by 
impaired complex clearance. In early studies, the use of IgG - and IgM-coated cells showed
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that IgG-complexes w ere cleared in the spleen while IgM-complexes showed transient 
retention in the liver (Davies et al., 1994).
Formed at equivalence, antigen-antibody complexes have been shown to 1) 
stimulate the release of prostaglandin E2 (PG E 2), T N F -a , IL-1 p and the IL-1 receptor 
antagonist, 2) to suppress IFN-y-induced M H C  class II expression and the expression of 
FcyRi. Berger et al., (1996b) showed in vitro that immune complexes induce human  
monocytes to secrete IL-6 and IL-10 in a dose-and antigen: antibody-ratio -dependent 
manner. Previous studies showed IL-10 secretion is augm ented in a paracrine m anner by 
P G E 2 synthesised upon stimulation by immune complexes but immune complex induced IL- 
10 secretion is not dependent on PG E2. Immune complex induced IL-6 secretion is 
increased by P G E 2 but the synthesis of both is decreased by IL-10. iL-6 is involved in the 
growth and differentiation of B cells and increases the production of antibodies. IL-6, IL-10  
and PG E 2 are closely associated with Th2-iike immune responses. As a regulatory factor, 
P G E 2 induces Th2 while it acts with IL-10 to suppress the production of the Th1-stimulatory 
cytokines. Thus, the presence of immune complexes may result in the secretion of IL-6 and 
IL-10 that interferes with the developm ent of a Th1 response and therefore inhibits cell- 
mediated immunity to malignancies and intracellular pathogens.
1.8.1. Immune complexes and HIV-1
Feijoo et al., (1995), and Briant et al., (1996) have showed the interaction of gp120  
anti-gp120 immune complexes with PBM Cs latently infected with HIV-1 in the G 0/G rp h a s e  
induced the cells into the S /G 2/M -phases of the cell cycle and caused them to express  
C D 25 and HLA-DR. This activation caused provirus integration and virus production. In the 
presence of soluble gp120 alone, only AP-1 was indicating that cross-linking of C D 4 is 
required for N F-k B activation.
Circulating immune complexes (C lC /gp120-anti-gp120) which occur naturally in H iV  
infection has anti-CD4 activity and increase HIV-1 infection (Feijoo et al., 1995). Aceituno et 
al., (1997) demonstrated that naturally occurring circulating immune complexes from H IV+ 
patients induced apoptosis in normal hum an C D 4 lymphocytes which w as accompanied by 
increased expression of Fas (C D95; Oyaizu et ai., 1993). Recent reports noted that the 
cross-iinking of C D 4 with gp120-anti-gp120 in vitro resulted in cellular activation and 
induced apoptosis (Siliciano, 1996). O ther studies showed that stimulation of Fas antigen
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expression induced apoptosis in H IV + patients (Katsikis et ai., 1997, W ang et al., 1994). 
Results from Aceituno et al., (1997) showed Fas antigen expression preceding the induction 
of apoptosis by C IC -H IV + mainly in asymptomatic individuals and not in A ID S  patients. 
Interestingly it has been shown that uninfected cells undergo spontaneous apoptosis rather 
than infected ones. This implies that there are two different processes in destroying C D 4+ 
cells in H lV+ patients one spontaneous and the other mediated by virus containing immune 
complexes.
1.9. Cytokines and HIV
1.9.1. Cytokine-mediated regulation of HIV
In vitro, infected m acrophages treated with IL-4 (dose-dependent), IL-10, IL-12, IL- 
13 and interferon’s showed a decline in H IV  infection (Kornbluth e ta l., 1990). Interferon- 
gam m a (IFN-y) was most effective when added in the early stages of infection. W hen  
macrophages w ere treated for 5 days before infection with IL-4, they becam e completely  
resistances to H IV (Schuitem aker et al., 1992).
IL-6 and T N F -a  are believed to enhance the expression of H IV  in macrophages.
Also IL-1, IL-12, and T G F - up regulate viral expressionp. These cytokines stimulate 
m acrophage permissiveness to lymphocytotropic strains of H IV  (Kinter et al., 1995, Lazdins 
e ta l., 1991).
1.9.1.1. Effect of cytokines on the growth cycle of HIV-1 in macrophages
T N F - a ,  IL-1 p, and I F N - y  down regulate surface expression of C D 4  on human  
m acrophages. These cytokines act at the level of transcription. Acting on primary 
m acrophages, T N F - a ,  and I F N - y  inhibit HIV-1 infection. T N F - a  inhibits that part of the viral 
cycle concerned with fusion or uncoating. G M - C S F  increases C D 4  surface expression in 
primary macrophages but may not be involved in HIV-1 replication. (Herbein, 1997).
IL-2 and phytohemagglutinin A (PHA) activate T-lymphocytes allowing complete 
reverse transcription and production of proviral DNA, integration and active H IV  replication 
(Zack et al., 1990). In contrast to this, although the IL-2R is present on m ononuclear 
phagocytes, IL-2 does not cause modulation of HIV-1 replication in primary macrophages if
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they are treated after exposure to the virus (Allen et al., 1990, M ontaner et al., 1995). On 
the other hand TG F-p  inhibits HIV-1 replication in primary m acrophages (Poli et al., 1991) 
stimulates its growth if the cells are pre-treated (Lazdins et al., 1991). Also, the inhibition of 
initial reverse transcription by IL-10 prevents HIV-1 replication in primary m acrophages  
which may help the virus in m onocytes/macrophages to remain in a latent stage  
(Montagnier et al., 1994, Saville et al., 1994).
The cellular transcription factor N F-k B is bound to the inhibitory protein I-k B in the 
cytoplasm and is activated by T N F a  which stimulates infected m acrophages to produce 
infectious virus. A combination of phosphorylation and proteolytic degradation causes the 
dissociation of a p65/p50 hetrodimer from 1-k B followed by a translocation of NF-k B to the  
cell nucleus and recognition of target DNA sequences present in both cellular and viral 
genes. It binds to the long terminal repeat (LTR) sequence of the HIV promoter resulting in 
increased transcription and expression (Butera et al., 1993). T N F a  stimulates HIV-1 
replication by binding to the TNF-R1 but not the TN F -R 2 (Butera et al., 1993). Similarly IL- 
1(3 binding to the IL-1R1 rather than the IL-1R2 stimulates HIV-1 transcription through 
activation of NF-k B (Osborn et al., 1989, Poli et al., 1994). IL-13 inhibits HIV-1 replication 
during and after viral transcription in primary human m acrophages but not in peripheral 
blood lymphocytes (M ontagnier et al., 1993). IFN-a, p, y  w ere found to reduce HIV-1 
replication and to inhibit viral assembly and budding (Biswas et al., 1992).
1.10. AIMS OF PROJECT
The initial aims of the project w ere to develop a specific T  cell line to exam ine C D 80  
modulation on human monocytes and the effect of HIV infection. The  lack of success in 
establishing a specific T  cell line caused a change direction.
The new aim of this project w as to exam ine the effects of immune complexes on 
m ononuclear phagocytes (M Ps) and the influence of H IV and HIV-derived proteins on these  
effects. To m eet these aims, various types of immune complex w ere used at different 
concentrations including complexes comprising HIV-derived antigens and specific 
antibodies. The effect of their presence on M Ps surface antigen expression and cytokine 
production w ere exam ined in HIV-infected and non-infected monocytic cell lines and 
peripheral blood monocytes.
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2.0. MATERIALS and METHODS
2.1. MATERIALS
2.1.1. Chemicals and reagents
Chemicals, reagents and their suppliers used in this study are listed in Appendix B 
(page169).
2.2. METHODS
2.2.1. General Tissue Culture Methods
2.2.1.1. Heat inactivated foetal calf serum
All foetal calf serum (TC S  Biological Ltd, Claydon, Buckingham, UK) and human  
serum from pooled, male, AB plasma (Sigm a Chemical Co. Ltd, Poole, UK) w ere heat 
inactivated in a w ater bath (56°C, 30  minutes) and aliquoted in 50ml centrifuge tubes. The  
sera were stored at -20°C  until use.
2.2.1.2. Maintenance of cell lines
The B95-8 cells w ere obtained from the European Collection of Animal Cell Cultures, 
Porton Down, Wiltshire, UK. These cells release high titres of transforming Epstein-Barr 
virus (EBV) which was used to establish continuous lymphocyte lines from human donors. 
The human monocytic cell line THP-1 (Tsuchiya et al., 1980) was obtained from the sam e  
place. H9 cells, Hum an T-lymphocytic H9 cells (Popovic et al., 1984), originally derived from  
the H U T78 cell line, w ere obtained from the M RC A ID S Directed Programme. The Mono 
M ac 6-cell line established from the peripheral blood of a 64-year-old male with acute  
monocytic leukaem ia was obtained from the Germ an cell culture collection, Munich, 
Germ any, (Ziegler-Heitbrock et al., 1988). The cells w ere maintained in exponential growth 
phase by frequent sub-culturing into Roswell Park Memorial Institute 1640 (RPM i 1640) cell 
culture medium (Sigm a Chemical Co. Ltd, Poole, Dorest, UK) containing 10%  foetal calf 
serum (TCS Biological Ltd, Claydon, Buckingham, UK) or 10%  human serum from male AB
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plasma (complete RPM I-10AB; Sigm a Chemical Co. Ltd, Poole, UK), 200m M  L-glutamine 
(Sigma Chemical Co. Ltd, Poole, Dorest, UK) and 10mL penicillin-streptomycin solution 
(10 ,000  units penicillin and 10mg streptomycin per ml; Sigm a Chemical Co. Ltd, Poole, 
Dorest, UK). In long-term cultures the medium was supplemented with 80fj.g/ml Kanamycin  
(Sigm a Chemical Co. Ltd, Poole, Dorest, UK). All the cell lines used w ere grown in 
suspension and w ere sub-cultured at 3 -4  day intervals by dilution of the cells to a 
concentration of 2 x  105 /ml.
Cell lines w ere frozen and stored in liquid nitrogen at a concentration in excess of 1 
x 107/ml, using 70%  R P M I-1640 medium. 20%  foetal calf serum and either 10%  glycerol 
(for THP-1 cells; BHD Chemicals Ltd, Poole, Dorest, UK) or 10%  D M S O  (Sigm a Chemical 
Co. Ltd, Dorest, UK) as a sterile filtered, cryopreservant. W hen the cells were required, they 
w ere quickly defrosted, carefully diluted using complete medium (at 37°C) and centrifuged 
(200g /3  mins). The cells w ere resuspended in fresh complete medium and transferred to a 
37°C / 5%  C 0 2, humidified incubator. This procedure was designed to minimise the 
exposure of the ceils to the toxic cyropreservatives.
2.2.1.3. Isolation of peripheral blood mononuclear cells (PBMCs)
Human peripheral blood w as collected into a tube containing sufficient heparin to 
give a final concentration of 10U/m l (Sigm a Chemical Co. Ltd, Poole, Dorest, UK). The  
blood w as diluted using an equal volume of R P M I-1640 medium. Twelve millilitre volumes of 
‘Lymphoprep’ (Nycomed Ltd, Sheldon, Birmingham, UK) w ere pipetted into an appropriate 
num ber of 50-ml Nunc centrifuge tubes (Becton Dickinson UK Ltd, Coweley, Oxford, UK). 
Each tube was tilted to allow the diluted blood to be carefully layered onto the ‘Lymphoprep’ 
at a 3:1 ratio respectively. The tubes w ere centrifuged at 200g  for 30  minutes. The  majority 
of the medium above the ‘interface layer’ was removed and discarded. The ‘interface layer’ 
w as collected (using a sterile plastic Pasteur pipette) and twice washed using R P M I-1640  
medium (200g / 5 mins).
2.2.1.4. Culturing human monocyte-derived macrophages
Hum an peripheral blood m ononuclear cells w ere isolated as described in Section
2 .2 .1 .3  and w ere pipetted at 1 x 106/ml in 24-well plates which w ere incubated for 2 hours at
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37°C/  5%  C 0 2. The plates were washed with R P M I-1640  medium using sterile Pasture  
pipettes and incubated with 2ml complete RPM I- 10AB medium in each well.
2.2.1.5. Determination of viable cell concentration
The Trypan Blue dye exclusion test w as used to estimate the viable cell count. Equal 
volumes of the cell suspension and 0 .2%  Trypan Blue solution (2%  v/v in PBS; Sigm a  
Chemical Co. Ltd, Poole, Dorest, UK) w ere mixed and viable counts performed using an 
Improved Neubauer haemocytometer. Adherent cells were obtained by “cold-shock” 
(exposure to -20°C  for up to 3 minutes) prior to counting using the haemocytometer.
2.3. PRODUCTION OF Epstein-Barr VIRUS (EBV) AND GENERATION 
OF B-CELL LINES
2.3 .1 . Production of Epstein-Barr Virus (EBV)
B95-8 cells at a concentration of 1 x106/ml w ere incubated for 3 days in a humidified 
incubator (37°C, 5%  C 0 2>. The cells w ere over 90%  viable as determined by trypan blue 
exclusion. The cells w ere centrifuged for 10 minutes (200g, 4°C) and the supernatant 
containing EBV w as filtered using a 0 .20-pm  filter. Aliquots (2 .5 ml) w ere stored at -130°C  
liquid nitrogen.
2.3.1.1. Labelling mononuclear cells using MACS
Mononuclear cells (obtained as described in Section 2 .2 .1 .3 ) w ere washed using 5ml 
ice cold PBS containing 5m M ED TA  plus 1% FCS. The cells w ere resuspended in 80pl of 
ice cold buffer and 20pil of the M A C S anti-CD3 microbeads (Miltenyi Biotec. Inc, Sunnyvale, 
USA) per 107 m ononuclear cells w as added. A fter gentle mixing, the cells w ere incubated at 
6°C in the dark for exactly 15 minutes. The cells were centrifuged (200g) once and w ere  
resuspended in 1-ml cold buffer for immediate separation using the MACS.
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2.3.1.2. Separating mononuclear cells stained with magnetic beads
An A2 column fitted with a 25G  needle and side attached syringe w as used for the 
separation. The column was w ashed with several volumes of ice cold buffer and filled with 
buffer for approximately half an hour before separation of the cells. The mononuclear cell 
suspension (Section 2 .2 .1 .3 ) was loaded at the top of the column under sterile conditions 
immediately after m agnetic staining. The effluent cells w ere collected as the “non-m agnetic 
fraction” (B-lymphocytes and monocytes) after rinsing the column several time with ice-cold 
buffer. The 25G  needle w as changed to a 22G  “washing needle” and the columns flushed 
with ice cold buffer (the “wash fraction”). The column was removed from the m agnetic field 
and rinsed several times with ice cold buffer to collect the “m agnetic fraction” (T  
lymphocytes). The three fractions w ere centrifuged (200g; 5min); the supernatant decanted  
and 2.5m l complete R P M I-1640  medium added to each fraction. A viability count w as  
performed and the B cell fraction w as transferred into a 50ml Nunc centrifuge tube and  
2.5m l of culture supernatant from B 95-8 cells (containing EBV) w as added. A fter incubation 
for 2 hours in a 37°C w ater bath, a further 5 ml complete R P M I-1640  medium w as added,
10 ml of the cell suspension w as transferred to 25  cm2 vented cell culture flask and 
incubated at 37°C, 5%  C 0 2. A fter 3 -4  days, the suspension cells w ere diluted to a 
concentration of 5 x 105/ml and split betw een two, 25  cm2 vented cell culture flasks. The B 
lymphocyte cells transformed by EBV (B-transformed cells) w ere expanded into 75cm 2 
flasks then cryopreserved at -130°C  as described in Section 2 .2 .1 .2 .
2.3.1.3. METHODS FOR MEASURING CELLULAR PROLIFERATION
A solution of 3-[4,5-dimethylthiazol-2-yl3~2,5-diphenyltetrazolium bromide 
(MTT; Sigm a Chem ical Co. Ltd, Poole, Dorest, UK) was prepared by dissolving sufficient 
compound in PBS to give a final concentration of 5mg/ml. The solution was warm ed to 37°C  
to dissolve the MTT, and passed through a 0 .2-pM  filter. Shortly before use, pyruvic acid 
(S igm a Chemical Co. Ltd, Poole, Dorset, UK) w as admixed to give a final concentration of 
1mM. A 50-pJ volume of this solution w as added to each well on plates to be assayed for 
cellular proliferation and incubated for 3 hours (37°C / 5%  C 0 2). Dark Form azan crystals 
could be observed in wells contains live cells. The plates w ere centrifuged at 400g  for 
5minutes and the supernatant removed.
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Fifty microlitres of D M S O  w as added to every well, and the contents w ere mixed 
using a multichannel pipette, to dissolve any form azan crystals. The plates w ere agitated on 
a plate shaker (Model R100, Luckhams) for 5minutes and the optical density at 540nm  was  
recorded for each well using a Shim adzu, UV-1201 spectrophotometer.
2.4. LONG TERM HUMAN CELL LINE PRODUCTION
Hum an peripheral blood m ononuclear cells stimulated with adjuvant peptide (P PD ) 
and Bacilli Calm ette-Guerin (BCG ) w ere used in an attem pt to develop antigen-specific T  
cell lines.
2.4.1. Preparation of Live BCG Stocks
Previously cultured BCG (1ml) w as added to 17ml sterile middlebrook 7H 9  broth plus 
2ml-middlebrook O A D C  enrichment broth (Difico Laboratories Ltd, W es t Molesey, Surrey, 
UK) in a 25cm 2-vented tissue culture flask. The BCG culture was grown at 37°C and  
passaged every 7 days. A stock culture w as produced by growing the organism to density, 
which gave an absorbence of 0.1 at 280nm  using a Shim adzu, UV-1201  
spectrophotometer.
2.4.1.1. Determination of the optimal concentrations of PPD and BCG
Hum an m ononuclear cells at 4  x 106/m L obtained as described in Section 2 .2 .1 .3  
w ere incubated at an optimum concentration determined in preliminary experiments at 
8 x  105 cells/well with P P D  (0, 10, 20, 30, 40, and 50p.g/ml) or BCG (dilution of stock 
solution 0, 1:2, 1:4, 1:8, 1:16, and 1:32). The plates w ere incubated at 37°C, 5%  C 0 2for 7 
days and cellular proliferation assayed as described in Section 2 .3 .1 .3 .
2.4.1.2. Production of antigen specific T-cells using PPD
PBM NC w ere isolated as described in Section 2 .2 .1 .3  and re-suspended in complete 
R P M I-1640  medium with 80jig /m l kanamycin solution, 25m M  Hepes buffer, 200m M  L- 
glutamine and 10%  human serum from male AB plasma (complete R PM I-10A B). The
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mononuclear cells w ere w ashed with R P M I-1640  medium (200g; 10mins) suspended in 
complete RPM I-10A B  medium and a viable count w as obtained (Section 2 .2 .1 .5 ). Two  
millilitres of mononuclear cells (2 x  106 /m l) w ere placed in each well of a 24-well microtitre 
plate with enough P P D  suspension (Sigm a Chemical Co. Ltd, Poole, Dorest, UK) 
suspension to give a final concentration of 10pg/ml. The plates w ere incubated at 37°C / 5%  
C 0 2 for 7 days. On day 3, one millilitre of supernatant was removed from each well and 
replaced with one millilitre fresh complete R PM I-10A B  medium and 30U /m l of recombinant 
interleukin 2 (rlL-2, R&D System s Europe Ltd, Abingdon, UK). The  latter was also added  
every following alternate w eek  of culture. EBV-transform ed B cells from the sam e donor 
w ere incubated for 1 hour in mytomycin C solution (25pg/ml; Sigm a Chemical Co. Ltd,
Poole, Dorest, UK), washed three times in complete R PM I-10A B  medium (200g; 5mins) and 
re-suspended. The  m ononuclear cells incubated with PPD  for 7 days w ere layered on 
Lymphoprep, centrifuged for 30 minutes (200g), washed twice with R PM I-10A B  medium  
(200g; 5mins) and assayed for viability (Section 2 .2 .1 .5 ). Mytomycin C-treated B cells (2 x  
106 /ml) w ere mixed with 1 x 106 /ml autologous antigen specific T-cells and 200pl of the  
mixed cells were aliquoted in 96-well plates that w ere incubated a t 37°C/ 5%  C 0 2. O n day  
3, 50ptl of supernatant was removed and 50^1 of complete R PM I-10A B  medium was added  
to 96-well plates without rlL-2 (added only on alternate weeks).
A spectrophotometer (Shim adzu U V -1201) was used to determ ine the protein 
concentration of BCG solutions by measuring the optical density at 280nm  each time BCG  
was added to the cultures. The  BCG dilution used was the one with an absorbance of 0.1 
as determined in Section 2 .4 .1 .1 .
2.5. THE EFFECT OF CYTOKINES AND ACTIVE METABOLITES
2.5.1. Effect of cytokines and other stimulators on MM6 cells
Mono M ac 6 cells (M M 6 cells) at 2 x  105/ml were incubated (37°C / 5%  C 0 2) in 96- 
well round-bottomed plates for 3, 5, and 7  days. W ells w ere supplem ented with cytokines or 
other stimulators to give the following final concentrations: -
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PMA
(ng/ml)
VitD3
(M)
RIFN-y
(U/ml)
rM-CSF
(ng/ml)
rGM-CSF
(ng/ml)
rlL-6
(ng/ml)
rlL-10
(ng/ml)
TNF-a
(ng/ml)
1 10“' 10 1 1 0.05 0.05 0.05
5 10'e 50 5 5 0.1 0.1 0.1
10 10'b 100 10 10 0.5 0.5 0.5
30 - - 20 20 1 1 1
50 - - 30 30 5 5 5
Cells w ere assayed as described in Section 2 .3 .1 .3 . In some assays, cellular proliferation 
w as measured by tritiated thymidine incorporation as described in Section 2 .5.1 .1
2.5.1.1. Detecting MM6 cells proliferation using tritiated thymide (hf-TdR)
To each well of a 96-well plate containing stimulated cells w as added 10pJ of RPM I- 
1640 medium containing 1 jnCi H3-TdR  (Amersham Life Science, Little Chalfont, 
Buckinghamshire, UK). The  plates w ere incubated for 4hrs (37°C / 5%  C 0 2) and the cells 
harvested cells on to fibre glass filter discs (W hatm an International Ltd, Maidstone, UK) 
using an ILACON cell harvester. Each disc w as placed in a scintillation vial (W allac  
Scintillation products, Milton Keynes, UK) to dry and 4m L scintillation fluid (W allac  
Scintillation Products, Milton Keynes, UK) added. The associated radioactivity was  
m easured using a W allac  1410  Liquid Scintillation counter.
2.6. DETECTION OF SURFACE ANTIGEN EXPRESSION USING 
FLOW CYTOMETRY
All flow cytometric analyses w ere performed using a Becton Dickinson FACScan  
(Becton Dickinson UK Ltd, Cow eley, Oxford, UK) equipped with an argon ion laser (488nm; 
15m W ) and FACScan research software.
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2.6.1. Detection of surface antigen expression
PBM N C  w ere obtained as described in Section 2 .2 .1 .3 . Cells w ere resuspended at 
0.5-1 x 106 /ml in PBS and 100pl aliquots w ere mixed with appropriate volumes of 
monoclonal antibodies in FACScan tubes. Control cells w ere incubated with 10-pl mouse 
lgG 1-F lTC / mouse lgG 2a-P E  dual tag (Sigm a Chemical CO. Ltd, Poole, Dorest, UK). Test 
cells w ere stained with C D 3-P E  (1 Opil; S igm a Chemicals CO. Ltd, Poole, Dorest, UK) and 
C D 28-F ITC  (10pl; Sigm a Chem icals CO. Ltd, Poole, Dorest, UK). Tubes w ere incubated at 
4°C for 1 hr in the dark, w ere washed twice in PBS (200g/5m inutes; 4°C) and resuspended  
in 0.5m l cold PB S containing 2%  form aldehyde. The tubes w ere left on ice before being 
analysed by flow cytometry.
2.6.1.1. Effect of cytokines and other stimulators on surface antigen 
expression.
PBM NC w ere isolated as described in Section 2 .2 .1 .3  and 2 .2 .1 .4 . Hum an peripheral 
blood mononuclear cells or M M 6 cells w ere resuspended in R P M I-1640  complete medium  
at 2 x 105/ml and incubated in 25cm 2 vented tissue culture flasks with the concentrations of 
cytokines and stimulators shown below: -
PMA
(ng/ml)
VitD3
(M)
RIFN-y
(U/ml)
rM-CSF
(ng/ml)
rGM-CSF
(ng/ml)
RlL-6
(ng/ml)
rlL-10
(ng/ml)
RTNFa
(ng/ml)
10 1E-07 10 1 1 0 .05 1 0 .05
- - - 30 30 - - -
Flasks w ere incubated for 3, 5, and 7 days. Hum an monocyte-derived m acrophages w ere  
gently removed from the flask using a scraper (Marathon Laboratory Supplies, London, UK) 
and the cells w ere washed twice (200g, 5mins). M M 6 cells w ere washed similarly. Cells 
w ere stained for surface antigens as described in Section 2 .6 .1 . The following antibody 
combination w ere used at 10pl/m L for each antibody: -C D 1 6-F IT C / C D 80-P E  (Becton 
Dickinson UK Ltd, Coweley, Oxford, UK); C D 11c-F ITC / C D 23 -P E  (Sigm a Chemicals CO.
Ltd, Poole, Dorest, UK /  Becton Dickinson Ltd, Coweley, Oxford, UK); C D 14-F IT C / HLA -DR - 
PE (Becton Dickinson UK Ltd, Coweley, Oxford, UK); mouse lgG 1-F ITC / mouse lgG 2a-P E  
dual tag and mouse lgG 1-FITC /m ouse IgM -R -PE dual tag (Sigm a Chemicals CO. Ltd,
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Poole, Dorest, UK). The cells w ere incubated at 4°C for 1 hr in the dark, washed twice with 
cold PBS (200g, 5mins, 4°C), re-suspended in 0.5m l cold PBS and left on ice until analysed  
by flow cytometry.
2.6.1.2. Assessing viabiiity using propidium iodide
The viability of cells treated with cytokines or other stimulators w as assessed using 
propidium iodide. A fter incubation as described in Section 2 .5 .1 .1 , the cells w ere counted  
and aliquotted at approximately 0 .5 -1x106/m L in FACScan tubes. Th e  cells w ere washed  
twice using sterile PBS at room tem perature (200g, 5mins) and re-suspended in 900jxl 
sterile PBS at room tem perature. O ne hundred microlitres propidium iodide (400]ag/ml; 
Sigm a Chemical Co. Ltd, Poole, Dorest, UK) was added to each tube and incubated (37°C / 
5%  C 0 2) for 30minutes. The cells w ere analysed immediately using the FACScan.
2.7. CYTOKINE RELEASE BY IMMUNE COMPLEX STIMULATION OF
HUMAN BLOOD
W hole blood w as treated for various lengths of time with immune complexes and the 
resulting cytokine release w as assayed.
2.7.1. Optimisation of keyhole limpet hemocyanin (KLH)-containing immune 
complexes
A doubling dilution series using 20pl of rabbit antiserum to KLH in PBS (10.05m g/m l, 
Organon Teknika Cappel Co. Durham, NC, USA) was carried out in a 96-round bottom  
plate. To each well was added 2 0 j l l I  of KLH suspension in R P M I-1640  (10mg/ml; Sigm a  
Chemical Co.Ltd, Poole, Dorest, UK) and the plate was incubated at 4°C overnight. W ells  
w ere exam ined for the presence of precipitate and the dilution below the last well containing 
visible precipitate (1 :8) w as chosen. A sub agglutination titre of 1 :32 w as used also in 
experiments.
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2.7.1.1. Effect of KLH-containing immune complexes on human blood
Hum an peripheral blood w as collected in a 50ml syringe (Becton Dickinson UK Ltd, 
Cow eley, Oxford, UK) containing enough endotoxin-free heparin to give a final 
concentration of 10U/m l (Leo Laboratories Ltd, Risborough, Buckinghamshire, UK). O ne- 
millilitre aliquots of heparinised blood w ere pipetted into endotoxin-free cryovials. To control 
tubes was added 50pl of R P M I-1640  medium. Test vials were supplemented with 50pJ of 
either the 1:8 or the 1:32 dilution of KLH immune complexes, antibody alone or antigen  
alone. These cryovials w ere incubated for 0 .5 , 2, 4, 8 and 12 hours at 37°C / 5%  C 0 2. The  
tubes w ere centrifuged (800g; 5mins) and the serum collected using endotoxin-free gilson 
pipette tips. The serum was immediately frozen at -20°C until analysed by ELISA for 
cytokine production.
2.7.1.2. Preparation of stock rabbit or goat anti-human serum and rabbit or 
goat serum solutions.
Under sterile and endotoxin-free conditions, two dilutions of rabbit or goat anti­
hum an serum and rabbit or goat sera (1:50 and 1:100, Sigma Chemicals C O  Ltd, Poole, 
Dorest, UK) w ere prepared in R P M I-1640. The dilution’s w ere prepared in endotoxin free  
vials and stored a t 4°C for use in experiments.
2.7.1.3. Determination of the effect of in situ formed rabbit or goat antihuman 
Ig-human Ig complexes.
Blood w as collected as described in Section 2 .7 .1 .1 . Control tubes were  
supplemented with 1 0 - j l l I  com plete R P M I-1640  medium or 10pl of a 1:50 (or a 1:100) dilution 
of goat (or rabbit) serum. Test vials w ere supplemented with 10f.il of a 1:50 or a 1:100  
dilution of rabbit or goat anti-hum an immunoglobulin alone or with the sam e dilutions of a 
non-immune rabbit or goat serum. These cryovials w ere incubated for 0.5, 2, 4, 8, 12 and 
16 hours (37°C / 5%  C 0 2) centrifuged (800g; 5mins) and the serum collected and stored as 
described in Section 2 .7 .1 .1 .
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2.7.1.4. Detecting immune complexes in human blood using the FACScan
Hum an peripheral blood w as collected and prepared as described in Section 2 .7 .1 .1 . 
To control cryovials w as added either 10pl or 50pl of R P M I-1640 medium and to test 
cryovials, either 10pl or 50pl of rabbit or goat anti-human serum, or rabbit or goat non- 
immune sera (dilutions 1:50 or 1:100). These cryovials w ere incubated for 30 mins (37°C / 
5%  C 0 2). To prepare a control for FACScan analysis, 100pl of the samples w ere incubated  
with 10pl of either a 1:10 or a 1:20 dilution of monoclonal mouse lgG 1-F ITC / mouse lgG 2a- 
R -P E  Dual TA G  (Sigm a Chem icals CO . Ltd, Poole, Dorest, UK). Experimental samples 
were prepared by incubating 10Opil of each sample with 10pl of either 1:10 or 1:20 dilution 
of monoclonal mouse anti-goat IgG -F ITC  conjugate (Sigma Chemical CO . Ltd, Poole,
Dorest, UK), or monoclonal anti-rabbit-IgG FITC  conjugate (Sigm a Chemical CO. Ltd, Poole, 
Dorest, UK) as appropriate. The  tubes w ere gently vortexes and incubated (30mins) at room 
tem perature in the dark. Two millilitres of 1 x FACS lysing solution (Becton Dickinson UK  
Ltd, Coweley, Oxford, UK) w as added to each tube, gently vortexes and incubated for 10 
minutes at room tem perature in the dark. Tubes w ere centrifuged for 5minutes at 200g , the 
supernatant decanted and 2ml sterile PBS added. Tubes w ere centrifuged for 5minutes at 
200g, the supernatant decanted and the pellets re-suspended in Facsflow containing 1%  
v/v form aldehyde solution (BDH Chem icals Ltd, Poole, Dorest, UK). The samples w ere left 
at room tem perature until being analysed using the FACScan.
2.7.1.5. Preparation of rHIV-1 gp120 immune complexes
Com plexes containing HIV proteins w ere prepared in endotoxin-free cryovials as 
described in Section 2.7.1 using a 1:8 dilution of rabbit anti-serum to rHIV-1 MN gp120  
(M CR A ID S  Directed Programme, Potters Bars, Herts, UK) and a 1:8 dilution of sheep anti­
serum to rHIV-1 IIIB gp120 (CHO; M C R  A ID S  Directed Program m e, Potters Bars, Herts,
UK). The antigens used were rHIV-1 MN gp120 (200pg/mi; Baculovirus; M CR A ID S  Directed 
Programme, Potters Bars, Herts, UK) and rHIV-1 IIIB gp120 (200pg/m l; CHO; M CR A ID S  
Directed Programme, Potters Bars, Herts, UK).
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2.7.1.6. Effect of rHIV-1 gp120 immune compiexes on whoie blood
Hum an peripheral blood was collected in a 50ml syringe containing enough  
endotoxin-free heparin to give a final concentration of 10U/ml and aliquoted (1ml) in 
endotoxin-free cryovials. Control tubes w ere supplem ented with 50pl R P M I-1640  medium  
and test vials with 50jlxI of each of the complexes described Section 2 .7 .1 .5 . These cryovials 
w ere incubated for 8 and 12 hours (37°C/  5%  C 0 2). The tubes w ere centrifuged (800g; 
5minutes) and the serum collected with endotoxin-free gilson pipette tips. Serum w as stored 
at -20°C  until analysed for cytokine production.
2.8. EFFECT OF PREFORMED IMMUNE COMPLEXES ON HIV-1 
INFECTED CELLS
2.8.1. Production and Storage of Virus Stocks
Isolates of HIV-1 RF (A D P103; chronically infected H9 cells; Popovic et al., 1984a) 
and HIV-1 Ba-L (A DP118; a  monocytotropic strain; G artner et al., 1986) w ere obtained from  
the M R C A ID S Directed Programme. Stocks of these HIV-1 strains w ere produced by 
growing the virus in H9, THP-1 and Mono M ac 6 cell lines. Exponentially replicating cells 
w ere counted and approximately 2 x 105 cells w ere transferred to a centrifuged tube. The  
cells w ere pelleted by centrifugation (200g/3m ins) and washed using PBS (200g/3m ins). 
The appropriate strain of H IV  w as removed from storage at -70°C  and quickly defrosted. A  
100-pJ volume of virus suspension w as added to the cell pellet followed by 5ml fresh 
complete medium (without penicillin-streptomycin solution) and transferred to a 25cm 2- 
vented tissue culture flask. The infected cell suspension w as incubated at 37°C / 5%  C 0 2 for 
several days. Cell suspensions w ere observed daily for signs of cytopathic effects and were  
sub-cultured at 3 -4  day intervals by dilution of the ceils to a concentration of 2 x  105/ml. The  
use of K C 57-F ITC  in Sections 2 .8 .1 .1  determined the optimal infection of cells that w ere  
suspensed and transferred to a centrifuge tube and the ceils harvested by centrifugation 
(200g/3m ins). The cells w ere resuspended in 10ml fresh complete medium and incubated  
at 37°C / 5%  C 0 2for a further 2 4  hours. A fter this time, the cells w ere centrifuged  
(200g/3m ins) and 1 ml aliquots of the supernatant were placed in cryovials. Vials w ere  
stored at -70°C until use.
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2.8.1.1. Optimal infection of Mono Mac 6 and THP-1 cell lines
Mono M ac 6 and TH P-1 cell lines w ere infected with HIV-1 RF (H9), and HIV-1 Ba.L 
(H9) strains according to Section 2.8.1 for 3, 5, 10, and 20  days in 25cm 2 vented tissue 
culture flasks. The infected cells w ere harvested (350g/5m ins) and resuspended at 0.5-1 x 
106 viable cells/ ml in FACScan tubes. Cells w ere washed twice with PBS (150g/3m ins); 
resuspended in 80pl PBS and incubated with monoclonal antibodies as in Section 2 .6 .1 .1 .
In addition the monoclonal antibody K C 57-F ITC  (Coulter Immunology Co. Hialeah, FL, USA) 
which binds p24, the core protein of H IV-1, was used to stain cells according to the 
suppliers instruction (see appendix A). The  tubes were incubated at 4°C  for 1 hr in the dark, 
washed twice with cold PBS (200g/3m ins) and resuspended in 0.5m l cold PBS containing 
1-%  v/v form aldehyde. The tubes w ere kept at room tem perature until analysed by flow  
cytometry.
2.8.1.2. Surface antigen expression on human monocyte-derived macrophages
Hum an peripheral blood w as collected in a 50ml syringe containing endotoxin-free 
heparin to give a final concentration of 10U/m l blood. Peripheral blood mononuclear cells 
w ere isolated as described in Section 2 .2 .1 .3  and 2 .2 .1 .4 . The cells w ere washed (200g; 10 
mins) and resuspended in R P M I-10 complete medium before being incubated in 24-wel! 
plates (2ml cell suspension/well) with either 50pl of HIV-1 RF (H9), or HIV-1 Ba-L (H9). The  
plates w ere incubated for 5 days at 37°C/  5%  C 0 2. Monocyte-derived macrophages were  
gently removed by scraping. Cells w ere counted and resuspended at a  concentration of 0 .5  
x 106 viable cells/ ml in FACScan tubes. A fter washing twice with PBS (200g/3m ins), the 
cells w ere resuspended in 80pl PBS and incubated with monoclonal antibodies as 
described in Section 2 .6 .1 .1  The tubes w ere incubated at 4°C for 1 hr in the dark. The cells 
w ere washed twice with cold PBS (200g/3m ins/ 4°C) and resuspended in cold PBS  
containing 1% v/v form aldehyde. The tubes w ere left at room tem perature until being 
analysed by flow cytometry.
2.8.1.3. Preparation of HIV-infected Mono Mac 6 cells for electron microscopy
Mono M ac 6 cells w ere infected with H IV -1RF (H9), and HIV-1 Ba.L (H9) for 10 days as 
described in Section 2 .8 .1 .1 . The  cells w ere washed in PBS (200g/3m ins) and the cell
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pellets w ere transferred to Nunc Eppendorf tubes (Becton Dickinson UK Ltd, Coweley, 
Oxford, UK). G lutaraldehyde (G rade 1, 25%  v/v aqueous stock, Sigm a Chemical Co. Ltd, 
Poole, Dorest, UK) was diluted in PBS (2.5% v/v) and 1mL volumes w ere used to resuspend  
the cell samples. The  cells w ere immediately centrifuged (200g/3m ins). Supernatants w ere  
carefully discarded, with minimum disruption of the pellets, and 1mL (w/v) of 4%  
glutaraldehyde buffer (m ade with 0.1M  sodium cacodylate buffer pH7.4; Haym an Ltd 
W itham , Essex, UK) w as added. The  cells w ere left to fix in glutaraldehyde buffer 1 hour at 
room tem perature with the occasional gentle mixing, then centrifuged (200g/3m ins) and  
resuspended in PBS. A t this point if the samples could not be processed futher they w ere  
stored at room tem perature in fixative buffer (v/v; m ade up of 0 .2M  sodium cacodylate 
buffer at pH7.4, distilled water, 40% -w /v  form aldehyde, and 25% -w /v glutaraldehyde, 
Haym an Ltd W itham , Essex, UK). A fter fixing the cells in glutaraldehyde buffer, the ceils 
are thoroughly washed by decanting and resuspending a num ber of times (3 or 4) in 0 .1M  
sodium cacodylate buffer pH 7.4  over a period of 1hour.
Post-fixation of the cells utilised a 1-hour exposure to 2%  w /v osmium buffer (Sigm a  
Chemical Co. Ltd, Poole, Dorest, UK) at room tem perature in a fum e cupboard. This buffer 
w as prepared from 25m L distilled w ater/g of osmium tetroxide to form osmium acid then  
equal am ount of acid w as mixed with equal am ount of 0 .2M  cacodylate buffer. Cells w ere  
thoroughly w ashed using 3 changes of PBS over a 1-hour period. Cells w ere resuspended  
in increasing concentrations of alcohol (25% , 50% , 75% , 90% , and absolute alcohol 96% ; 
Haym an Ltd, W itham , Essex, UK) a t 20  minutes for each periods (room tem perature). Cells 
w ere centrifuged (200g/3m ins) and the supernatant carefully discarded at each stage. At 
this point the cells can be left overnight (room tem perature) in absolute alcohol if samples 
cannot be processed futher. A fter alcohol treatm ent the samples w ere resuspended in v/v 
Propylene oxide and absolute alcohol (1:1 ratio; Hayman Ltd W itham , Essex, UK) than  
Propylene oxide at 20  minutes for each periods (room tem perature). Cells w ere centrifuged 
(200g/3m ins) and the supernatant carefully discarded at each stage.
The resin w as prepared by mixing 12g Epon 812 (Taab Laboratories Equipment 
Ltd, Aldermaston, Berks, UK), 4 .75g  dodecenylsuccinic anhydride (DDSA; Taab  
Laboratories Equipm ent Ltd, Aldermaston, Berks, UK) and 8 .25g  (2,4,6-tri 
(dimethylaminomethyl) phenol) (MNA; Taab  Laboratories Equipm ent Ltd, Aldermaston, 
Berks, UK) in a polycarbonate beaker using a wooden spatula. Shortly before use, 0 .5g  of 
2,4,6-tris- (dimethylaminomethyl) (D N P-30; Taab  Laboratories Equipm ent Ltd, Aldermaston,
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Berks, UK) w as mixed with the resin. A 2:1 ratio of acetone (Haym an Ltd W itham , Essex, 
UK) to resin was prepared and specim ens w ere exposed to this for 60  minutes at room  
temperature. The cells w ere centrifuged (200g/3m ins) and a 1:2 ratio of acetone to resin 
mixture was carefully added. A fter 60  minutes at room tem perature the samples w ere  
centrifuged (200g/3m ins) and resin alone w as added to every sample, care being taken not 
to disturb the pellets. These w ere maintained at room tem perature for approximately 4  
hours, to allow the resin to penetrate. The samples w ere transferred to an oven, w here the 
resin was cured by incubating at 60°C for 16 hours. Ultrathin sections w ere cut using an  
ultramicrotome and placed onto copper grids. Than each section w ere stained with a drop 
of 2%- w /v uranyl acetate (20 minutes at 60°C) then w ashed with distilled w ater and a drop 
of 4 - mg/ml lead citrate was added on each section and left at room tem perature for 7 
minutes. All samples w ere exam ined using a Phillips T400  transmission electron 
microscope.
2.9. HIV-INFECTED, HUMAN MONOCYTE-DERIVED MACROPHAGES 
AND IMMUNE COMPLEXES
Hum an monocyte-derived m acrophages infected with H IV  w ere incubated with 
immune complexes. Surface antigen expression was analysed by flow cytometry and  
supernatants w ere collected to detect any cytokines released.
2.9.1. Effect of Immune Complexes on HIV-Infected Human Monocyte-Derived 
Macrophages
Hum an peripheral blood was collected in a 50ml syringe containing endotoxin-free  
heparin (final oncentration10U/m! blood). P B M N C  w ere stained as described in Sections
2 .2 .1 .3  and 2 .2 .1 .4 . Cells w ere aliquoted (1ml) in quadruplicate in the wells of a 24-well 
plate. For each complex (described in Sections 2 .7 .1 .2  and 2 .7 .1 .5 ) two wells w ere  
supplem ented with 50pl HIV-1 Ba-L (H 9) and two with 50pl medium. Each plate was  
incubated for 5 days (37°C/ 5%  C 0 2) and the wells washed twice with RPM 1-1640 medium  
using a sterile Pasture pipette. W ells w ere supplemented with 1ml complete R PM I-10  
medium and either 50pl RPM 1-1640 or an immune complex. Preparation was such that H IV-
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infected and control cells w ere each incubated with and without immune complexes.
Identical plates w ere incubated for 8hrs or 12 hours (37°C/ 5%  C 0 2).
Supernatants from each well w ere collected after 8 or 12 hours in cryovials and 
immediately frozen at -20°C  until used to detect the cytokines released by ELISA. Cells 
w ere gently scraped from each well, counted using Trypan Blue and divided between five 
FACScan tubes. Cells w ere analysed for surface antigen expression as described in 
Section 2 .6 .1 .1 .
2.9.1.1. Effect of sera from HIV+ve patients on HIV-infected human monocyte- 
derived macrophages
Hum an peripheral blood w as collected in a 50ml syringe containing endotoxin-free  
heparin (final concentration 10U/m l blood). Peripheral blood mononuclear cells w ere  
collected as described in Section 2 .2 .1 .3  and 2 .2 .1 .4 . Twenty-four well plates w ere  
prepared and treated as described in Section 2.9.1 but instead of the addition of prepared  
immune complexes, 50jil of H IV+sera w as added to each well. Duplicate wells w ere  
supplem ented with 50fil R P M I-1640  medium to act as control.
2.10. ANALYSIS OF CYTOKINE PRODUCTION
Supernatants from stimulated cells w ere analysed for the presence of IL-6, IL-10 and T N F -a  
using "in-house” ELISA assays.
2.10.1. Detecting cytokines using ELISA
The ELISAs performed w ere ‘capture’ assays. The  first antibodies used w ere mouse 
anti-human IL-6 (4fig/ml; M A B206, Serotec Ltd, Kidlington, Oxford, UK), mouse anti-human  
T N F -a  (4fxg/ml; A B 210N A , Serotec), and mouse anti-human IL-10 (8pg/ml; M C A 926, 
Serotec Ltd, Kidlington, Oxford, UK). ELISA plates (96-well flat bottomed plates) w ere  
incubated with 50pl/well of the appropriate first antibody diluted to 4pg/m i in carbonate- 
bicarbonate coating buffer (0 .2M ; pH 9.6). The plates w ere incubated at 4°C overnight, 
washed five times with distilled water, blotted and air-dried. This washing procedure w as  
carried out each time the plates w ere incubated. Plates w ere blocked by incubating 1% w/v
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Marvel dried milk powder in PBS (50jal/well) for 30  minutes at room temperature, and drying 
as before. Test samples w ere diluted 1:4 and 1:8 in 1% w/v Marvel and 50j.il w ere added to 
each well. Plates w ere incubated for 4  hours at room temperature, washed and dried as 
before and incubated with 50pl/well of the appropriate second antibody diluted in 1-%  w/v  
Marvel. The second antibodies used w ere goat anti-human IL-6 (2p.g/ml; A B 206N A , Serotec  
Ltd, Kidlington, Oxford, UK), mouse anti-hum an T N F -a  (2pg/ml; M C A747M , Serotec Ltd, 
Kidlington, Oxford, UK), and goat anti-human IL-10 (8|_ig/ml; 1-5020, Sigma Chemical CO. 
Ltd, Poole, Dorest, UK). Plates w ere incubated for 4  hours at room tem perature, washed  
and dried as before and 50pl/well of the appropriate third antibody was added at a dilution 
of 1:1000 in 1-%  w/v Marvel. Anti-goat IgG alkaline phosphatase conjugate w as used for IL- 
6  and IL-10 (A -2168, Sigm a Chem ical CO . Ltd, Poole, Dorest, UK) whilst anti-mouse IgG  
alkaline phosphatase conjugate w as used for TN F -a (A -4312 , Sigm a Chemical CO. Ltd, 
Poole, Dorest, UK). Plates w ere incubated for 4 hours at room tem perature, w ashed and  
dried as before and 50|il/we!l of p-nitrophenyl phosphate substrate (pNPP, N -1891, S igm a  
Chem ical CO. Ltd, Poole, Dorest, UK) w as added to each well at final concentration of 
1 mg/ml dissolved in distilled water. Plates w ere incubated for 1 hr in the dark at room  
tem perature and w ere read at 405nm  on a spectrophotometer (Labsystems, Basingstoke, 
Hants, UK)
2.11. STATISTICS
The statistical significance of the data was determined using appropriate analysis 
methods and the Statview analytical com puter package. Non-param etric data w as analysed  
using the M ann-W hitney U te s t Param etric data was analysed using a factorialised, 
analysis of variance and Post-hoc Fisher’s tests.
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3.0. RESULTS
3.1. Determination of the optimal concentration of PPD and BCG for 
the production of T cell lines.
Cells w ere stimulated with PPD  and BCG as described in Section 2.4.1 .1  and cellular 
proliferation was m easured using the M TT assay. The results are shown in Figure 3.1A-B.
The concentrations of PPD  and BCG that produced the highest optical density (O .D ) with 
the M TT assay w ere found to be 10|ig/m l (P P D ) and a dilution of 0 .06 2 5  (BCG). However, 
these values w ere not greater than baseline values obtained with non-stimulated cells. 
Stimulation of mononuclear cells with BCG showed no significant effect on cellular 
proliferation m easured by tritiated thymidine incorporation (Section 2 .5.1 .2 ; Figure 3 .1C -D ).
3.1.1. Production of an antigen-specific T-cell line
O ne of the initial aims of the project was to exam ine the effect of immune complexes 
on antigen presentation in H IV  infection. In order to exam ine this, an attempt was m ade to 
establish antigen specific T  cell lines using peripheral blood m ononuclear cells stimulated 
with P P D  (10jj,g/mL) or BCG (dilution at absorbance of o.1). However, the production of 
antigen-specific T  cells, by discontinuous stimulation with either antigen was not successful. 
Initial stimulation produced antigen specific T  cell blasts but the cell count decreased  
thereafter. The use of IL-2 at 10U /m L in discontinuous stimulation did not support T-blast 
formation. Culturing the cells with BCG for 5 or 7 days had no effect on the discontinuous 
stimulation of antigen-specific T-cell lines.
The discontinuous stimulation assay w as repeated 44-tim es for PPD  and BCG. 
Stimulating T  cells with PPD  and with either 10U/m L or 30U /m L IL-2 showed an initial 
difference in T-cell blast numbers but the end result was the sam e as indicated by the exam ple  
of two donors in Table 3.1.
6Q
Table 3.1. Effect of IL-2 concentration on discontinuous stimulation of human T  cells.
W eeks 10U/m L 30U /m L
1 2 x 10® cell/mL 2 x 1 0 ®  cell/mL
2 * 0 .66  x 10® ceil/mL 1.59 x  10® ceil/mL
3 ceils too low to 
detect
4 .44  x  10® cell/mL
4 * 3 .2  x 10® cell/mL
5 cells too low to 
detect
*  = Stimulation of resting cells with IL-2 after they have previously been stimulated with 
PPD.
This indicates that after each stimulant, the cell num ber increased when 30U /m L IL-2 
was used compared to 10U/m L.
T  cells stimulated with BCG w ere also supplemented with 10U/m L IL-2 but different 
feeder cells w ere used and the iL-2 w as added on different days as indicated by the  
exam ple of two donors in Table 3.2.
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A. Determination of the Optimal concentration of PPD for 
stimulation of mononuclear cells proliferation
Concentration of PPD (ng/ml)
B. Determination of the Optimal concentration of BCG for 
stimulation of mononuclear cells proliferation
Dilution of BCG
Figure 3.1 A and B. Determination of the Optimal concentration of PPD and BCG by MTT 
assay
After incubating hum an m ononuclear cells in 96-well plates for 7 days with PPD (A) and BCG  
(B) at various concentrations (37°C /5%  C 0 2), cellular proliferation w as assayed using MTT. 
Form azan crystals were solubilized using D M SO  and the optical density of each well m easured  
at 540nm . The results show the m ean and standard deviation with n=15.
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C. Evaluation of the effect of BCG on the proliferation 
mononuclear cells assested by tritium 
incorporation
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Figure 3.1 C and D. Determination of cellular proliferation using tritiated thymidine 
incorporation
After incubating human mononuclear cells (C) and T-cell blasts (D) in 96-weil plates for 7 
days with BCG at various concentration (37°C /5%  C 0 2) cellular proliferation w as assayed  
using tritiated thymidine incorporation. Form azan crystals w ere solubilized using D M S O  and 
the optical density of each well m easured at 540nm . The results show the m ean and 
standard deviation with n=15
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Table 3.2. Effect of different feeder cells on discontinuous stimulation of human T  cells.
W eeks D onorl Donor2
1 2 x 1 0 fa cell/mL 2 x 1 0 b cell/mL
2 * 1.56 x 1 0 y cell/mL 3 .65  x 10 b cell/mL
3 0 .75  x 1 0 s cell/mL 4 .75  x 10 b cell/mL
4 * 1.3 x 10 & cell/mL 3.3  x 1 0 b cell/mL
5 4 .5  x 1 0 b cell/mL 13.4x 1 0 b cell/mL
6 * 5.1 x  10 5 cell/mL 0.55  x 1 0 b cell/ml
7 9 .0  x 10 b cell/ml cells too low to 
detect
8 * 2 .65  x 1 0 b cell/mL
9 1 . 3 x 1 0 6 cell/mL
1 0 * 2 .8  x  10 b cell/mL
11 1.3 x  10 s cell/mL
* = Stimulation of resting cells with IL-2 after they have previously been stimulated with 
BCG. Feeder cells used for donorl were homologous, EBV transformed B cells and for 
donor 2 were homologous mononuclear cells.
Another technique used to produce T  cell lines w as to stimulate the cells with 
30U /m L IL-2 on day 4 then re-stimulate them with BCG on day 7. In this experim ent the cell 
count gradually decreased from 2 x 10 6 /m L to 1.38 x 10 6 /m L to 0 .37 5  x 10 6 /m L  
respectively. A continuous technique was used in which 30U /m L IL-2 w as added each day 
for one w eek but the result w as similar. W ith ail the techniques used, the sam e pattern was 
observed in that IL-2 addition give a transient increase in T-cell proliferation.
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4.0. IMMUNE COMPLEXES
4.1. EFFECT OF IMMUNUNE COMPLEXES ON HUMAN MONOCYTES 
DERIVED MACROPHAGES IN VITRO
Due to the failure to obtain antigen specific T  cel! lines, the project was adapted to 
look at the effect of immune complexes on human monocytes derived macrophages in 
A IDS. In order to understand the role immune complexes play in A ID S  study the effect of 
immune complexes on normal monocytes to establish normal parameters.
4.2. SURFACE ANTIGEN EXPRESSION AND ITS MODULATION BY 
CYTOKINES AND OTHER STIMULATORS
In order to establish the effect of immune complexes on the phenotypic and 
functional activities of mononuclear phagocytes, it was necessary to establish base-line  
cellular characteristics and how both cytokines and other stimulators may m oderate these.
4.2.1. Effect of cytokines and other stimulators on MM6 cells
Mono Mac 6 cells (M M 6) w ere incubated with cytokines and other stimulators at 
various concentrations to determ ine their effect on cell proliferation and differentiation as 
described in Sections (2 .5 .1 .1 , 2 .5 .1 .2 , and 2 .6 .1 .2 ). Initially an M TT assay was used to 
measure cellular proliferation (Figures 4 .1A -4 .8A ). Subsequently, because the readings with 
M TT appeared to be so low, the experiments were repeated using tritiated thymidine 
(Figures 4 .1B -4.8B ). To determ ine if cytokines and other stimulants w ere inhibiting cellular 
proliferation or being toxic to the cells, the experiment w as repeated again using propidium  
iodide to detect non-viable cells as described in Section 2 .5 .1 .1  (Figures 4 .1C -4 .8C ). The  
effect of the individual treatments is described below.
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4.2.1.1. Phorbol myristate acetate (PMA)
Previous work has shown that PM A induces monocytic differentiation (Ziegler- 
Heitbrock et al., 1994). Cells cultured with PMA showed a significant decrease in respiration 
and therefore proliferation at all concentrations tested, with a profound effect at 10ng/mL, 
30ng/m L, and 50ng/m L on days 5 and 7 (Fishers post hoc test: p< 0 .0001; Figure 4.1 A). 
Similar results w ere obtained using tritiated thymidine to assess cellular proliferation (Figure 
4.1 B, Fishers post hoc test: p< 0 .0001). Analysis using propidium iodide showed a 
Significant rise in the num ber of dam aged cells at the lower concentrations of PMA (Figure 
4.1C , Fishers post hoc test: p<0 .0001). However, at concentrations of 30ng/m L and 
50ng/m L, PMA did not appear to cause cell death.
These results suggest that at 30  and 50ng/m L, PMA inhibited the proliferation of MM 6  
cells by promoting their differentiation into more mature cells that lack the capacity for 
proliferation. It also suggests that PMA, even at low concentration is toxic for rapidly 
proliferating cells.
4.2.1.2. 1,25 dihydroxyvitamin D3 (VitD3)
VitD3 can control the growth and differentiation of several cell types (Oberg et al., 
1993). Using the M TT assay, cells cultured with V itD3 appeared to show a significant 
increase in respiration and therefore proliferation at a concentration of 10'7M/m L after 3 
days in culture (Figure 4.2A ). O ther concentrations of Vit D3 showed no effect. In contrast 
to this, when proliferation w as m easured using the tritiated thymidine assay, VitD3  
significantly inhibited cellular proliferation at all concentrations tested (Figure 4.2B; Fisher 
post hoc test: p<0 .0001). This inhibition appeared to be due in part to a decrease in cell 
viability since propidium iodide incorporation was significantly greater in treated cells than  
controls (Figure 4.2C; Fisher post hoc test: p<0.0001).
Thus, these results suggest that VitD may inhibit cellular proliferation through 
inducing differentiation but that it may also be toxic to M M 6 cells at the concentrations 
tested. Again it appears that it is most toxic in rapidly proliferating cells.
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A. Evaluation of the effect of PMA on the proliferation of MM6
cells using the M TT  assay
Concentration of PMA (ng/mL)
Figure 4.1 A and B. The effect of PMA on the proliferation of MM6 cells
M M 6 cells w ere incubated for 3, 5 and 7 days (37°C /5%  C 0 2) in the presence of a range of 
cytokines and other stimulators and their effect on cell proliferation was assessed using an 
M TT assay (A); tritiated thymidine incorporation (B). Results are expressed as the mean  
and standard deviation with n=15.
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C. Evaluation of the effect of PMA on the viability
of MM6 cells using PI after day 3
Concentration of PMA (ng/mL) 
—
Figure 4.1 C. Effect of propidium iodide on MM6 cell viability
M M 6 cells w ere incubated for 3 days (37°C /5%  C 0 2) in the presence of a range of cytokines 
and other stimulators and their effect on cell viability was assessed using an propidium  
iodide assay (C). Results are expressed as the mean and standard deviation with n=15.
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A. Evaluation the effect of VitD3 on the proliferation of MM6 cells
using the M TT  assay
Concentration of VitD3 (M/mL)
Figure 4.2 A and B. The effect of VitD3 on the proliferation of MM6 cells
M M 6 cells were incubated for 3, 5 and 7 days (37°C/5%  C 0 2) in the presence of a range of 
cytokines and other stimulators and their effect on cell proliferation w as assessed using an 
M TT assay (A); tritiated thymidine incorporation (B). Results are expressed as the mean  
and standard deviation with n=15.
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C. Evaluation of the effect of VitD3 on the viability of MM6 cells
using PI after day 3
0 1 00E-07 1 00E-06 1.00E-05
Concentration of VitD3 (M/mL)
Figure 4.2 C. Effect of propidium iodide on MM6 cell viability
M M 6 cells were incubated for 3 days (37°C /5%  C 0 2) in the presence of a range of cytokines 
and other stimulators and their effect on cell viability was assessed using an propidium  
iodide assay (C). Results are expressed as the mean and standard deviation with n=15.
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4.2.1.3. Interferon gamma (IFN-y)
IFNy induces the differentiation of cells in vitro such that they express characteristics 
of mature monocytes (Ziegler-Heitbrock et al., 1994). IFN-y appeared to have no effect on 
cellular proliferation when assayed using the M TT assay (Figure 4.3A ). However, the 
incorporation of tritiated thymidine w as significantly inhibited by the presence of IFN-y at all 
concentrations tested (Figure 4.3B , Fisher post hoc test: p<0 .0001). This may be due in part 
to a toxic effect of IFN-y on M M 6 cells since propidium iodide incorporation was significantly 
increased at all concentrations tested (Figure 4.3C; Fishers post hoc test: p<0.0001).
These results suggest that IFN-y inhibit cellular proliferation by causing dam age to the 
rapidly proliferating cells.
4.2.1.4. Monocyte colony stimulating factor (M-CSF)
M -C SF has been shown to support the differentiation and survival of cells (Vincent 
et al., 1992). M M 6 cells cultured with M -C S F showed no significant difference in their growth 
characteristics when assayed using M TT (Figure 4.4A). However, when cell proliferation 
w as assessed by tritium incorporation, M -C S F showed a significant inhibitory effect on 
cellular proliferation at all concentrations tested (Figure 4.4B; Fishers post hoc test: 1ng/mL, 
5ng/mL, p<0.0001; 10ng/mL, p=0.0005; 20ng/m L, p=0.0008; 30ng/m L, p=0.0062). 
Propidium iodide incorporation was significantly increased by M -C S F treatm ent at all 
concentrations tested (Figure 4 .4C , Fishers post hoc test: p<0 .0001).
These results suggest that M -C S F cause a decrease in cellular proliferation that may 
be due to toxic effects on the rapidly proliferating cells.
4.2.1.5. Granulocyte-monocyte colony stimulating factor (GM-CSF)
G M -C S F  supports the differentiation and survival of cells (Vincent et al., 1992). M M 6  
cells cultured with G M -C S F  showed significant difference in their growth characteristics at 
day 5 when assayed using M TT except at the 10ng/mL concentration (Figure 4.5A; Fishers 
post hoc test: 1ng/mL, p=0.0268; 5ng/m L, p=0.0079; 20ng/m L, p=0.0001; 30ng/m L, p<. 
0001). However, when cellular proliferation was assessed by tritium incorporation, G M -C S F  
showed an effect on cellular proliferation although it’s not inhibiting proliferation at 1ng/mL,
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A. Evaluation of the effect of rIFN-y on the proliferation of MM6
cells using the M TT  assay
Concentration of rIFN-y (U/mL)
B. Evaluation of the effect of rIFN-y on the proliferation 
of MM6 cells assessed by tritium incoporation 
after day 3
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Figure 4.3 A and B. The effect of IFN-y on the proliferation of MM6 cells
MM6 cells w ere incubated for 3, 5 and 7 days (37°C /5%  C 0 2) in the presence of a range of 
cytokines and other stimulators and their effect on cell proliferation was assessed using an 
MTT assay (A); tritiated thymidine incorporation (B). Results are expressed as the mean  
and standard deviation with n=15.
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C. Evaluation of the effect rlFN-y on the viability of MM6 cells
using PI after day 3
Concentration of rlFN ^ (U/mL)
Figure 4.3 C. Effect of propidium iodide on MM6 cell viability
MM6 cells were incubated for 3 days (37°C /5%  C 0 2) in the presence of a range of cytokines 
and other stimulators and their effect on cell viability was assessed using an propidium  
iodide assay (C). Results are expressed as the mean and standard deviation with n=15.
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A.Evaluation of the effect of M -CSF on the proliferation
of MM6 cells using the M TT  assay
■Day3
Day5
Day7
Concentration of M -CSF (ng/mL)
B. Evaluation of the effect of M -CSF on the proliferation 
of MM6 cells assessed by tritium incorporation 
after day 3
Concentration of M -CSF (ng/mL)
Figure 4.4 A and B. The effect of M-CSF on the proliferation of MM6 cells
M M 6 cells w ere incubated for 3, 5 and 7 days (37°C /5%  C 0 2) in the presence of a range of 
cytokines and other stimulators and their effect on cell proliferation w as assessed using an 
M TT assay (A); tritiated thymidine incorporation (B). Results are expressed as the m ean  
and standard deviation with n=15.
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C. Evaluation of the effect M -CSF on the viability of MM6 cells
using PI after day 3
Concentration of M -CSF (ng/mL)
Figure 4.4 C. Effect of propidium iodide on MM6 cell viability
M M 6 cells were incubated for 3 days (37°C /5%  C 0 2) in the presence of a range of cytokines 
and other stimulators and their effect on cell viability was assessed using an propidium  
iodide assay (C). Results are expressed as the mean and standard deviation with n=15.
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and 5ng/m L (Figure 4.5B; Fishers post hoc test: 1ng/mL, p=0.0158; 5ng/m L, p=0.0169). 
Propidium iodide incorporation w as significantly increased by G M -C S F  treatm ent at all 
concentrations tested (Figure 4 .5C , Fishers post hoc test: p<0 .0001).
These results suggest that G M -C S F  cause cellular differentiation but that the  
decrease in proliferation m ay be due to toxicity.
4.2.1.6. Interleukin-6 (IL-6)
This multifunctional cytokine is synthesised by many different cells after appropriate  
stimulation. It exerts multiple functions during the immune response including 
hematopoiesis, neural differentiation and the acute phase reaction (Schoester et al., 1994). 
M M 6 cells cultured with IL-6 showed a slight increase in proliferation at day 3 and a  
decrease by day 5 when assessed by M TT (except at 1ng/mL and 5ng/m L). This suggest 
that IL-6 promotes growth and differentiation of these cells (Figure 4.6A; Fishers post hoc 
test: 0.05ng/m L, 0.1ng/m L, p<0001; 0.5ng/m L, p=0.0003). However, when ceil proliferation 
w as assessed by tritium incorporation, IL-6 showed no significant effect since the 
proliferation of the non-treated cells w as similar to that of the treated cells (Figure 4.6B ). 
Propidium iodide incorporation w as significantly increased by IL-6 treatm ent at all 
concentrations tested (Figure 4.6C ; Fishers post hoc test: 0 .05ng/m L, 0.1ng/m L, 1ng/mL, 
5ng/mL, p<. 0001; 0.5ng/m L, p=0.0002).
These results suggest that IL-6 m ay have had an effect on cellular proliferation (as 
evidenced by the increase in the M TT assay) but that the inability to detect this as with 
tritium incorporation. This may have been due to the toxic effect of IL-6 as evidenced by the 
increase in cell death.
4.2.1.7. Interleukin-10 (IL-10)
This cytokine is secreted by the ThO and Th1 subsets of C D 4+  and the TsO and Ts1 
subsets of C D 8+  cells, activated B lymphomas, Epstein-Barr virus-transformed Burkitt’s 
lymphoma lines, m onocytes/m acrophages and keratinocytes. IL-10 has pleotropic effects 
on different cell types (Spittler et al., 1995). M M 6 cells cultured with IL-10 showed no overall 
difference in proliferation when assayed using M TT (Figure 4.7A ). However, when cell 
proliferation w as assessed by tritium incorporation, IL-10 showed a significant effect on
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A. Evaluation of the effect of G M -CSF on the proliferation
of MM6 cells using the M TT  assay
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B. Evaluation of the effect of GM -CSF on the proliferation 
of MM6 cells assessed by tritium incorporation 
after day 3
Concentration of G M -CSF (ng/mL)
Figure 4.5 A and B. The effect of GM-CSF on the proliferation of MM6 cells
M M 6 cells were incubated for 3, 5 and 7 days (37°C /5%  C 0 2) in the presence of a range of 
cytokines and other stimulators and their effect on cell proliferation was assessed using an 
M TT assay (A); tritiated thymidine incorporation (B). Results are expressed as the m ean  
and standard deviation with n=15.
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C. Evaluation of the effect of G M -CSF on the viability of MM6
cells using PI after day 3
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Figure 4.5 C. Effect of propidium iodide on MM6 cell viability
M M 6 cells w ere incubated for 3 days (37°C /5%  C 0 2) in the presence of a range of cytokines 
and other stimulators and their effect on cell viability was assessed using an propidium  
iodide assay (C). Results are expressed as the m ean and standard deviation with n=15.
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A. Evaluation of the eeffect of IL-6 on the proliferation of MM6
cells using the M TT  assay
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Figure 4.6 A and B. The effect of IL-6 on the proliferation of MM6 cells
M M 6 cells were incubated for 3, 5 and 7 days (37°C /5%  C 0 2) in the presence of a range of 
cytokines and other stimulators and their effect on cell proliferation was assessed using an 
M TT assay (A); tritiated thymidine incorporation (B). Results are expressed as the m ean  
and standard deviation with n=15.
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C. Evaluation of the effect of IL-6 on the viability of MM6 cells
using PI after day 3
Concentration of IL-6 (ng/mL)
Figure 4.6 C. Effect of propidium iodide on MM6 cell viability
M M 6 cells w ere incubated for 3 days (37°C /5%  C 0 2) in the presence of a range of cytokines 
and other stimulators and their effect on cell viability was assessed using an propidium  
iodide assay (C). Results are expressed as the mean and standard deviation with n=15.
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cell proliferation (Figure 4.7B; Fishers post hoc test: 0.05ng/m L, p=0.04; O .Ing/m L, 
p=0.0048; 0.5ng/m L, p=0.0013; 1ng/mL, 5ng/mL, p<. 0001). Propidium iodide incorporation 
w as significantly increased by IL-10 treatm ent at all concentrations tested (Figure 4.7C , 
Fishers post hoc test: p<. 0001).
These results suggest that IL-10 causes a decrease in cellular proliferation that may 
be in part due to induced differentiation but m ay also be due to cellular dam aged induced  
by the presence in culture of IL-10.
4.2.1.8. Tumour necrosis factor-a (TNF-a)
This cytokine is secreted by activated m onocytes/macrophages and exerts anti­
proliferative effects and leads to differentiation. M M 6 cells cultured with T N F -a  showed a 
significant decrease in proliferation using the M TT assay at day 5 except at 0 .1ng/m L and 
0.5ng/m L (Figure 4.8A; Fishers post hoc test: 0.05ng/m L, 5ng/mL, p<. 0001; 1ng/mL, 
p=0.0466). W hen cell proliferation w as assessed by tritium incorporation, T N F -a  showed a 
tendency to inhibit cellular proliferation which reached significance at 5ng/m L (Figure 4.8B , 
Fishers post hoc test: 5ng/m L, p<. 0001). Propidium iodide incorporation was significantly 
increased by T N F -a  treatm ent at all concentrations tested (Figure 4.8C ; Fishers post hoc 
test: 0.05ng/m L, 0.1ng/m L, 0.5ng/m L, p< 0001; 5ng/mL, p<. 0002).
These results suggest that T N F -a  m ay cause differentiation and a decrease cellular 
proliferation but some of the decrease may be due to the toxic effects of this cytokine. 
Toxicity is less at dose that gives maximal inhibition of proliferation.
4.2.2. Effect of cytokines and other stimulators on surface antigen expression on 
human macrophages and MM6 cells
To determ ine if cytokines or other stimulants cause a change in surface antigen expression 
associated with cellular proliferation or differentiation the following markers w ere exam ined  
C D 80, C D 23, HLA-DR, CD 11c, C D 14  and C D 16.
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A. Evaluation of the effect IL-10 on the proliferation on MM6 cels
using the M TT  assay
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B. Evaluation of the effect of IL-10 on the proliferation of MM6 
cells assessed by tritium incorporation
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Figure 4.7 A and B. The effect of IL-10 on the proliferation of MM6 cells
M M 6 cells were incubated for 3, 5 and 7 days (37°C /5%  C 0 2) in the presence of a range of 
cytokines and other stimulators and their effect on cell proliferation was assessed using 
M TT assay (A); tritiated thymidine incorporation (B). Results are expressed as the m ean  
and standard deviation with n=15.
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C. Evaluation of the effect of IL-10 on the viability of MM6 cells
using PI after day 3
Concentration of IL-10 (ng/mL)
Figure 4.7 C. Effect of propidium iodide on MM6 cell viability
M M 6 cells were incubated for 3 days (37°C /5%  C 0 2) in the presence of a range of cytokines 
and other stimulators and their effect on cell viability was assessed using an propidium  
iodide assay (C). Results are expressed as the mean and standard deviation with n=15.
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A. Evaluation of the effect of TN F -a  on the proliferation
of MM6 cells using the M TT  assay
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B. Evaluation of the effect of TNF-a on the proliferation on MM6 
cells assessed by tritium incorporation 
after day 3
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Figure 4.8 A and B. The effect of TNF-a on the proliferation of MM6 cells
M M 6 cells were incubated for 3, 5 and 7 days (37°C /5%  C 0 2) in the presence of a range of 
cytokines and other stimulators and their effect on cell proliferation was assessed using an 
M TT assay (A); tritiated thymidine incorporation (B). Results are expressed as the mean  
and standard deviation with n=15.
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C. Evaluation of the effect of TNF-<x on the viability of MM6 cells
using PI after day 3
Concentration of TNF-<x (ng/mL)
Figure 4.8 C. Effect of propidium iodide on MM6 cell viability
M M 6 cells w ere incubated for 3 days (37°C /5%  C 0 2) in the presence of a range of cytokines 
and other stimulators and their effect on cell viability was assessed using an propidium  
iodide assay (C). Results are expressed as the mean and standard deviation with n=15.
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4.2.2.1. CD16
C D 16 is expressed at very low levels on monocytes but its expression is greater on 
fully differentiated macrophages. Only 2%  (+1 .8) of control peripheral blood monocytes 
chemicals was not as marked with M M 6 cells which show a higher constitutive expression of 
C D 16  than cultured, control, peripheral blood monocytes (5 .2+ /- 0 .2%  versus 2.1 + /-1 .8%  
Figure 4.9B ). This expression w as particularly significantly increased in cells treated with 
0.05ng /m L T N F a  (p<0.0001); 30ng/m L G M -C S F  (p=0.0002), 10'7M Vit D3 (p=0.0007), 
1ng/m L IL-10 (p=0.0041), 0 .5ng/m L IL-6 (p =0.0099), 1ng/mL M -C S F (p=0.0316), and over 
the whole incubation period. Expression reached a maximum at day 5 with these stimulators 
and thereafter declined.
4.2.2.2. CD80
C D 80 is expressed at very low levels on monocytes but its expression is greater on 
fully stimulated differentiated macrophages. Only 3 .28%  (+1 .21 ) of control peripheral blood 
monocytes incubated for three days exhibited C D 80 (Figure 4 .10A ). This expression w as  
significantly inhibited by PM A on blood monocytes and w as significantly increased by IL-6 
(17 .77  + /- 0.5), IL-10 (19 .58  + /- 0 .95 ) and 0.05m g/m L T N F a  (11 .05  + /- 0 .64). The effect was  
most obvious at day 3, levels of expression falling by days 5 and 7 (Figure 4.10A , Fishers 
post hoc test: 0 .05ng /m L IL-6, 1ng/m L IL-10 and 0 .05ng/m L T N F -a , p< 0001).
The effect of the various cytokines and chemicals was not as marked with M M 6 cells which 
show a lower constitutive expression of C D 80  than cultured control peripheral blood 
monocytes (0 .53  + /- 0 .03  versus 3 .28  + /-1 .21; Figure 4 .1 0B). This expression was  
particularly significantly increased in cells treated with 1ng/mL G M -C S F  (p<0.0001); 
0.05ng /m L IL-6 (p<0.0001); 1ng/m L IL-10 (p<0.0001); 0 .05ng /m L T N F -a  (p <0 .0001) over 
the whole incubation period. Expression reached a maximum at day 5 for IL-10 and  
T N F a  (and thereafter declined) but reached a maximum for IL-6 at day 7.
4.2.2.3. CD11c
C D 11c is expressed at very high levels on monocytes but its expression is greater on fully 
differentiated macrophages. It is also up regulated by inflammatory mediators (Kishimoto et
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A. The effect of cytokines and stimulators on CD16 antigen
expression on peripheral blood monocytes
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B. The effect of cytokines and stimulators on CD16 antigen expression
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Figure 4.9 A and B. The effect of cytokines and stimulators on surface antigen 
expression
Human peripheral blood monocytes (obtained by separation over lymphoprep and 
adherence to plastic) and M M 6 cells were incubated for 3, 5, and 7 days (37°C /5%  C 0 2) 
with a range of cytokines and stimulators. Cells were recovered and were stained with an 
anti-CD16 monoclonal antibody and analysed by flow cytometry. Results are expressed as 
the m ean % cells (± standard deviation) expressing C D 16 with n=5.
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Figure 4.10 A and B. The effect of cytokines and stimulators on surface antigen 
expression
Hum an peripheral blood monocytes (obtained by separation over lymphoprep and 
adherence to plastic) and M M 6 cells were incubated for 3, 5, and 7 days (37°C /5%  C 0 2) 
with a range of cytokines and stimulators. Cells were recovered and w ere stained with an 
anti-CD80 monoclonal antibody and analysed by flow cytometry. Results are expressed as 
the m ean % cells (± standard deviation) expressing C D 80 with n=5.
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al., 1989; Arnaout, 1990; Patarroyo et al., 1990). Control peripheral blood monocytes 
incubated for three days showed a high level of C D 11c expression (72 .12+ 14.65% , 
Figure4.11A). PMA, Vit D3 and I F N y ,  an effect that persisted throughout the experim ent 
significantly inhibited this expression at day 3. After 5 days in culture, IL-6, IL-10 and T N F - a  
had also significantly reduced C D 11c  expression. By contrast, M M 6 cells which show a 
lower constitutive expression of C D 11c  than cultured control peripheral blood monocytes 
(9 .86  + /- 0 .27%  versus 71 .12  + /-14 .65% ; Figure 4.11B ) showed a significant increase in 
C D 11c after 3 days treatm ent with 10ng/ml PMA (p<0.0001) which slowly declined over the  
incubation period. Additionally, IL-6 induced a  significant increase in C D 11c  expression 
after 5 days in culture that rapidly declined thereafter. Unstimulated cells did not show a 
significant change despite the fact that over 7 days in culture monocytes on the 
characteristics of macrophages.
4.2.2A. CD23
C D 23 is expressed by a large variety of hematopoietic cells and is implicated in the 
initiation and developm ent of parasitic and allergic reaction and in the differentiation of cells 
of the myelomonocytic lineage (Dugas et al., 1996). C D 23 is expressed at low levels on 
monocytes but its expression is greater on fully differentiated macrophages. Only 4 .49 %  
(+4 .65) of control peripheral blood monocytes incubated for three days exhibited C D 23  
(Figure 4.12A ). This expression w as significantly increased particularly by 10U/m l I F N - y  
(21 .0  + /- 3 .16% ) and 30ng/m L G M -C S F  (43 .42  + /- 1.11). The effect was most obvious at 
day 3, decreasing with increasing length in culture (Fishers post hoc test: 10U/m L I F N - y ,  
p<0.0001, 30ng/m L G M -C S F, p<0.0001). G M -C S F at 1ng/mL dramatically increased C D 23  
expression at day 7 (19 .66  + /- 0 .64 , Figure 4.12A , p<0.0001).
The effect of the various cytokines and chemicals on M M 6 cell was not as marked as 
with peripheral blood mononuclear cells which showed a lower constitutive expression of 
C D 23 than M M 6 cells (4 .49  + /-0 .5 8 %  versus 7 .22  +/- 0 .43% ; Figure 4 .12  A and B). C D 23  
on M M 6 cells was particularly significantly increased in cells treated with 1ng/mL M -C S F  
(p<0 .0001) and 30ng/m L G M -C S F  (p <0.0001) over the whole incubation period.
Expression, reached a maximum at day 5  for 10U/m L I F N -  y  (p<0 .0001), 1ng/mL M - C S F  
(p<0 .0001), 30ng/m L M - C S F  (p <0 .0001), and 1ng/mL G M - C S F  (p<0 .0001) then declined 
thereafter to day 7 .  IL-6, IL-10 and T N F - a  all inhibited C D 2 3  expression at days 3  and 5 .  At
89
day 7, expression in IL-10 treated cells was enhanced (Fishers post hoc test for change in 
IL-10 expression over the course of the experiment; p<0 .0001).
4 .2 .23 . CD14
The C D 14  antigen is expressed on monocytes and macrophages and w as originally 
identified as a myeloid differentiation antigen also involved in triggering the activation of 
myelomonocytic cells (Bosco et al., 1997). The m ean percentage of cells expressing C D 14  
is higher for fully differentiated macrophages than for monocytes. C D 14  was found to be 
expressed on 88 .5 6  % (±6.87) control peripheral blood cells at (Figure 4.13A ). This 
expression significantly reduced by all cytokines and stimulants tested with the exception of 
M -C S F at a concentration of 1ng/mL. Especially potent w ere PMA (6 .03+0 .59% ), 10'7M/m L  
V itD 3 (60 .88  + /- 2 .16% ), IFN-y (38 .18+ 5 .5% ), 30ng/m L G M -C S F  (28 .22  + /- 0 .66% ),
30ng/m L M -C SF (43 .73+ /- 2 .37% ), and T N F -a  (31 .89+ /- 2 .78 % ) all with p<0.0001 value. 
The effect of PMA w as similar throughout the course of the experiment. The effect of those 
cytokines inducing differentiation e.g. IFN-y, G M -C S F30 and T N F -a  was maximal at day 
seven of culture.
Again the effect of the various cytokines and chemicals on M M 6 cells w as not 
as marked. These cells show a lower constitutive expression of C D 14  than cultured control 
peripheral blood monocytes (12 .33  + /- 0 .52%  versus 88 .56  + /-6 .87% , Figure 4 .13B ). This 
expression w as particularly significantly increased in cells treated with 10ng/m L PMA  
(p<0 .0001) and 10'7M/ml V itD3 (p <0 .0001) for three and five days. A t day 3, the remaining 
cytokines showed a slight inhibitory effect on C D 14 expression. However, by day five, 
significant increases w ere caused by 0.05ng/m l IL-6 (p<0.0001), 1ng/ml IL-10 (p<0.0001), 
0.05ng/m l T N F -a  (p<0.0001), which returned to normal by day 7.
4.2.23. HLA-DR
Figure 4 .14A  and B shows a high level of HLA-DR expression on fully differentiated  
macrophages and on the mature monocyte phenotype, M M 6 cells. As many as 
96 .28 + 2 .6 1 %  of control peripheral blood monocytes incubated for three days exhibited 
HLA-DR (Figure 4.14A ). This expression was significantly decreased after 3 days in culture 
W ith all cytokines and stimulants tested (with the exception of the lower concentrations
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Figure 4.11 A and B. The effect of cytokines and stimulators on surface antigen 
expression
Hum an peripheral blood monocytes (obtained by separation over lymphoprep and 
adherence to plastic) and M M 6 cells w ere incubated for 3, 5, and 7 days (37°C /5%  C 0 2) 
with a range of cytokines and stimulators. Cells were recovered and w ere stained with an 
anti-CD11c monoclonal antibody and analysed by flow cytometry. Results are expressed as 
the m ean % cells (± standard deviation) expressing C D 11c with n=5.
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Figure 4.12 A and B. The effect of cytokines and stimulators on surface antigen 
expression
Hum an peripheral blood monocytes (obtained by separation over lymphoprep and 
adherence to plastic) and M M 6 cells were incubated for 3, 5, and 7 days (37°C /5%  C 0 2) 
with a range of cytokines and stimulators. Cells were recovered and w ere stained with an 
anti-C D 23 monoclonal antibody and analysed by flow cytometry. Results are expressed as 
the m ean % cells (± standard deviation) expressing C D 23 with n=5.
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Figure 4.13 A and B. The effect of cytokines and stimulators on surface antigen 
expression
Hum an peripheral blood monocytes (obtained by separation over lymphoprep and 
adherence to plastic) and M M 6 cells w ere incubated for 3, 5, and 7 days (37°C /5%  C 0 2) 
with a range of cytokines and stimulators. Cells were recovered and w ere stained with an 
anti-CD14 monoclonal antibody and analysed by flow cytometry. Results are expressed as 
the m ean % cells (± standard deviation) expressing C D 14 with n=5.
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Figure 4.14 A and B. The effect of cytokines and stimulators on surface antigen 
expression
Hum an peripheral blood monocytes (obtained by separation over lymphoprep and 
adherence to plastic) and M M 6 cells were incubated for 3, 5, and 7 days (37°C /5%  C 0 2) 
with a range of cytokines and stimulators. Cells were recovered and w ere stained with an 
anti-HLA-DR monoclonal antibody and analysed by flow cytometry. Results are expressed  
as the mean % cells (± standard deviation) expressing HLA-DR with n=5.
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M -C S F and G M -C S F). This effect reached a maximum at day 7 for IFNy and 30ng/m L G M - 
C SF. The effect of the other stimulants either remained constant or diminished with longer 
culture periods.
The effect of the various cytokines and chemicals w as not as marked on M M 6 cells 
which showed a lower constitutive expression of HLA-DR than cultured control peripheral 
blood monocytes (65 .62  + /- 0 .48%  versus 96 .2 8  + /-2 .61% ; Figure 4 .14B ). This expression 
w as decreased after 3 days incubation with PMA, (38 .46  + /-1 .49 ), V itD3 (48 .54+ /-1 .37 ), 
0.05ng /m L IL-6 (37 .19  + /- 0 .47% ), 1ng/m L IL-10 (35 .02  + /- 0 .64% ), 0 .05ng/m L T N F -a  
(39 .17  + /-1 .6 0 % ) the effect remaining constant throughout the period of the experiment. 
The remaining stimulants caused a significant decrease in HLA -DR expression after 5 days 
in culture that becam e less evident by day 7 (Figure 4 .14 , Fishers post hoc test for the time- 
related changes in antigen expression: 10ng/m L PMA, 10'7M /m L VitD3, 10U/m L IFN-y, 
1ng/mL M -CSF, 30ng/m L M -C S F, 1ng/m L G M -C S F, 30ng/m L G M -C S F, 0 .05ng /m L IL-6, 
1ng/mL IL-10, 0 .05ng /m L T N F -a , p<0 .0001).
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5.0. IMMUNE COMPLEX-STIMULATED RELEASE OF 
CYTOKINES FROM HUMAN BLOOD
5.1. KLH-stimulated cytokine release
Hum an blood w as incubated with immune complexes containing KLH for various lengths of 
time. Supernatants w ere analysed for the presence of IL-6, IL-10, and T N F -a  cytokines as 
described in Sections (2.7.1 and 2 .7 .1 .1 ). Cells w ere incubated with immune complexes 
(m ade with higher (Ab1) and lower (Ab2) concentrations of antibody) or with antigen or 
antibody alone as controls.
5.1.1. IL-6
Unfortunately, both the antigen alone and the highest concentration of antibody 
alone stimulated IL-6 production (Figure 5.1 A; Fishers post hoc test (5%  level): p = 0 .0015  
and p<0.0001 respectively). However, the lower concentration of antibody alone did not 
significantly induce IL-6 production. The presence of the immune complexes significantly 
increased the production of IL-6 when compared to non-stimulated controls. The Ab2Ag  
immune complex was the only complex to reached true significance since it caused a  time- 
dependent increase in IL-6 which was significantly greater than that produced by the Ag or 
Ab alone (Table 5.1 shows the Fishers post hoc analysis). The effect was apparent at 4 
hours but increased with time.
Table 5.1: Fishers post hoc analysis at 5%  level for IL-6
Concentrations Mean
Diff
P-value
Control, Abi -82.221 <.0001
Control, AblAg -1 0 6 .26 4 <.0001
Control, Ab2 -2 8 .1 48 0.1591
Control, Ab2Ag -1 04 .543 <.0001
Control, Ag -64 .5 63 0 .0015
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Figure 5.1 A. The effect of Keyhole Limpet Hemocyanin on the IL-6 release in whole 
blood
W hole blood was incubated with a complex comprising Keyhole Limpet Hemocyanin (KLH) 
and rabbit anti-KLH for 0 .5, 2, 4 ,8 , and 12 hours (37°C /5%  C 0 2). A fter incubation the 
supernatant was harvested and analysed for IL-6 (A). Using an ELISA. Ab1=1:4 dilution of 
rabbit anti-KLH; A b2=1:8 dilution of rabbit KLH; A b lA g  or Ab2Ag= immune complexes 
constituted with 1:4 or 1:8 dilution of anti-KLH (n=5).
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Figure 5.1 B. The effect of Keyhole Limpet Hemocyanin on the IL-10 release in whole 
blood
W hole blood was incubated with a complex comprising Keyhole Limpet Hemocyanin (KLH) 
and rabbit anti-KLH for 0 .5, 2, 4 ,8 , and 12 hours (37°C /5%  C 0 2). A fter incubation the 
supernatant was harvested and analysed for IL-10 (B). Using an ELISA. A b1=1:4  dilution of 
rabbit anti-KLH; A b2=1:8 dilution of rabbit KLH; A b lA g  or Ab2Ag= immune complexes 
constituted with 1:4 or 1:8 dilution of KLH (n=5).
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Figure 5.1 C. The effect of Keyhole Limpet Hemocyanin on the TNF-a release in whole 
blood
W hole blood was incubated with a complex comprising Keyhole Limpet Hemocyanin (KLH) 
and rabbit anti-KLH for 0 .5, 2, 4 ,8 , and 12 hours (37°C /5%  C 0 2). After incubation the 
supernatant was harvested and analysed for T N F -a  (C). Using an ELISA. A b1=1:4 dilution 
of rabbit anti-KLH; A b2=1:8 dilution of rabbit KLH; A b lA g  or Ab2Ag= immune complexes 
constituted with 1:4 or 1:8 dilution of KLH (n=5).
99
5.1.2. IL-10
Due to the large standard deviations and the variation in IL-10 detection overtim e, 
no significant effect of the immune complexes on IL-10 production w as detected (Figure 
5.1B).
5.1.3.TNF-a
Both the A b lA g  and the Ab2Ag immune complexes stimulated significant release of 
TN Fa compared to non-stimulated cells (Figure 5.1 C, Fishers post hoc test: p<0.0001 and  
p = 0 .0002  respectively). However, Ab1 and Ag alone also stimulated TN Fa release which 
was significantly higher than in control cells (p=0.015; p<0 .0001) suggesting that the TN Fa 
release seen with the immune complexes may not be complex-dependent.
5.2. Rabbit or goat anti-human IgG immune complex-stimulated 
cytokine release from whole blood.
Hum an blood w as incubated for various times with rabbit or goat anti-human IgG or 
with rabbit or goat serum (as controls) to detect if the complexes form ed in situ stimulated 
the release of IL-6, IL-10 or TN F-a  as described in Sections 2 .7.1.2 and 2 .7.1.3.
5.2.1. IL-6
Despite repetition on several occasions, the release of IL-6 by non-stimulated cells 
w as always greater than any of the treated cells (Figure 5.2). This IL-6 production was  
switched off almost completely in the presence of immune complexes formed in situ with 
both the higher and the lower concentrations of rabbit anti-human IgG (Table 5 .2  shows the 
Fishers post hoc test (5%  level): p<0 .0001). Rabbit serum at lower concentrations inhibited 
IL-6 production (Fishers post hoc test (5%  level): p<0 .0001). IL-6 production was inhibited 
by goat anti-human IgG and goat serum at both concentrations over an 8-hour incubation 
period (Fishers post hoc test (5%  level): p<0 .0001). RS1 caused the release of IL-6 at 
higher concentrations than the control at 4hrs whilst GS1 did not have the sam e effect until 
after 12 hours in culture.
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Figure 5.2 A and B. The effect of rabbit and goat anti-human IgG on release of IL-6 
from whole blood
W hole blood was incubated for 0.5, 2, 4, 8, 12, and 16 hours (37°C /5%  C 0 2) to form  
complexes in the blood using rabbit anti-hum an IgG (Fc specific; A) and goat anti-human  
IgG (Fc specific; B). The supernatant was analysed using ELISA. Two concentrations of 
anti-serum were used i.e.: 1:50(HR1 or H G 1) and 1:100(H R 2 or HG 2). As a control, normal 
rabbit or goat serum (10}iL) was added to the blood. Again two concentrations w ere used 
1:50(RS1 or G S 1) and 1:100(R S 2 o rG S 2 , n=5)
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Table  5.2: Fishers post hoc analysis at 5%  level for IL-6
Concentrations Mean Diff P-value
C, HR1 7 3 .3 7 4 <.0001
C, RS1 -2 .312 0 .6799
HR1, RS1 -7 5 .6 8 7 <.0001
C, HR2 8 0 .525 <.0001
C, RS2 6 5 .7 2 7 <.0001
HR2, RS2 -1 4 .7 98 0 .0088
C, HG1 70 .9 5 5 <.0001
C, GS1 6 8 .6 8 7 <.0001
HG1, GS1 -2 .2 6 8 0 .6857
C, HG2 7 4 .9 2 6 <.0001
C, GS2 6 3 .1 7 6 <.0001
HG2, GS2 -1 1 .7 50 0 .03 7 0
5.2.2. IL-10
Despite repetition on several occasions, the release of IL-10 by non-stimulated cells 
was always high, and in m any cases higher than that of the treated cells (Figure 5 .3). This 
IL-10 production w as reduced in the presence of either rabbit or goat serum, the presence  
of the immune complexes form ed in situ showing a trend towards reversing this inhibition, 
particularly after 8 hours incubation. IL-10 was significantly inhibited by rabbit serum at both 
concentrations (Table 5 .3  shows the Fishers post hoc test (5%  level): p=0.0093; p = 0 .0398) 
and rabbit anti-human IgG reversed this effect.
After 30  minutes incubation, all control cultures showed high levels of IL-10  
production. This w as decreased in the presence of either goat or rabbit serum but this effect 
w as reversed by the presence of in situ form ed complexes.
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Figure 5.3 A and B. The effect of rabbit and goat anti-human IgG on release of IL-10 
from whole blood
W hole blood was incubated for 0.5, 2, 4, 8, 12, and 16 hours (37°C /5%  C 0 2) to form  
complexes in the blood using rabbit anti-human IgG (Fc specific; A) and goat anti-human  
IgG (Fc specific; B). The supernatant was analysed using ELISA. Two concentrations of 
anti-serum w ere used i.e.: 1:50(HR1 or HG 1) and 1:100(HR2 or HG 2). As a control, normal 
rabbit or goat serum (1 0 jjL) was added to the blood. Again two concentrations were used 
1:50(RS1 or G S 1) and 1:100(R S 2 o rG S 2 , n=5).
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Table 5.3: Fishers post hoc analysis at 5%  level for IL-10
Concentrations Mean Diff P-value
C, HR1 2 7 .607 0 .21 1 6
C, RS1 57.795 0 .0093
HR1, RS1 30.188 0.1721
C, HR2 13.896 0 .52 8 9
C, RS2 45 .576 0 .0398
HR2, RS2 31.680 0 .1519
C, HG1 7 8 .553 0 .00 0 4
C, GS1 114.709 <.0001
HG1, GS1 36 .156 0 .1023
C, HG2 88.537 <.0001
C, GS2 107.821 <.0001
HG2, GS2 19.285 0 .3824
5.2 .3 . T N F -a
Despite repetition on several occasions, the release of TN F-a  by non-stimulated 
cells w as not significantly different to the treated cells (Figure 5.4). Fisher’s post hoc 
analysis showed that over the time course examined there w ere significant differences in 
TN Fa production between the control cells and those treated with either serum or in situ 
formed immune complexes. However, owing to the large standard deviations, none of the 
individual observations reached significance. However, the trend was for an increase in 
TN Fa production with increasing time in culture.
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Figure 5.4 A and B. The effect of rabbit and goat anti-human IgG on release of TNF-a 
from whole blood
W hole blood was incubated for 0.5, 2, 4, 8, 12, and 16 hours (37°C /5%  C 0 2) to form  
complexes in the blood using rabbit anti-human IgG (Fc specific; A) and goat anti-human  
IgG (Fc specific; B). The supernatant w as analysed using ELISA. Two concentrations of 
anti-serum w ere used i.e.: 1:50(HR1 or H G 1) and 1:100(H R 2 or HG 2). As a control, normal 
rabbit or goat serum (10pL) w as added to the blood. Again two concentrations w ere used 
1:50(RS1 or G S 1) and 1:100(R S 2 o rG S 2 ; n=5).
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Table 5.4: Fishers post hoc analysis at 5%  level for T N F -a
Concentrations Mean Diff P-value
C, HR1 17.506 0 .37 3 3
C, RS1 45 .4 1 0 0 .02 1 6
HR1, RS1 27 .904 0 .15 6 4
C, HR2 83 .340 <.0001
C, RS2 53.886 0 .00 6 5
HR2, RS2 -2 9 .4 54 0 .1348
C, HG1 105.582 <.0001
C, GS1 78 .5 0 4 <.0001
HG1, GS1 -27 .0 78 0 .1690
C, HG2 101.023 <.0001
C, GS2 96 .736 <.0001
HG2, GS2 -4 .287 0 .8273
5.3. Identification of the ceils binding rabbit or goat anti-human IgG 
containing immune complexes in whole blood using flow cytometry
W hole blood was incubated with various dilutions of either rabbit or goat anti-human  
IgG as test samples and either rabbit or goat sera as controls. Cells w ere assayed by flow  
cytometry in an attem pt to identify to which cell type the complexes w ere binding. As 
described in Section 2 .7 .1 .4 .
5.3.1. Analysis of adherence of complexes to lymphocytes
The results of the analysis are shown in Figure 5.5. Generally, the goat serum and 
the goat complexes bound to lymphocytes more effectively than the rabbit complexes or 
rabbit serum (Fishers post hoc test (5%  level): p<0.0001). Additionally, the complexes (both 
rabbit and goat) bound to more lymphocytes than the serum alone (p<0.0001). The effect 
seem ed to be more pronounced using a 1 /20 dilution of the fluorescent second antibody
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Figure 5.5. Detecting rabbit or goat anti-human IgG on lymphocytes in whole blood
Rabbit or goat anti-human IgG and rabbit or goat serum were incubated for 0 .5  hour 
(37°C /5%  C 0 2) in whole blood to form complexes. The rabbit or goat anti-human IgG (Fc  
specific) was added to whole blood (10pL/m L) at 1:50 and 1:100 dilution (HR1 or HG1 and 
HR2 or HG 2). The rabbit or goat serum (10pL/m L) was added at 1:50 and 1:100 dilution 
(RS1 or GS1 and RS2 or G S 2) respectively. The whole blood w as then incubated with 
either 1:10 or 1:20 dilution of fluorescent antibody (10mins) and the red blood cells were  
lysed with 1x FACS lysing solution for 0 .5  hour. Cells w ere analysed using a FACScan  
(n=5, 10 ,000  events).
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(p<0 .0001) with the goat immune complexes binding most cells at a 1 in 5 000  dilution and 
the rabbit immune complexes showing optimal binding between the 1 /1250  and 1 /2500  
dilutions.
5.3.2. Analysis of adherence of complexes to Monocytes
Adherence of immune complexes to human monocytes was most obvious using the 1/20  
dilution of the fluorescent antibody (Figure 5.6, p<0.0001). At a dilution of 1 /2500 there was  
a clear difference between the effect of the serum and the effect of the immune complexes  
on the monocyte, the complexes showing a significantly higher level of binding than the 
serum Alone (HRvRS: p<0.0001; HG v GS: p=0.0004) The higher level of binding with the 
rabbit complexes and serum might be expected since rabbit antibody will bind to human Fc 
receptors with greater ease than goat antibody.
5.3.3. Analysis of adherence of complexes to Neutrophils
The binding of HR and HG immune complexes to neutrophils w as more evident 
using the 1/10 dilution of the FITC labelled second antibody (Figure 4.7; p<0 .0001). At this 
dilution, a significant difference was seen between HR and RS at the 1 /10000  and the  
1 /1250 dilution of immune complexes. However, the most dramatic effect was observed  
with HG versus G S  at a dilution of 1 /2500  (p<0.0001).
5.4. rHIV-1 gp120-containlng immune complexes release of 
cytokines
Hum an blood was incubated for various lengths of time with the following pre-formed  
immune complexes: rabbit anti-serum to rHIV-1 MN gp120 and rHIV-1 MN gp120; sheep  
anti-serum to rHIV IIIB gp120 (C H O ) and rHIV-1 IIIB gp120 (C HO ). The presence of the 
cytokines IL-6, IL-10, and T N F -a  in the supernatant of these cultures was assayed as 
described in Sections (2 .7 .1 .5  and 2 .7 .1 .6 ).
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Figure 5.6. Detecting rabbit or goat anti-human IgG on monocytes in whole blood
Rabbit or goat anti-human IgG and rabbit or goat serum were incubated for 0 .5 hour 
(37°C /5%  C 0 2) in whole blood to form complexes. The rabbit or goat anti-human IgG (Fc  
specific) was added to whole blood (10}iL/m L) at 1:50 and 1:100 dilution (HR1 or HG1 and  
HR2 or HG2). The rabbit or goat serum (lO ^L/m L) was added at 1:50 and 1:100 dilution 
(RS1 or GS1 and RS2 or G S 2) respectively. The whole blood was then incubated with 
either 1:10 or 1:20 dilution of fluorescent antibody (10mins) and the red blood cells were  
lysed with 1x FACS lysing solution for 0 .5  hour. Cells were analysed using a FACScan  
(n=5, 10 ,000  events).
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Figure 5.7. Detecting rabbit or goat anti-human IgG on neutrophils in whole blood
Rabbit or goat anti-human IgG and rabbit or goat serum w ere incubated for 0 .5  hour 
(37°C /5%  C 0 2) in whole blood to form complexes. The rabbit or goat anti-human IgG (Fc 
specific) was added to whole blood (10pL/m L) at 1:50 and 1:100 dilution (HR1 or HG1 and 
HR2 or HG2). The rabbit or goat serum (10pL/m L) was added at 1:50 and 1:100 dilution 
(RS1 or GS1 and RS2 or G S 2) respectively. The whole blood was then incubated with 
either 1:10 or 1:20 dilution of fluorescent antibody (10mins) and the red blood cells were  
lysed with 1x FACS lysing solution for 0 .5  hour. Cells w ere analysed using a FACScan  
(n=5, 10,000 events).
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5.4.1. Stimulation of IL-6 by HIV protein containing immune complexes in whole blood
Neither MN nor C H O  antigens affected the constitutive release of IL-6 by whole  
blood. (Figures 5 .8  A and B). By contrast, immune complexes containing these antigen  
significantly enhanced the release of IL-6 by whole blood (MN: p=0.005; CHO: p<0.0001). 
The increase was evident after 8 hours culture with the CHO-containing immune complexes 
but w as only significant at 12 hours with the MN containing immune complexes.
5.4.2. Stimulation of IL-10 by HIV protein containing immune complexes in whole blood
Although relatively high levels of IL-10 were detected in the presence of either 
immune complex, similar levels w ere detected in untreated cells. Thus, there was no 
significant effect overall of the immune complexes on IL-10 release by whole blood (Figure 
5.9  A and B)
5.4.3. Stimulation of TN F -a  by HIV protein containing immune complexes in 
whole blood
Neither immune complex had a significant effect on the release of T N F -a  by whole  
blood (Figure 5 .10  A and B). However, this may be due to the fact that the supernatants  
were only analysed after 8 and 12 hours incubation. The slop of the graphs is negative  
suggests that T N F -a  is possibly released earlier and may be switched off by the production 
of IL-6.
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Figure 5.8 A and B. The released of IL-6 from complexes incubated with whole blood
The complexes rHIV-1 MN gp120 anti-HIV-1 gp120 (A) or rHIV-1 IIIB gp120 C H O  anti-HIV-1 
IIIB gp120 C H O  (B) were incubated in whole blood for 8hrs and 12hrs (37°C /5%  C 0 2). After 
incubation the supernatant was harvested and analysed for IL-6 using an ELISA. 
Untreated=no complex added; AbAg=im m une complex formed with a 1:4 dilution of antigen; 
Ag=antigen used at 1:4 dilution (n=5).
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Figure 5.9 A and B. The released of IL-10 from complexes incubated with whole blood
The complexes rHIV-1 MN gp120 anti-HIV-1 gp120 (A) or rHIV-1 IIIB gp120 C H O  anti-HIV-1 
IIIB gp120 C H O  (B) w ere incubated in whole blood for 8hrs and 12hrs (37°C /5%  C 0 2). After 
incubation the supernatant was harvested and analysed for IL-10 using an ELISA. 
Untreated=no complex added; AbAg=im m une complex formed with a 1:4 dilution of antigen; 
Ag=antigen used at 1:4 dilution (n=5).
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Figure 5.10 A and B. The released of TNF-a from complexes incubated with whole 
blood
The complexes rHIV-1 MN gp120 anti-HIV-1 gp120 (A) or rHIV-1 IIIB gp120 C H O  anti-HIV-1 
IIIB gp120 C H O  (B) w ere incubated in whole blood for 8hrs and 12hrs (37°C /5%  C 0 2). After 
incubation the supernatant was harvested and analysed for T N F -a  using an ELISA. 
Untreated=no complex added; AbAg=im m une complex formed with a 1:4 dilution of antigen; 
Ag=antigen used at 1:4 dilution (n=5).
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6.0. INVESTIGATION OF HIV-1 INFECTED CELLS 
INCUBATED WITH PREFORMED IMMUNE COMPLEXES
6.1. HIV-infection of MM6 cells
In order to determine microscopically whether or not M M 6 cells were being 
productively infected with H IV -1Ba-L(H9) and HIV-1 RF(H9), cells w ere incubated for ten days 
with the virus and prepared as described in Sections 2.8.1 .1  and 2 .8 .1 .3 . Figures 6.1 -6. 3  
show that both the Ba-L and RF strains of H IV  have infected M M 6 cells. A small num ber of 
virus particles w ere detected in vacuoles as shown in Figures 6 .2 -6 .3  suggesting a low level 
of virus production. The level of p24 detected by KC57 monoclonal antibody showed a 50%  
increase from day3 to day 5 but from day 5 the level of p24 rem ained the sam e until day 20  
(Figures 6 .5  and 6.6). Microscopically, virus particles could not be observed in infected cells 
until day 10 of culture and the cells appeared similar to controls (Figure 6.1). In Figure 6.1 , a 
non-infected cell shows a normal nucleus with typical cytoplasmic inclusions. However, in 
Figures 6 .2A  and B and 6 .3  numerous large mitochondria can be seen as well as diverse 
vesicles and large vacuoles containing virus and w hat appears to be the break down of the 
nucleolus (Figure 6.3).
6.2. Surface antigen expression on HIV-1 infected of MM6 and THP-1 
cell lines
An initial study was performed using the M M 6 and THP-1 cell lines which were  
incubated for 10 days with H IV -1Ba-L (grown in H9; 200jil) and H IV -1RF (grown in TH P-1; 
100|il) as described in Sections 2.81 and 2 .8 .1 .1 . Surface antigen expression on the cell 
lines was analysed using flow cytometry as described in Section 2 .8 .1 .1 .
6 .2 .1 . C D 16
Less than 10%  of M M 6 cells and about 10%  of THP1 cells expressed the C D  16 
(FcyRIII) antigen. W hen infected with H IV  of either strain, both cell lines showed a
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Figure 6.1. A transmission electron micrograph of a control MM6 cell
M M 6 cells were incubated for 10 days (37°C /5%  C 0 2) then they w ere fixed using 2 .5%  
glutaraldehyde, post-fixed with 4%  glutaraldehyde buffer, and dehydrated through an 
ethanol series. Sam ples w ere em bedded in Epon 812 resin and ultrathin sections w ere cut 
and stained using lead citrate and uranyl acetate. Examination by transmission electron 
microscopy indicated that cells contained a relatively large, lobate nucleus (N) that often 
contained a prominent nucleolus (NE). A thin layer of heterochromatin (H) typically 
surrounded the nucleus. Few  vesicles such as lysosomes (L) and mitochondria (M) could be 
identified in the cytoplasm of most cells, and endoplasmic reticulum (ER) was sparse (x 6  
000).
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Figure 6.2 A. A transmission electron micrograph of a MM6 cell infected with 
HIV-1 ea-L
M M 6 cells w ere incubated with HIV-1 Ba-L for 10 days (37°C /5%  C 0 2) and exponentially 
replicating cells w ere fixed using 2 .5%  glutaraldehyde, post-fixed with 4%  glutaraldehyde  
buffer, and dehydrated through an ethanol series. Samples w ere em bedded in Epon 812  
resin and ultrathin sections were cut and stained using lead citrate and uranyl acetate. 
Examination by transmission electron microscopy indicated that cells contained many 
relatively large, vacuoles (VO ), lysosomes (L), mitochondria (M), endoplasmic reticulum  
(ER) and virus (V) could be identified in the cytoplasm of cells shown (A x 36 000).
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Figure 6.2 B. A transmission electron micrograph of a MM6 cell infected with 
HIV-1 ea-L
M M 6 cells were incubated with HIV-1 Ba-i_ for 10 days (37°C /5%  C 0 2) and exponentially 
replicating cells w ere fixed using 2 .5%  glutaraldehyde, post-fixed with 4%  glutaraldehyde  
buffer, and dehydrated through an ethanol series. Sam ples w ere em bedded in Epon 812  
resin and ultrathin sections w ere cut and stained using lead citrate and uranyl acetate. 
Examination by transmission electron microscopy indicated that cells contained many 
relatively large, vacuoles (VO ), lysosomes (L), mitochondria (M), Golgi vesicles (G), 
endoplasmic reticulum (ER) and virus (V) could be identified in the cytoplasm of cells shown 
(x 36 000).
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Figure 6.3. A transmission electron micrograph of a MM6 cell infected with 
HIV-1 RF
M M 6 cells w ere incubated with HIV-1 RF for 10 days (37°C /5%  C 0 2) exponentially replicating 
cells w ere fixed using 2 .5%  glutaraldehyde, post-fixed with 4%  glutaraldehyde buffer, and 
dehydrated through an ethanol series. Sam ples were em bedded in Epon 812 resin and 
ultrathin sections w ere cut and stained using lead citrate and uranyl acetate. Examination  
by transmission electron microscopy indicated that cells contained many large, vacuoles 
(VO ), lysosome vesicles (L), mitochondria (M), endoplasmic reticulum (ER), virus (V) and 
nuclei material (NM) could be identified in the cytoplasm of cell shown (x 6 000).
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significant increase in the expression of this antigen (Figure 6.4). However, the HIV-1 Ba-L 
had a more profound effect than the RF strain (Fishers post hoc test (5%  level): p<0.0001).
6 .2 .2 . C D 80
Less than 10%  of M M 6 cells and few er than 5%  of THP1 cells expressed the, T  cell 
co-stimulatory antigen C D 80. W hen  infected with HIV (Ba-L), both cell lines showed a 
significant increase in the expression of this antigen (Figure 6 .4). A similar effect w as seen  
with the RF strain but the effect w as greater on THP-1 cells than on MM 6 cells (Fishers post 
hoc test (5%  level): p<0 .0001).
6 .2 .3 . C D 11c
Approximately 10%  of both M M 6 and THP1 cells expressed the C D 11c antigen  
constitutively (Figure 6 .4). W hen infected with either strain of HIV, both cell lines showed a 
highly significant increase (p <0 .0001) in the expression of this antigen (Figure 6.4).
However, the effect on THP1 cells w as greater than that on M M 6 cells (Fishers post hoc 
test (5%  level): p<0 .0001).
6 .2 .4 . C D 23
Approximately 15%  and 8%  respectively for both M M 6 and THP1 cells expressed the 
C D 23 antigen constitutively (Figure 6 .4). W hen  infected with either strain of HIV, both cell 
lines showed a highly significant increase (p<0.0001) in the expression of this antigen 
(Figure 6.4).
6 .2 .5 . C D 14
Approximately 52%  M M 6 cells and 2%  THP1 cells expressed the C D 14  antigen  
constitutively (Figure 6 .4). Infection with either strain of HIV had a highly significant effect on 
both cell lines (Fishers post hoc test (5%  level): p<0.0001). However, the effect on THP1  
cells w as to increase C D 14  expression whilst that on M M 6 cells was the opposite.
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Figure 6.4. Antigens expression of HIV infected MM6 and THP-1 cells
MM 6 and THP-1 cells were incubated for 10days with HIV-1 Ba-L (H9; 200pL) and HIV-1 RF
(THP-1; 100pL) then incubated with a range of monoclonal antibodies for one hour in the
dark (4°C). The cells w ere analysed using a FACScan (n=5, 10 ,000  events).
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6.2.6. HLA-DR
Approximately 40%  and 5%  respectively for both M M 6 and THP1 cells expressed the  
HLA-DR antigen constitutively (Figure 6 .4). W hen infected with either strain of HIV, both cell 
lines showed a highly significant increase (p<0.0001) in the expression of this antigen  
(Figure 6 .4). However, the Ba-L strain on THP1 cells was greater than that on M M 6 cells 
(Fishers post hoc test (5%  level): p<0 .0001).
6.2.7. KC57
Approximately 5%  and 2%  to M M 6 and THP1 cells respectively wre positive for p24  
antigen due to non-specific binding of the antibody (Figure 6 .4). W hen  infected with either 
strain of HIV, both cell lines showed a significant increase in the expression of this antigen, 
which w as highly significant for THP1 cells (p<0.0001; Figure 6.4).
6.3. Kinetics of HIV-1 induced alteration in cell surface antigen 
expression on MM6 and THP-1 cell lines
Having established that H IV  has an effect on the expression of a range of surface 
antigens, the time after infection at which this change occurs w as examined. The M M 6 and 
THP-1 cell lines w ere incubated for 3, 5, 10, and 20  days with either HIV-1 Ba-L (H9; 100|iL) 
or HIV-1 RF (H9; 100p,L) as described in Sections 2.81 and 2 .8 .1 .1 . Surface antigen  
expression on cell lines w as analysed using flow cytometry.
6.3.1. CD16
At day three, infection with the Ba-L strain eliminated the expression of C D 16  on 
M M 6 cells (Figure 6.S -6.6). However, a very high proportion of cells w ere expressing C D 16  
by day 5, which remained high at day 10 but decreased by day 20. A similar time 
dependent effect was observed with the RF strain. That an increased percentage of cells 
expressed the antigen at day 3 compared to control cells.
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Figure 6.5. A ntigens on HIV infected MM6 cells
M M 6 and THP-1 cells w ere incubated for 3 and 5days with H IV -1Ba-L (H9; 100^iL) and HIV-
1RF (H9; 100 jiL) then incubated with a range of monoclonal antibodies for one hour in the
dark (4°C). The cells w ere analysed using a FACScan (n=5, 10 ,000  events).
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Figure 6.6. A ntigens on HIV infected MM6 cells
M M 6 and THP-1 cells were incubated for 10 and 20days with HIV-1 ea-L (H9; 100(iL) and
HIV-1 RF (H9; 100pL) then incubated with a range of monoclonal antibodies for one hour in
the dark (4°C). The cells w ere analysed using a FACScan (n=5, 10 ,000  events).
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In THP1 cells, both virus strains showed a similar time dependent effect on C D 16  
expression but the increase observed on day 3 was significantly greater with the RF strain 
than with the Ba-L strain (Figure 6 .7 -6 .8 ).
6 .3 .2 . C D 80
C D 80 expression was virtually eliminated by infection with either strain in M M 6 cells. 
This expression recovered, reaching control levels by day 10 and being significantly 
increased by day 20  (Figure 6 .5 -6 .6 ).
Very few  THP1 cells naturally express C D 80. A t day 3, H IV  infection did not affect 
this expression (Figure 6 .7 -6 .8 ). At day 5, an increased percentage of control and test cells 
exhibited C D 80 but this did not reach significance. By day 10, a small but significant 
proportion of RF infected cells expressed C D 80  that increased by day 20. The Ba-L strain 
also caused an increase by day 10 that reached significance by day 20.
6 .3 .3 . C D 11c
Infection of M M 6 cells with either strain of H IV severely reduced the percentage of 
cells expressing C D 11c  (Figure 6 .5 -6 .6 ). This effect was reversed by day 5, with both 
strains showing a significant increase in the percentage of cells expressing C D 11c  (the 
effect being most profound with Ba-L). The effect was maximal around day 10 with the 
percentage of cells expressing C D 11c, decreasing by day 20.
In THP1 cells, the percentage expressing C D 11c was significantly increased by day 
3 in culture (Figure 6 .7 -6 .8 ). This reached a maximum around day 5 which was sustained 
until day 10 with the RF strain but which started to decline by day 10 with the Ba-L strain. 
Both strains showed a  continued decrease by day 20, again the effect being more profound 
with the Ba-L strain.
6 .3 .4 . C D 23
Infection of M M 6 cells with either strain of HIV severely reduced the percentage of 
cells expressing C D 23  (Figure 6 .5 -6 .6 ). Although by day 5, C D 23  could be detected on 
virally infected cells and this proportion increased with time in culture, the control ceil
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Figure 6.7. A ntigens expression of HIV infected TH P -1  cells
THP-1 cells w ere incubated for 3 and 5days with H IV -1Ba-L (H9; 100pL) and H IV -1RF (H9;
100pL) then incubated with a range of monoclonal antibodies for one hour in the dark (4°C).
The cells were analysed using a FACScan (n=5, 10,000 events).
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Figure 6.8. Antigens expression of HIV infected THP-1 cells
THP-1 cells were incubated for 10 and 20days with HIV-1 Ba-L (H9; 100pL) and HIV-1 RF (H9;
100fiL) then incubated with a range of monoclonal antibodies for one hour in the dark (4°C).
The cells were analysed using a FACScan (n=5, 10 ,000 events).
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expression of C D 23  also increased. This m eans that the level of expression of this antigen 
in virally infected cells remained significantly lower than in control cells throughout the 
experiment.
The percentage of THP1 cells expressing C D 23 was significantly higher on those 
infected with H IV  than on control cells after 3 days in culture (Figure 6 .7-6 .8 ). Expression 
reached a maximum by day 10 that w as sustained throughout the experiment. The RF  
strain was most effective at inducing C D 23  expression particularly from day10 onward.
6 .3 .5 . C D 14
Infection of M M 6 cells with either strain of H IV dramatically decreased the 
percentage of cells expressing C D 14  during the early stages of culture (Figure 6 .5 -6 .6 ). 
However, by day 20  of culture, virus-infected cell expression of C D 14  had recovered 
considerably.
The percentage of THP1 cells expressing C D 14 was significantly increased in virus 
infected cells after only 3 days in culture (Figure 6 .7-6 .8 ). This effect reached a maximum  
around day 5 and w as much more pronounced with the RF strain.
6 .3 .6 . H LA -DR
Infection of M M 6 cells with either strain of H IV severely reduced the percentage of 
cells expressing HLA-DR (Figure 6 .5 -6 .6 ). This effect was maximal after 3 days in culture 
with expression only returning to near normal levels by day 20  of culture.
In THP1 cells, HLA-DR could not be detected in non-infected cells but a small 
percentage of cells in infected cultures showed expression of this antigen (Figure 6 .7 -6 .8 ). 
Expression reached a maximum around day 10 and was particularly evident with the RF  
strain.
6 .3 .7 . KC 57
Infection of M M 6 cells with either strain of H IV dramatically increased percentage of 
cells expressing p24 antigens (Figure 6 .5 -6 .6 ). After only 3 days in culture, approximately 
50%  of MM 6 cells w ere positive for p24. By day 5, this had reached almost 100% . Both 
strains seem ed equally effective.
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By contrast, a p24 antigen (Figure 6 .7 -6 .8 ) was not detected in THP1 cells until day 
5 when 100%  of cells w ere positive. Again, both virus strains were equally effective in 
infecting the ceils.
6.4. Effect of immune complexes on HIV-1 infected monocyte-derived 
macrophage surface antigen expression.
Hum an monocyte-derived macrophages w ere infected with HIV-1 Ba_L (H9) for 5 days 
and subsequently incubated with either rabbit, goat or rHIV-1 IIIB gp120 (C H O ) containing 
immune complexes as described in Section 2 .9 .1 .
Immune complexes containing human IgG and either rabbit or goat IgG w ere formed  
by incubating rabbit and goat anti-human IgG (50jxl/ml of 1 /50 dilution) in human blood for 
30  minutes. The blood was centrifuged (800g; 5mins) and the serum (which should contain 
the rabbit and goat complexes) collected and used as described in Section 2 .9 .1 . The  
surface antigen expression w as exam ined using flow cytometry. In general, owing to the 
large standard deviations recorded, there was no apparent effect of immune complexes on 
surface antigen expression in virus infected cells at the times exam ined (Figures 6 .9  - 6 .11).
6.5. Effect of immune complexes on cytokine release by HIV-1 
infected monocyte-derived macrophages.
Hum an monocyte-derived m acrophages w ere infected with HIV-1 Ba.L (H9) for 5 days 
and subsequently incubated with rHIV-1 IIIB gp120 (CHO), rabbit and goat complexes as 
described in Section 2 .9 .1 .
6.5.1. rHIV-1 IIIB gp120 (CHO) containing complexes
The presence in culture for 8 hours of HIV protein-containing immune complexes led 
to a slight but significant increase in IL-6 secretion. This effect w as lost in H IV  infected cells 
(Figure 6 .9  and Figure 6 .12 ). By 12 hours culture, this effect of the immune complexes was  
no longer evident but non-infected cells showed much higher release of IL-6 than infected  
cells (Figure 6.9; Fishers post hoc: p<0.0001).
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Figure 6.9. The expression of surface antigen on monocyte-derived macrophages 
incubated with rHIV-1 IIIB gp120 (CHO) complex
Monocyte-derived m acrophages w ere infected with HIV-1 Ba-L (H9; 100pL) for 5 days, 50- 
pL R P M I-1640 medium was added to control and 50pL rHIV-1 IIIB gp120 (C HO ) complex to 
all test wells. Plates w ere incubated for 8hrs, and 12hrs (37°C /5%  C 0 2) and the cells 
incubated with a range of monoclonal antibodies for one hour in the dark (4°C). The surface 
antigen expression was analysed using the FACScan. Controls cells were treated with 
FITC /P E  dual labelled monoclonal antibodies isotype controls. Cell treatment: M=control 
uninfected; MC=with complex; M I=HIV-infected; M IC=HIV-infected with complex. All results 
were gated using these (n=5, 10 ,000  events).
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Figure 6.10. The expression of surface antigen on monocyte-derived macrophages 
incubated with rabbit anti-human complex
Monocyte-derived m acrophages were infected with HIV-1 Ba-L (H9; 100pL) for 5 days, 50pL  
R P M I-1640 medium was added to control and 50-pL rabbit anti-human complex to all test 
wells. Plates were incubated for 8hrs, and 12hrs (37°C /5%  C 0 2) and the cells incubated 
with a range of monoclonal antibodies for one hour in the dark (4°C). The surface antigen  
expression was analysed using the FACScan. Controls cells w ere treated with F ITC /P E  dual 
labelled monoclonal antibodies isotype controls. Cell treatment: M=control uninfected; 
MC=with complex; M I=HIV-infected; M IC=HIV-infected with complex. All results were gated  
using these (n=5, 10 ,000  events).
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Figure 6.11. The expression of surface antigen on monocyte-derived macrophages 
incubated with goat anti-human complex
Monocyte-derived m acrophages w ere infected with HIV-1 Ba-L (H9; 100pL) for 5 days, 50 |iL  
R P M I-1640 medium was added to control and 50-pL goat anti-human complex to all test 
wells. Plates were incubated for 8hrs, and 12hrs (37°C /5%  C 0 2) and the cells incubated 
with a range of monoclonal antibodies for one hour in the dark (4°C). The surface antigen  
expression was analysed using the FACScan. Controls cells w ere treated with F ITC /P E  dual 
labelled monoclonal antibodies isotype controls. Cell treatment: M=control uninfected; 
MC=with complex; M I=HIV-infected; M IC=HIV-infected with complex. All results w ere gated  
using these (n=5, 10 ,000  events).
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Figure 6.12. The detection of cytokines from HIV infected monocyte-derived 
macrophage incubated with rHIV-1 IIIB gp120 (CHO) complex
Monocyte-derived m acrophages w ere infected with HIV-1 Ba.L (H9, 100pL) for 5days. 50pL  
R P M I-1640 medium was added to control and 50pL rHIV-1 IIIB gp120 (C HO ) complex to all 
test samples which were and incubated for 8hrs and 12hrs(37°C /5%  C 0 2). The release of 
IL-6, IL-10, and T N F -a  was detected in the supernatant using ELISA.Cell treatment: 
M=control uninfected: MC=with complex; M I=HIV-infected; M IC=HIV-infected with complex 
(n=7).
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After eight hours in culture, the presence of HIV-protein containing immune 
complexes significantly increases the release of IL-10 by both infected and non-infected  
cells (Figure 6.12; Fishers post hoc: p<0.0001). This effect remains evident at 12 hours 
(Figure 6 .12 , Fishers post hoc: p<0.0001).
Little TN F-a  was detected after incubation with HIV-protein containing immune 
complexes for 8 hours (Figure 6 .12). A fter 12 hours incubation, TN Fa production is greater 
from infected cells than non-infected but the presence of immune complexes seem s to 
inhibit this release (Figure 6 .12).
6.5.2. Rabbit immune complexes
In general, rabbit immune complexes had no significant effect on cytokine release  
from monocyte-derived m acrophages incubated for 5 days with or without HIV (Figure 6 .10  
and Figure 6 .13). After incubation for 8 hours, IL-10 could be detected in all cultures at the 
sam e level (Figure 6 .13 ). iL-6 and T N F a  could barely be detected. A fter 12 hours however, 
a significant increase in IL-6 release by non-infected cells (compared with 8 hours) could be 
detected (Figure 6 .13 ). Also, the level of IL-6 present in the supernatant of H IV  infected,
H IV  complex-containing cultures w ere greater than that of cultures containing H IV  alone. No 
difference in TNFa levels w as observed.
6.5.3. Goat immune complexes
in general, goat immune complexes had no significant effect on cytokine release from  
monocyte-derived macrophages incubated for 5 days with or without H IV (Figures 6.11 and  
Figure 6 .14).
6. 6. Effect of serum from HIV+ individuals on surface antigen 
expression on HIV-1 infected monocyte-derived macrophages.
Hum an monocyte-derived m acrophages w ere infected with H IV -1Ba-i_ (H9) for 5 days and 
subsequently incubated with H IV +sera as described in Section 2 .9 .1 .1 . Surface antigen  
expression was assayed using flow cytometry. Owing to the large standard deviations
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Figure 6.13. The detection of cytokines from HIV infected monocyte-derived 
macrophage incubated with rabbit anti-human IgG complex
Monocyte-derived m acrophages were infected with HIV-1 Ba-L (H9; 100|iL) for 5 days then 
R P M I-1640 medium (50pl_) was added to control wells and 50pL rabbit anti-human IgG  
complex to all test wells and the plates w ere incubated for 8hrs and 12hrs(37°C /5%  C 0 2). 
The release of IL-6, IL-10, and TN F-a  from supernatant was detected using an ELISA. Cell 
treatment: M=control uninfected; MC=with complex; M I=HIV-infected; M IC=HIV-infected with 
complex. Results represent the m ean and standard deviation with n=7.
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Figure 6.14. The detection of cytokines from HIV infected monocyte-derived 
macrophage incubated with goat anti-human IgG complex
Monocyte-derived macrophages w ere infected with HIV-1 Ba-L (H9; 100pL) for 5 days then 
R P M I-1640 medium (50pL) was added to control wells and 50pL goat anti-human IgG 
complex to all test wells and the plates were incubated for 8hrs and 12hrs(37°C /5%  C 0 2). 
The release of IL-6, IL-10, and TN F-a  from supernatant was detected using an ELISA. Cell 
treatment: M=control uninfected; MC=with complex; MI=HIV-infected; M IC=HIV-infected with 
complex. Results represent the m ean and standard deviation with n=7.
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Figure 6.15. Surface antigen expression on HIV infected monocyte-derived 
macrophage incubated with HIV-sera
Monocyte-derived m acrophages were infected with HIV-1 Ba-L (H9; 100pL) for 5days, 50pL  
R P M I-1640 medium w as added to control and 50pL HIV-sera to all test wells. Plates were  
incubated for 8hrs, and 12hrs (37°C /5%  C 0 2) and the cells incubated with a range of 
monoclonal antibodies for one hour in dark (4°C). The surface antigen expression was 
analysed using the FACScan. Control cells were treated with F ITC /P E  dual labelled 
monoclonal antibodies isotype controls. Cell treatment: M=control uninfected; MC=with 
complex; M I=HIV-infected; M IC=HIV-infected with complex. All results were gated at 2500  
events (n=5).
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observed, it w as not possible to identify any effect of HIV serum on surface antigen 
expression (Figure 6 .15).
6.7. Effect of serum from H!V+ individuals on cytokine production by 
HIV-1 infected monocyte-derived macrophages.
Hum an monocyte-derived macrophages were infected with HIV-1 Ba-L (H9) for 5 days 
and subsequently with H IV-sera as described in Section 2 .9 .1 .1 . The supernatants w ere  
analysed using ELISA. A fter 8 hours, IL-6 and TN Fa could not be detected in the 
supernatants from either infected or non-infected cells (Figure 6 .16 ). By contrast, IL-10 was  
clearly detectable in all cultures.
After 12 hours, IL-6 could be detected in all cultures (Figure 6 .16). W hilst the level 
produced by non-infected cells was the sam e regardless of the presence of HIV serum, in 
H IV  infected cells the presence of serum appeared to increase IL-6 production (although 
this just failed to reach significance). IL-10 was present in all cultures at significantly higher 
levels than after 8 hours. The presence of H IV+ sera in the H IV  infected cultures appeared  
to cause a significant increase in IL-10 production.
T N F a  production was detected in control, non-treated cells that disappeared in 
serum-treated cells. No T N F a  production was detected in H IV  infected cells.
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Figure 6.16. Detecting cytokines released from HIV-infected monocyte-derived 
macrophage incubated with HIV+ sera
Monocyte-derived m acrophages w ere infected with HIV-1 Ba-L (H9; 100pL) for 5days, 50pL  
R P M I-1640 medium was added to control and 50pL HIV+sera to all test wells. Plates were  
incubated for 8hrs, and 12hrs (37°C /5%  C 0 2). The supernatant was analysed for IL-6, IL- 
10, and TN F-a using the appropriate ELISA (n=5).
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7.0. DISCUSSION
7.1. Introduction
The  original aim of this project w as to investigate the role of C D 80  in H IV infection. It 
w as based on the observations that patients with full-blown A ID S  are unable to develop  
secondary immune responses. It is known that antigen presentation without appropriate co­
stimulation through C D 80  leads to anergy and failure to produce memory cells. It was  
thought possible that failure to produce appropriate cytokines (due to a tendency to mount a 
TH 2-type response) m ay prevent appropriate C D 80 expression in HIV-infected individuals.
To this end, an attem pt w as m ade to establish antigen specific T  cell lines to be used 
in exam ine antigen presentation. Also, the effect of cytokines on monocyte surface antigen  
w as investigated in order to understand their role in modulating the functional 
characteristics of these cells.
7.1.1. Development of antigen specific T cell lines
The classical pathway used by other researchers for setting up antigen specific T  
cells lines, did not succeed in the present study as it resulted in a limited production of T  cell 
blasts. Several techniques w ere used to obtain these antigen specific T  cells, which ended  
with the sam e disappointing results. Discontinuous and continuous stimulation protocols 
used w ere with PPD  or BCG and with various concentration of IL-2. No definitive effect was  
observed. Therefore, a different technique w as tried using PBM N C  as feeder cells that w ere  
incubated with 30U/m l IL-2 to stimulate T  cell blasts. Unfortunately, the cells died which 
w ere possibly due to apoptosis or bacterial infection.
O ther researchers have been able to establish antigen specific T  cell lines using 
P P D  and live BCG (Pancholi et al., 1992, Fazal et al., 1995). There are several possible 
explanations why antigen specific T  cell lines were not obtained. Firstly, the initial 
stimulation was not strong enough to give adequate endogenous IL-2 production. Secondly, 
not enough IL-2 w as present during resting phase. Thirdly, the concentration of antigen was  
not high enough to stimulate antigen specific T  cell proliferation. The presence of antigen  
presenting cells (APC) is vital for IL-2 production (Lombardi et al., 1994; Torm ey et a lM 
1997) but feeder cells such as the EB V B-transformed cells used in this study may not 
produce IL-2 although they m ay act as presenting cells. S ander et al., (1995) studied the
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production of Th1 and Th2 cells in response to live BCG and detected that stimulating 
peripheral blood mononuclear cells with BCG results in the production of fourteen cytokines 
including IL-2. It w as found that 2%  v/v IL-2 w as detected from day 2  to day10. Other 
studies indicated those IL-2 peaks first at days 4 -5  and again at days 7 -8  allowing 
restimulating of T  cell clones and up-regulating B7 expression. This suggested that enough 
IL-2 was present to stimulate an initial antigen-specific reaction (Sansom  and Hall, 1993; 
W yss-Coray et al., 1993; S ander et al., 1995;).
There is a possibility that stimulated cytotoxic T  cells could inhibit a BCG specific 
response by destroying infected antigen presenting cells. Turner and Dockrell, (1996) 
showed that PBM C incubated with live BCG for 7-days activated C D 8+ T  cells which 
showed cytolytic activity against target cells infected with live mycobacterium. It is known 
from previous work by Rook et al., (1985) that BCG grows poorly in RPMI 1640 medium and 
also is inhibited by human serum at concentrations of >5%  v/v but this contrast to the  
current study which indicates no effect on the cells responding to live BCG.
The use of IL-2 concentrations greater then 10U/ml during the resting phase improved 
T  cell proliferation as shown in Section 3.1. The study by Cohen et al., (1996) demonstrated  
that incubating human PBM C with IL-2 (with or without IL-4) yielded predominantly Th1-type  
clones. These Th1 clones induced proliferation of both naive C D 45R B hl and memory 
C D 45R B loCD4+ T  cells which are B7 dependent and the addition of IL-2 (20-100U /m l) to the  
culture prevented the hyporesponsiveness of B7- transfected cells (Ding and Shevach, 
1994).
The concentrations of PPD  or live BCG in the current study w ere similar to those used  
by others. However, no dose effect was observed (Figure 3 .1 ,A and B). This m aybe due to 
the induction of high or low dose although this seems unlikely. The  response may not be 
antigen-dependent but may be due to defective antigen presentation (Fidler et al., 1996; 
Khalili et al., 1997,). O ther antigens that are strong stimulators have been used to produce 
T  cell lines. Stimulators such as Phaseolus vulgaris agglutinin (PHA), tetanus toxoid (TT), 
Concanavalin A (Con A), and mouse anti-human C D 3 monoclonal antibody (OKT3, 
Keystone et al., 1993; LI e t al., 1995; Thom ssen et al., 1995; Fazal et al., 1995; Cohen et 
al., 1996). In response to Con A, activated T  cells show increased expression of C D 80  (B7- 
1) and C D 86 (B7-2) molecules. The blocking of both molecules completely suppresses 
proliferation and IL-2 production. These molecules individually play a different role in 
proliferation and cytokine production as anti-CD86 Fab partially inhibited the Con A
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stimulated response w hereas anti-C D 80 Fab had no effect. Therefore, C D 86  is required in 
part by Con A while other stimulators require both C D 80  and C D 86  (Perrin et al., 1997).
O ne important possible difference between the present study and work done by 
others is the choice of donors. O ther studies used subjects who w ere BCG-vaccinated. In 
the present study, the immune status of the individual was unknown. Although the ceils 
from individual donors w ere stimulated by P P D  and BCG the response was not a constant 
gradual increase in T  cell numbers (Section 3 .1) as shown by others. O ne other possible 
reason for the lack of T  cell line establishment is that the environment was not compatible.
7.2. Cellular differentiation and proliferation
Hum an T  celis subsets, T  helper 1 (Th1) and Th2 cells produce cytokines originally 
described from mouse C D 4+ T-cell clones (Mosmann et al., 1986; Cherwinski et al., 1987; 
Del Prete et al., 1991). The subsets produce different cytokines with Th1 cells producing • 
interleukin 2 (IL-2), interferon y (IFN-y) and tumour necrosis factor a (T N F -a ) and Th2 cells 
producing IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13. Both subsets secrete IL-3, tumour necrosis 
factor a  (TN F-a), granuiocyte-m acrophage colony-stimulating factor (G M -CSF), and 
members of the chemokine (CK) families. ThO is a precursor cell that expresses both 
patterns of cytokines (Sad and Mosm ann, 1994). Th2~type cytokines encourage antibody 
production and are associated with strong antibody and allergic responses (Mosmann and 
Coffman, 1989). Antibodies against C D 80  or C D 86 on A PC s inhibit the developm ent of Th1 
and Th2 responses both in vitro and in vivo which influence T-cell differentiation 
(Thompson, 1995). The differentiation of Th1 cells is stimulated by m oderate doses of 
antigen, whereas Th2 cells are stimulated by a w ider range of concentrations and a higher 
dose of antigen may switch the immune response from Th1 to Th2 (Fitch et al., 1993; 
Hosken et al., 1995).
To understand the effect of Th1 and Th2 cytokines on monocyte-derived 
macrophages (M DM ) and the immature monocytic cell line, Mono M ac 6  (M M 6) cells w ere  
incubated in vitro with cytokines and chemical stimulants to exam ine differentiation, 
proliferation and surface antigen expression. The chemical stimulants PMA and Vit D3 both 
cause the differentiation of M DM  and M M 6 cells. PMA is highly potent, especially at higher 
concentrations. Differentiation, evidenced by the inhibition of cellular proliferation, was  
caused by both chemical stimulants but Vit D3 may have been toxic at the concentrations
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tested. IFN-y, a Th1-type cytokine, induced the differentiation of M M 6 cells thus inhibiting 
cellular proliferation. This may have been partly due to a toxic effect in this study. The  
synthesis of IFN-y is known to be enhanced by IL-2, IL-12 and IL-4 w hereas IL-10 inhibits 
Th1 cytokine synthesis (Fiorentino et al., 1989; S eder and Paul, 1994; Trinchieri et al.,
1997).
Smith et al., (1998) showed that M -C S F (at higher concentrations than those used in 
the current study) induced monocytes to differentiate into m acrophages resulting in down- 
regulation of IL-12 which is important for Th1 cell differentiation. The current study showed 
that M -C SF caused a decrease in M M 6 cellular proliferation that may in part be due to 
toxicity but may be due to M -C S F inducing cellular differentiation toward a mature 
phenotype. G M -C SF, a Th2-type cytokine caused cellular differentiation and the decrease  
in proliferation at the higher concentrations used. Eischen et al., (1991) showed that 5ng/mi 
G M -C S F  caused monocytes to differentiated into macrophages and promoted better cell 
survival in a dose dependent manner. The  Th2-type cytokines IL-6, IL-10 and T N F -a  
caused differentiation and decreased cellular proliferation but this was not obvious due to 
the low growth rate found in this study. These results demonstrated that both Th1- and Th2- 
type cytokines and chemical stimulants used caused the differentiation of MDM and M M 6  
cells. Most of the stimulants used appeared to increase cell death as well as inhibit cellular 
proliferation. This may be due to deactivation of these monocytic cell lines initiating 
apoptosis (Heidenreich et al., 1997).
7.2.1. Surface antigen expression on differentiated cells
7.2.1.1. CD16
An increase in CD 16 receptor expression has been shown to be associated with 
monocyte differentiation. This surface antigen was increased by all cytokines and 
stimulators used but particularly by IL-6, IL-10 and TN F-a  (Section 4 .2 .2 .1 ). The effect of 
these cytokines w as obvious at day 3 and levels decreased on days 5 and 7. A llavena et 
al., (1998) showed that incubating human monocytes for 3 days with IL-10 (20ng/ml) 
induced high levels of CD 16 but this expression declined thereafter. This was also observed  
by the use of a lower concentration of IL-10 (1 ng/ml) in present study. Incubating human  
monocytes with IFN-y and GM -CSF using different units of concentration, from the one used
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in present study, showed a dose dependent decrease in C D 16  expression (Olikowsky et al., 
1997; Kruger e ta l., 1996).
These results suggest that M M 6 cells are less responsive to the effects of the 
stimulants used than peripheral blood monocytes. The later time of maximum expression 
suggests that the immature M M 6 cells m ay have needed to differentiate before expression 
could be enhanced and that this m ay have depleted levels of stimulant resulting in a lower 
level of expression of the surface antigen. O r that MM6, being a transformed cell line, may 
not be able to express normal levels of the antigen. This indicates that C D 16 expression is 
influenced in particular by Th2-type cytokines and is dose dependent.
7.2.1.2. CD80
C D 80, a costimulatory molecule is present on antigen presenting ceils (Lenschow et 
al., 1996). This surface antigen is expressed at very low levels on monocytes but its 
expression is greater on stimulated, fully differentiated macrophages. Expression on blood 
monocytes was strongly inhibited by PMA (p<0 .0001) and significantly increased at day 3 
by the Th2-type cytokines IL-6 (p<0.0001 day 3 v day 7) and IL-10 and by T N F -a  (Section 
4 .2 .2 .2 ) but the level decreased on days 5 and 7. O ther have shown that in resting C D 14+  
monocytes high concentrations of IL-6 (50ng/m l), TN F-a(40ng/m !) and G M -C S F (50ng/m l) 
did not alter C D 80  expression (Creery et al., 1996). In the current study low concentration 
IL-6, and T N F -a , increased C D 80 expression but G M -C S F w as unaltered. Other, have show  
that IL-10 m oderately increased C D 80  expression as observed in this current study (Creery  
et al., 1996).
MM6 cells showed a lower expression of CD80 than peripheral blood monocytes, 
which was significantly increased by TN F-a  and the Th2-type cytokines GM-CSF, IL-6, and 
IL-10. The expression reached a maximum at day 5 for IL-10 and TN F-a  but reached a 
maximum for IL-6 at day 7. These results indicate that MM6 cells require a greater exposure  
time compared to peripheral blood monocytes suggesting that the immature MM6 cells may 
need to differentiate before expression be enhanced. This m ay have depleted the level of 
the stimulators resulting in lower levels of expression of the surface antigen. The results 
suggest that a range of cytokines may affect CD80 expression on monocytes but that the 
effect is not as great on the immature MM6 cells.
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C D 11c /C D 18  is an adhesion molecule, which allows contact between cells and 
between cells and the matrix (Dustin and Springer, 1991). This surface antigen is expressed  
at high levels on monocytes but its expression is greater on fully differentiated  
macrophages. PMA, V itD3 and IFN-y w ere found to inhibit the high constitutive expression 
of C D 11c  after 3 days incubation. Krugluger et al., (1997) demonstrated that blood 
monocytes incubating for 3 days with IL-6, IL-10, TN F-a  and Vit D3 resulted in decreased  
C D 11c expression. In the current study, which used different concentrations of IL-6, IL-10, 
and TN F-a  to the previous study, a decrease in C D 11c expression w as seen on day 5 and 
with Vit D3 on day 3. It seem s that C D 11c  expression is affected only moderately by 
stimulants (with the exception of PMA) on M DM  and that both Th1- and Th2-type cytokines 
are able to maintain this expression.
PMA, which is potent in inducing differentiation, rapidly increased expression of 
C D 11c  on M M 6 cells (p<0 .0001). IL-6 showed a similar pattern to PMA but maximum  
expression of C D 11c  appeared at day 5 and then declined. Vit D3 and G M -C S F30  
respectively increased and decreased C D 11c  on M M 6 cells with maximum expression on 
day 3 (p<0 .0047  and p <0 .0173) declining thereafter. How ever the effect of TN F-a  and IL-10  
on C D 11c expression was maximal at day 5 (p<0.0001 for TN F-a  and IFN-y; p < 0 .0129  for 
IL-10).
7.2.1 A . CD23
CD23 is expressed at low levels on monocytes but its expression is greater on fully 
differentiated m acrophages, in the present study, peripheral blood monocytes expressed  
low levels of CD23 which w as increased by IFN-y (p<0 .0001), and GM -CSF (p <0 .0001) by 
day 3 and decreased thereafter. Alderson et al., (1992) detected an increase in CD23 
expression at early as 2 4  to 48  hours after incubating human monocytes with GM -CSF (10- 
30ng/m l). This slightly declined at 72  and 96  hours as observed in current study. The low  
concentration of GM -CSF (1ng/mi; p <0 .0001) dramatically increased CD23 on day 7 as 
observed in the present study. IL-6 and IL-10 (p<0.0001) caused an increase in CD23 
expression. O ther studies which used different concentrations did not show this increase  
after 3 days (Willheim et al., 1991, Spittler et al., 1995). TN F-a  also causes an increase that 
like IL-6 and IL-10 declined by days 5 and 7.
7.2.1.3. CD11o
145
MM 6 cells expressed low levels of C D 23. Its expression, which was increased by M- 
CSF, G M -C S F and IFN-y (p <0 .0001), reached a maximum at day 5 then declined. IL-6, IL- 
10 and TN F-a  (p<0 .0001) all inhibited C D 23  expression on days 3 and 5 in the present 
study. Other researchers showed that T H P -1 , MM6, and U 937 cells incubated for 3 days 
with different concentrations of IL-6, IFN-y, and TN F-a  increased C D 23  expression. (Gessl 
et al., 1993). Also, IL-10 augm ented C D 23  expression on U 937 cells in a concentration-and  
tim e-dependent m anner (Alderson et al., 1992). Thus, the present results for M M 6 cells do 
not agree closely with previously published results but this m ay be due to different 
concentrations used or due to non-standardisation between flow cytometric analyses. The  
results in the present study suggest that the expression of C D 23  on MM 6 cells and 
peripheral blood monocytes be regulated in a similar manner.
7.2.1.5. CD14
C D 14 is expressed at high levels on monocytes but its expression is greater on fully 
differentiated m acrophages. C D 14  expression was high on control peripheral blood cells. 
This expression was decreased by all cytokines and stimulators used with the exception of 
the lower M -C SF dose (Section 4.2.2.S ). Others have shown that incubating human  
monocytes with higher concentrations of IL-10 and different units for M -C SF and G M -C S F  
caused an increase in C D 14  expression (Buelens et al., 1997, Chapuis et al., 1997). The  
effect of IL-10 was dose dependent and w as best added at initiation of the culture, as 
addition on day 3 was less stimulatory. If IL-10 was added at day 6 it did not increase C D  14 
expression (Allavena et al., 1998).
M M 6 cells showed a lower expression of C D 14 than peripheral blood monocytes. 
PMA and Vit D3 increased C D 14  on days 3 and 5. At day 3, the remaining cytokines 
showed a slight decrease effect on C D 14  expression. On day 5 significant increases were  
caused by IL-6, IL-10 and TN F-a  which returned to normal by day 7. These results suggest 
that a high proportion of M M 6 cells can be induced to express C D 14  when treated with 
cytokines or stimulants that are associated with the induction of differentiation. W eb er et al.,
(1993) demonstrated that TN F-a  increased phagocytosis and induced C D 14  expression on 
M M 6 cells, in part supporting the current study.
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The  results indicate that all the stimulants used increased C D  14 expression on M M 6  
cells. On MDM, Vit D3, G M -C S F  and M -C S F w ere more effective in affecting C D 14  
expression.
7.2.1.6. HLA-DR
HLA-DR was expressed on a large proportion of peripheral blood monocytes after 
incubation for 3 days. This expression w as significantly decreased after 3 days in culture 
with all cytokines and stimulants tested (with the exception of the lower concentrations M- 
C SF and GM-CSF). This effect reached a maximum at day 7 for IFN-y, and GM -CSF 
(higher concentration). The  effect of the other stimulants either remained constant or 
diminished with longer culture periods. By contrast, Torm ey et al., (1997) have shown that 
IFN-y (at higher concentrations than that used in the present study), IL-6, and TN F-a  (used 
at different units/ml) enhanced HLA-DR expression. The sam e study by Torm ey et al.,
(1997) showed VitD3 (10 '8 M/ml; lower than the concentration used in the present study) 
downregulated H LA -DR expression. Hum an monocytes in the presence of IL-10 (10ng/m l 
and 20ng/m l) have been shown to inhibit antigen presentation by lowering the level of M HC  
class II as observed in the present study (Thomssen et al., 1995; Allavena et al., 1998). The  
effect of IL-10 w as dose dependent and was best added at the initiation of the culture, as 
addition on day 3 was less inhibitory. If IL-10 was added at day 6, only a modest reduction 
of M H C classll was observed (Allavena et al., 1998).
M M 6 cells express lower levels of HLA-DR then control peripheral bloods monocytes 
but overall the chemical stimulants and cytokines inhibited the expression of HLA-DR. A  
decrease in expression was noted at day 3 for PMA, IL-10, and TNF-a, the effect remained  
constant throughout the period of experiment. The other stimulants caused a significant 
reduction after day 5 with little change thereafter. These results suggest that M M 6 cells and 
peripheral blood monocytes respond in a similar m anner to the cytokines and stimulants 
used with respect to HLA-DR expression. This response is to both Th1-type and Th2-type  
cytokines.
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7.3. The effect of immune complexes on whole blood
The inability to develop antigen specific T  cell lines necessitated a change in 
direction for the project. Clinical observation demonstrated the presence of immune  
complexes in terminal A ID S  patients and others have shown {in vitro) that immune 
complexes may affect cytokine secretion (Trial et al., 1995; Manetti et al., 1996). It was  
shown that the cytokines T N F -a , IL-10 and IL-6 were affected by immune complexes have  
been the cytokines shown in the present study to be most active in affecting monocyte 
activation and differentiation. The role of monocyte activation in H IV replication is still 
uncertain but immune complexes in vivo m ay stimulate the release of cytokines that alter 
M N P activation leading to enhanced H IV  replication and exacerbation of disease. To this 
end, the present study was modified to exam ine the effect of immune complexes on 
m ononuclear phagocytes and to determine if H IV infection, or complexes containing HIV  
proteins, has an effect on the outcome.
7.3.1. KLH-stimuIated cytokine release
Mixing the antigen with rabbit anti-KLH serum at sub-agglutinating concentrations 
m ade keyhole limpet hemocyanin containing immune complexes. Com plexes form ed in 
antigen excess stimulated high levels of IL-6 release in whole blood which reached  
significance after 12 hours. At 30 minutes after stimulation, the Ab2Ag complex stimulated  
the highest levels of IL-10 but this failed to reach significance due to the high levels of IL-10  
induced by the untreated cells and by anti-KLH alone. This early production of IL-10 may 
favour IL-6 production that switches off TN Fa production, preventing a significant rise in this 
cytokine. A study carried out by Berger et al (1996b), showed that the incubation of human  
monocytes in vitro with immune complexes formed at equivalence with tetanus toxoid and  
polyclonal anti-tetanus toxoid antiserum induced the release of IL-6, and IL-10 in a Ab: Ag 
ratio-dependent manner. The synthesis of IL-10 affected the immune complex-induced  
secretion of TN F-a  since IL-10 suppresses the production of the Th1-type cytokines IL-2, IL- 
12 and IFN-y. These results, together with those of the present study suggest that immune 
complex formed at equivalent or in Ag excess cause a bias towards a Th2-type response. 
The results of the present study w ere complicated by the use of whole blood which is 
considered to be physiologically more relevant. KLH was used since it is considered to be a 
“neo” antigen. However, it has been shown recently that sera from non-immunised donors
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contain natural antibodies (IgM and IgG) which bind KLH. These natural antibodies form  
immune complexes (1C) with KLH antigen, activate the classical complement pathway and  
affect cytokine secretion (Thornton et al., 1996). This may explain the cytokine responses to 
antigen alone seen in the present study.
7.3.2. Rabbit or goat anti-human IgG immune complex stimulated cytokine release 
from whole blood.
Although fluctuations in IL-10, IL-6, and T N F -a  could be detected in the 
supernatants, the cultures containing goat or rabbit immune complexes did not show a 
difference to those control cultures containing goat or rabbit serum alone. Differences w ere  
greater with rabbit serum compared to goat serum this may be due to rabbit antibody 
binding to FcyR1 receptors. Laufer et al., (1995) showed that IgA and IgG immune 
complexes incubated with monocyte-derived macrophages for 24  hours increased levels of 
the complement protein C 3 which enhanced the production of T N F -a . Also, it has been  
shown that tetanus toxoid complexes incubated with human monocytes in vitro inhibit IL12  
secretion via TN F-a-induced IL-10 and prostaglandin synthesis. This indicates a Th1 to Th2  
shift (Berger et al., 1997). The production of cytokines appears to depend on the 
antigen/antibody ratio. Tetanus toxoid antigen alone induced a typical Th1-like cytokine 
release with high levels of IL-12 and IFN-y. Immune complexes form ed at equivalence  
induced a marked secretion of IL-6 and IL-10 therefore inhibiting IL-2 and IFN-y secretion. 
This indicates that these immune complexes occur during the course of chronic infectious 
disease with a Th1 to Th2 switch (Berger et al., 1996a).
In the present study it w as not practically possible to m easure the Ab:Ag ratio in the 
complexes used, information which would have allowed a more in-depth discussion.
7.3.2.1. Identification of the celis binding rabbit or goat anti-human IgG human 
blood using flow cytometry
W hole blood w as incubated with various dilutions of either rabbit or goat anti-human  
IgG as test samples and either rabbit or goat sera as controls. Cells w ere assayed by flow  
cytometry in an attempt to identify to which cell type the complexes w ere binding.
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Generally, the goat serum and goat complexes bond to lymphocytes more effectively 
than the rabbit complexes or rabbit serum. This is unusual since rabbit antibodies are  
known to bind to hum an FcR more effectively those goat antibodies. This suggests that the 
human Ig in goat complexes w as binding to the FcR or that the goat antibody had a greater 
affinity for human Ig, with the resulting complexes binding to cellular FcR and com plem ent 
more effectively than those containing rabbit antibodies. Maximum binding levels for the 
complexes w ere 18%  of lymphocytes, 25%  of monocytes and 20%  of neutrophiles. This 
may explain some of the differences observed in immune complex induced cytokine 
secretion between the present study and others. The goat and rabbit immune complexes  
w ere formed in plasma that contained complement. Also, engagem ent of different FcR and 
CR or different cells by immune complex leads to a variety of sequelae (Ross and Medof, 
1985; M asuda and Roos, 1993; Ohkuro et al., 1995)
In particular, Voice and Lachm ann, (1997) demonstrated that immune complexes  
form ed from four IgG subclasses varied in size and binding specificity. The immune 
complex bound to human neutrophils and induced specific granule release via Fey (C D 16, 
C D 32) and com plem ent (CR1 and C R 3) receptors. The combination of receptors used 
varying with the isotype of the IgG in the complex. Release of granule contents would have  
a range of effects of other cells in whole blood and would influence cytokine release.
7 .3 .3 . rHIV-1 gp120-containing immune complexes release of cytokines
Hum an blood w as incubated for various lengths of time with the following pre-formed  
immune complexes: rabbit anti-serum to rHIV-1 MN gp120 and rHIV-1 MN gp120; sheep  
anti-serum to rHIV IIIB gp120 (C H O ) and rHIV-1 IIIB gp120 (C H O ). Neither MN nor C H O  
antigens affected the constitutive release of IL-6 by whole blood. By contrast, immune  
complexes containing this antigen significantly enhanced the release of IL-6 by whole blood 
(M N). The increase was evident after 8 hours culture with the CHO-containing immune 
complexes but was only significant at 12 hours with the MN containing immune complexes. 
The release of IL-6 seem ed to reduce the release of TN F a. No significant effect of the 
presence of either immune complex w as seen on the release of IL-10 or T N F -a  by whole  
blood. However, this m ay be due to the fact that the supernatants w ere only analysed after 
8 and 12 hours incubation. IL-10 release probably occurred much earlier and it is possible
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that T N F a  was released earlier due to the negative value of the slope of the graph  
obtained.
Others have shown an effect of H IV  proteins on cytokine release. The incubation of 
PBM C with HIV-1 transm em brane glycoprotein gp41 induced an increase in IL-10  
production within 3 hours and a reduction of IL-2 and IFN-y. This reaction was also 
observed when recombinant HIV-1 gp120 was used (Barcova et al., 1998, Koutsonikolis et 
al., 1997). HIV-1 gp120 molecule (FLgp120) and its fragments (rp120cd and rp120) 
incubated with human monocytes caused an upregulation of C D 14  and C D 44. The rp120cd  
peptide significantly increased the expression of C D 16 and the TNF-receptor type II. 
However, rp120 downregulated HLA-DR, C D 64, IFN-y receptor and induced IL-10  
production. These types of changes are seen in blood of A ID S  patients (Zem bala et al., 
1997).
7.4. HIV-1 infected MM6 cells and surface antigen a pilot study
This pilot study indicated that both strains of H IV w ere more effective in infecting T H P - 
1 cells than M M 6 cells. However, both cell lines showed significant changes in the 
expression of the surface antigens exam ined as a result of virus infection. This change in 
expression was similar for both cell lines with the exception of the C D 14  and HLA-DR  
antigens which w ere down-regulated by virus infection in M M 6 cells and up-regulated by 
infection in THP1 cells.
7.4.1. Kinetics of HIV-1 induced alteration in cell surface antigen expression on MM6 
and THP-1 cell lines
MM 6 and THP-1 cell lines w ere infected for 3, 5, 10, and 20  days with either HIV-1 Ba_ 
l (H 9; 100jil) or H IV -1RF (H9; 100jil) to detect any changes in morphology and surface 
antigen expression. W hen  exam ined microscopically, MIV16 cells w ere productively infected  
with HIV-1 Ba.L(H9) and HIV-1 RF(H9), and showed a small num ber of virus particles in 
vacuoles at day 10 but not at day 5. By day 20, many cells w ere dead and no virus was  
visible.
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7.4.1.1. Surface antigen expression on HIV-1 Ba-L infected MM6 cells
Nottet et al., (1993) showed that H IV -1-infected monocyte-derived m acrophages and 
non-infected m acrophages express the sam e level of Fey and complement receptors. The  
present study concurs with these results for C D 16  (Figure 6 .9). However, in M M 6 cells, 5 
days after HIV-1 infection, cells expressed higher levels of CD  16 than non-infected cells 
(Figure 6.5). Others have shown that HIV-1 infection did not alter receptor function as 
internalisation and killing of opsonized Esherichia coii (E. coli) was just as effective in H IV- 
infected and non-infected m acrophages (Nottet et al., 1993).
In the present study, infection by Ba-L and RF strains of H IV  caused an increase in 
the % of cells expressing C D 23, a receptor for IgE. This m ay be indicative of a Th2 switch in 
HIV-infected patients that enhances IgE production in the early, intermediate or advanced  
phases of infection (Manetti et al., 1996). Also, C D 14, HLA-DR and C D 80  expression 
increased indicating that M M 6 cells w ere maturing and that antigen presentation was not 
impaired by H IV  as dem onstrated by Nottet et al., (1993). C D 80  expression increased at 
day 5 but reached a maximum at day 10 for both strains of the virus. Although, the 
expression of C D 23, C D 14, C D 80, and HLA-DR was below the level of controls this 
continued to day 20. However, both virus strains caused an increase in C D 16 and CD 11c,
(a cell adhesion molecule that allows the transfer of virus to adjacent cells) which reached a 
maximum at day 10. This suggests that the virus regulated the biological function of M M 6  
cells without impairing their ability to present antigen.
Thieblem ont et al., (1995) dem onstrated that circulating peripheral blood monocytes 
of HIV-infected individuals exhibit an abnormal level of C D 16 and HLA-DR antigens 
compared to seronegative individuals. Two subpopulations of C D 14  w ere detected in H IV- 
infected individuals expressing a t C D 14 l0WC D 1 6 h,gh and C D 14 hi9hC D 1 6 l0W' The C D 14 low 
C D 1 6 h'9h subpopulation comprised 40%  of the monocyte population in A ID S  patients but 
less than 5%  of the total in H IV  seronegative individuals. Also, HIV-infected individuals 
exhibited low levels of soluble circulating C D 14  but high levels of C D 16, the latter 
decreasing in A ID S  patients. It w as noted that C D 14 l0WC D 1 6 hlsh population produced higher 
levels of TNF-a, and IL-1a than c D 1 4 hl9hC D 1 6 lowfrom A ID S patients. O ne possible reason 
for the em ergence of the C D 14 !owC D 1 6 high population m ay be due to a Th2 switch as it is 
known that IL-1, IL-4, IL-6, IL10, TNF-a, IFN-y, TGF-p, and GM -CSF modulate the 
expression of C D 14 and C D 16  (Thieblem ont et al., 1995).
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Another early study by Thieblem ont et al., (1995) demonstrated that C D 80 is 
expressed at lower levels on monocytes from HIV-1 infected patients than from controls, an 
observation which concurs with the present study. A study by M ontaner et al., (1994) 
showed that by treating cells with IL-10 before infection produces lower levels of virus with 
those treated after. This probably explains the results of Orlikowsky et ai., (1996) that 
demonstrated H IV -dependent modulation of antigen expression. The  study treated H IV- 
infected macrophages with IL-10 and IFN-y. The cytokines alone or together prevented an 
increase in C D 80. C D 16  expression w as increased with IL-10 but decreased by IFN-y 
(Orlikowsky et al., 1996). The results of Orlikowsky et al., (1996) also showed that non-H IV  
infected MDM  treated with IFN-y showed decreased C D 80 and C D 16  expression this 
implies that another cytokine is required to induce expression. The present study support 
Orlikowsky et ai., (1996) findings as non-H IV infected MDM treated with IL-10 showed both 
antigen receptors increasing after 3 days (Figure 4.9A -4 .10A ).
7.4.2. Effect of immune complexes on surface antigen expression on HIV-1 infected 
monocyte-derived macrophages.
Hum an monocyte-derived macrophages were infected with HIV-1 Ba-u (H9) for 5 days 
and subsequently incubated with either rabbit, goat or rHIV-1 IIIB gp120 (C HO ) containing 
immune complexes. Owing to the large standard deviations recorded, there was no 
apparent effect of immune complexes on surface antigen expression in virus infected cells 
at the times examined.
7.4.2.1. Effect of immune complexes on cytokine release by HIV-1 infected 
monocyte-derived macrophages.
It has been shown that monocytes infected with HIV-1 show increased production of 
many cytokines although production of IL-12 (a Th1-type cytokine which induces IFN-y 
production) is inhibited (Chehimi et al., 1994, Manetti et al., 1993). HIV-infected monocytes 
produce increased levels of IL-6 in serum which may contribute to polyclonal B-cell 
activation (Breen et al., 1990, Trentin e t al., 1992). HIV-infection in monocytes also induced 
high levels of intracellular TN F-a  (Thieblem ont et al., 1995) and IL-10 both in vitro and in 
vivo which inhibited antigen-dependent T-cell responses (Manetti e t al., 1996; Del Prete et
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al., 1993). The present study detects cytokines such as IL-6, IL-10, and TN F-a  released in 
vitro from HIV-infected M DM  incubated with immune complexes (Figure 6 .12 -6 .14 ).
7.4.3. rHIV-1 IIIB gp120 (CHO) containing complexes
M DM  incubated with H IV  containing (C H O ) complexes showed a significantly 
increase in IL-10 secretion compared to control cells. This was evident at both 8 and 12 
hours and the levels w ere not affected by H IV  infection of the cells. A t 8 hours, the 
complexes failed to stimulate significant levels of IL-6. However, by 12 hours of culture, the 
level of IL-6 had significantly increased (com pared to 8 hrs) in the presence of immune 
complexes. This increase w as lost in H IV  infected cells. Levels of TN F-a  were barely 
detectable at 8 hours. A fter 12 hrs of culture, TN F-a  was detected in the supernatant 
infected cells; this level being significantly reduced by the presence of immune complexes.
These results suggest that early production of IL-10 inhibit the production of IL-6. 
However, over a longer period, the reduced rate of production of IL-10 allows IL-6 
production. Indeed, it has been shown that the production of IL-6 by H IV  protein-stimulated  
THP-1 cells could be increased by adding a neutralising anti-IL-10 antibody to the culture 
Takeshita et, 1995). Also, Sutterwala et al., (1998) demonstrated that genetically modified 
mice lacking the FcRy chain failed to produce IL-10 in response to stimulation with immune 
complexes.
In the present study, it was shown the release of TN F-a  in H IV  infected cells. It has 
been shown that such release inhibits IL-6 production providing the appropriate conditions 
for virus proliferation (Finnegan et al., 1996). Interestingly, the presence of H IV -C H O  
complexes appeared to inhibit TN F-a  production by infected cells suggesting that the 
complexes may prevent viral replication. However, such effects m ay depend on the size  
and concentration of the complexes that could not be determined in the present study due  
to the limited availability of reagents.
7.4.3.1. Rabbit and goat immune complexes on HIV-infected monocyte-derived 
macrophages
Rabbit and G oat antibody containing complexes had no effect on IL-10, IL-6 or TN F - 
a production by control or H IV-infected MDM. This contrasts with the effect of H IV -C H O  
complexes. This difference m ay be due to the size or concentration of the respective
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complexes but may also indicate that effects observed with the H IV -C H O  complexes may 
be due wholly or in part to the antigen as suggested by the work of Takeshita et al., (1995). 
This could not be verified in the present study due to the limited am ount of virus antigen 
available from the M R C repository.
7. 5. Effect of serum from HIV+ individuals on surface antigen 
expression on HIV-1 infected monocyte-derived macrophages.
Hum an monocyte-derived m acrophages w ere infected with H IV -1Ba-L (H9) for 5 days 
and subsequently incubated with H IV+ sera. Surface antigen expression was assayed using 
flow cytometry. Owing to the large standard deviations observed, it w as not possible to 
identify any effect of H IV  serum on surface antigen expression. This may have been due to 
the length of the incubation period that was required for collection of supernatants.
Previous experiments in this study dem onstrated that changes w ere usually maximal after 3 
or 5 days depending on the cell type used.
7.5.1. Effect of serum from HIV* individuals on cytokine production by HIV-1 infected 
monocyte-derived macrophages.
Hum an monocyte-derived macrophages were infected with HIV-1 Ba.L (H9) for 5 days 
and subsequently with H IV-sera. A fter 8 hours, IL-6 and T N F -a  could not be detected in the  
supernatants from either infected or non-infected cells. By contrast, IL-10 w as clearly 
detectable in all cultures. A fter 12 hours, IL-6 could be detected in all cultures. W hilst the 
level produced by non-infected cells w as the sam e regardless of the presence of H IV  
serum, in HIV-infected cells, the presence of serum appeared to increase IL-6 production 
(although this just failed to reach significance). Also after 12 hrs IL-10 was present in all 
cultures at significantly higher levels than at 8 hours. The presence of HIV-s- sera in the HIV  
infected cultures appeared to cause a significant increase in IL-10 production.
T N F a  production w as detected in control, non-treated cells that disappeared in 
serum -treated cells. No T N F a  production w as detected in H IV  infected cells. These results 
suggest a possible Th1 to Th2 switch since IL-6 was produced later in the response. 
However, the presence of immune complexes in the sera could not be determined due to 
the limited volume available. Also, clinical data could not be divulged.
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7.6. Conclusion
The developm ent of antigen-specific T  cell lines in order to investigate the effect of 
immune complexes on m acrophage function w as not successful. Others have achieved  
such lines but the choice of stimulator cells or donors in the current study may have  
affected the outcome. Clearly future experiments would include the use of alternative 
sources of stimulator cells, selection of donors by skin reactivity to a Mantoux test and a  
w ider range of antigen concentrations.
The role of immune complexes in disease is clearly a complex one which m ay depend  
on their concentration, the type of antibody involved, the antibody: antigen ratio within the 
complex, the involvement of complement, the site of formation, the cells involved and other 
physiological and pathological complications. In H IV  infection, complexes containing HIV  
proteins have been demonstrated in the circulation of patients in later clinical stages of the 
disease. However, little is known about the effect of immune complexes on monocytes (one 
of the main sites of infection in HIV). Alterations in surface antigen expression as a direct or 
indirect result of binding immune complexes m ay affect monocyte circulation and migration 
as well as promoting inflammation and localised tissue dam age. Thus, this study set out to 
exam ine the effect of immune complexes on monocyte surface antigen expression and  
cytokine secretion. Also, to determ ine the effect of those cytokines on monocyte surface  
antigen expression and to investigate how this is altered by H IV  infection and specifically by 
immune complexes comprising H IV  derived proteins.
To this end, monocytes and the cell line MM 6 w ere exam ined for the effect of a 
w ide range of cytokines on surface antigen expression (cellular proliferation being used as 
a m easure of w hether or not the cytokines w ere having the expected physiological effect on 
the cells). This study dem onstrated that PMA, V it D3, IFN-y, M -CSF, G M -C S F, IL-6, IL-10, 
and TN F-a  stimulate the differentiation of M M 6 cells. IL-6, IL-10, and TN F - increased  
CD16a for M DM  with lower levels of expression on MM 6 cells. The costimulatory molecule 
C D 80 w as expressed at lower levels on M DM  than M M 6 cells. IL-6, TNF-a, and G M -C S F  
increased its expression whilst PMA strongly inhibited it. M M 6 cells C D 80  expression w as  
increased by IL-6, IL-10, TNF-a, and G M -C S F. The expression of the adhesion C D 11c  
expression on MDM  was inhibited by all stimulants. The same w as true for C D 11c  
expression on M M 6 cells except for IL-6 and PMA which increased C D 11c. C D 23
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expression on MDM  was increased by IFN-y, G M -C S F, IL-6, and IL-10 while M M 6 cells w ere  
induced to express C D 23  by IFN-y, M -C S F, G M -C S F. However, IL-6, IL-10, and TN F-a  
inhibited C D 23 expression on M M 6 cells C D  14 expression was reduced by all stimulants on 
M DM  while PMA, Vit D3, IL-6, IL-10, and TN F-a  caused an increase in its expression on 
M M 6 cells. The expression of the antigen-presenting molecule HLA -DR w as inhibited by all 
stimulants for both M DM  and M M 6 cells.
W hen cells were incubated with immune complexes containing the naive antigen  
KLH, they w ere found to produce high levels of IL-6 in whole blood and low levels of TN F-a  
(with IL-10 failing to reach significance after 30 minutes) suggesting a Th2 type response. 
W hen  whole blood was incubated with rabbit or goat anti-human IgG or rabbit or goat 
serum, rabbit complexes played an important part in stimulating and inhibiting cytokine 
release. IL-10 was detected at 30  minutes, which may have been inhibited by IL-6, 
production that reached a maximum between 4 and 8 hours. However, TN F-a  reached  
significant levels between 8 and 16 hours. G oat complexes had a fluctuating effect on the 
release of cytokines. If these results are compared, whole blood incubated with KLH or 
rabbit anti-human IgG both produce IL-10 as early as 30  minutes and produce similar levels 
of IL-6. However, KLH containing complexes do not stimulate the release of any TNF-a. By 
contrast, rabbit complexes stimulate the release of significant levels of TN F-a  between 8 
and 16 hours. This suggests that the various complexes may show different affinities for 
FCRs and/or com plem ent leading to distinct cytokine secretion patterns
The incubation of M DM  for 3 days with IL-6, IL-10, T N F -a  increased the expression  
of C D 16  and C D 80  but decreased the expression of the surface antigens CD 11c, C D 23, 
C D 14, and HLA-DR. All surface antigens decreased at 5 and 7 days. W hen such cells w ere  
incubated with immune complexes containing rabbit or goat antibodies no significant effect 
on surface antigen expression was observed, probably due to high standard deviations. 
Thus it w as not possible to determ ine w hether or not the cytokines released due to the 
presence of immune complexes affected the surface antigen expression and hence  
function of the peripheral blood m ononuclear cells. W hen similar experiments w ere carried 
out with immune complexes containing H IV  proteins, cells in whole blood released  
significant levels of IL-6 at 8 hours and 12 hours (for C H O - and MN-containing immune 
complexes respectively). IL-10 and T N F -a  w ere not detected.
W hen M DM  w ere incubated with H IV  protein containing immune complexes (C H O ) a 
slight but significant release of IL-6 w as observed compared to that in the supernatants of
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M DM  alone. This IL-6 release w as not affected by HIV infection of M DM . IL-10 production 
by M DM  was significantly stimulated by the presence of immune complexes but again this 
production w as not affected by H IV infection. By contrast, T N F - a  production by H IV  infected  
M DM  was significantly greater than by non-infected cells (evident after 12 hrs). However, 
the presence of HIV-protein containing immune complexes, reduced T N F - a  production by 
infected cells. This suggests that the presence of circulating immune complexes in H IV  
infected individuals promotes a greater Th2 type response than in non-infected persons due  
to the effect of H IV  infection on T N F - a  production. The affect of H IV -sera on surface 
antigen expression w as not clear due to the high standard deviations. However, H IV-sera  
did stimulate the release of cytokines. IL-6 w as not detected at 8 hours but at 12 hours for 
non-infected and infected cells. IL-10 w as detected at 8 and 12 hours but T N F - a  was not 
detected at all. These results suggest that these sera from H IV  infected individuals may  
contain immune complexes or H IV  protein promoting a Th2-type response.
H IV  infection seem ed to increase the expression of C D 16  and C D 80 reducing the 
expression of other antigens as indicated by HIV-infection of M M 6 cells. Unfortunately, 
significant changes in the expression of surface antigens on HIV-infected M DM  could not be  
detected due to high standard deviations. However, the high release of IL-10 by immune 
complexes indicates a Th2-type response. A  previous study has dem onstrated that IL-10  
and T N F - a  are required for H IV  replication but by blocking IL-10 production using 
monoclonal antibodies and increasing T N F - a  production, H IV  replication may be reduced. 
Thus, the presence of immune complexes, which promote IL-10 and reduces T N F - a ,  may 
stimulate H IV  replication and progression to full blown A IDS. Thus, the manipulation of 
cytokine levels or blocking of Fc and com plem ent receptors may prove beneficial in the 
treatm ent of advanced cases.
7 .6 .1 . Future w o rk
Clearly further work needs to be performed comparing the effects of HIV-protein  
complexes and non-HIV-protein complexes, to determine the effect of HIV immune  
complexes on disease progression. O f particular importance would be to determine the 
effect of immune complex size and concentration and to clearly define the kinetics of the  
reaction. Also, of importance would be to determine the role of com plem ent in these
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phenom ena observed in the current study and to investigate the intracellular signalling 
pathways involved.
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8.0. APPENDIX
APPENDIX A: STAINING CELLS WITH KC57 ANTIBODY
Preparation of 20pg/ml lysoiecithin in 1% paraformaldehyde
Ten grams of paraform aldehyde w ere dissolved in 100ml 1N NaO H  and m ade up to 
800m l with PBS. The solution was titrated to pH 7 .2  +/-0.1 using 4N  HCI then m ade up to 
one litre with PBS. Ten  milligram of lysoiecithin w as dissolved in 500m l 1%  
paraform aldehyde solution, mixed and stored at 2-8°C.
Preparation of 0.1% NP-40
A 0 .5  ml aliquot of Nonidet P -40  w as added to 4 99 .5  ml PBS mixed and stored at 2-
8°C.
Preparation of cells for stain with KC57 antibody
Cells (106) was centrifuged (350g/3m ins) and fixed by adding (1ml) 20-|ig /m l 
lysoiecithin in 1-%  paraform aldehyde, gently vortexing and incubating for two minutes at 
room tem perature. The cells w ere centrifuged (350g/5m ins; 4°C), the supernatant decanted  
and 2ml cold absolute methanol (100% ; -1 0  to -20°C) was added. The  cells were incubated  
on ice for 15 minutes then centrifuged (350g/5m ins, 4°C) and supernatant decanted. Cells 
w ere incubated for 5minutes with 1ml of 0 .1%  N P -40  (2-8°C) and kept on ice. After 
centrifugation (350g/5m ins; 4°C) supernatant w as decanted and 5pl K C 57-F ITC  with 195pl 
PBS w as added to the cells and incubated for 15 minutes at room tem perature. The cells 
w ere centrifuged (350g/5m ins, 4°C) in 1ml PBS, supernatant decanted and 1ml PBS added. 
Cells w ere analysed using the FACScan.
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APPENDIX B: SUPPLIERS OF CHEMICALS AND APPARATUS
Abbott Laboratories Limited, Queenborough, Kent, ME11 5EL, U.K.
Butterfly needle (21-G )
Amersham International pic, Am ersham  Place, Little Chalfont, Buckinghamshire, HP7  
9NA, U.K.
[Methyl-3Hj Thymidine: *PC= TR K  120 B353, specific activity 925  Gbq/mmol, and 
25Ci/mmol.
Anachem Ltd, 20 Charles street, Luton, BED S LU2 OEB, U.K.
Treff, Tips (200pl).
Becton Dickinson UK Limited, Between Towns Road, Coweley, Oxford, Oxon, 0 X 4  3LY, 
U.K.
Anti-human C D 80  PE conjugate: PC= 340294 , containing gelatin and 0 .1%  azide; 
Anti-human HLA-DR phycoerythrin conjugate: PC= 7367, containing gelatine and 0 .1%  
azide; Anti-human Leu-20 (C D 23) F ITC  conjugate: PC= 7797, containing gelatine and 0 .1%  
azide; Anti-human Leu-11c (C D 16) phycoerythrin conjugate: PC= 7617, containing gelatine  
and 0 .1%  azide; Anti-hum an Leu-M 3 (C D 14) FITC conjugate: PC= 7493, containing 
gelatine and 0 .1%  azide; Becton Dickinson FACScan; equipped with an argon ion laser 
(488nm ; 15m W ); G oat anti-mouse IgG FITC conjugated: PC= 349031; Nunc centrifuge 
tubes, 50ml Blue M ax polypropylene tubes, Falcon: PC= 2070; Nunc Eppendorf tubes;
Nunc 24-microwell plates; Syringe 50mi.
Beckman Instruments, (U.K.) Ltd, Oakley Court, Kings Mead, 1 Business Park, High 
W ycom be, Bucks HP11 1JU, U.K.
Centrifugation.
*PC= Product Code
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BHD Chemicals Limited, Broom Road, Poole, Dorest, U.K.
Formaldehyde solution (40%  w/v), (H .C H O ), analytical grade, BDH: P C = 10113, M.wt.
30 .03; Sodium carbonate; Sodium bicarbonate; Sodium hypochlorite solution (14%  
available chlorine): P C = 30169.
Bibby Sterilin Limited, Tilling Drive, Staffordshire, S T15 0SA, U.K.
Pasture pipettes (5ml); Pipettes (10mL); Universal tubes (20m L).
Bio-gen Ltd, 6  The Business Centre, Harvard way, Kimbolton, Huntingdon, CAM BS, P E 18  
0NJ, U.K. Tel no:
Interferon gam m a (rIFN-y; 13.1 x  106U/mL): PC= C 84-016P .
Coulter Immunology, 440 Coulter W ay, Hialeah, FL 33010, USA.
Anti-KC57-FITC: PC= PN 66 04 6 6 5 , for detection of intracellular p24 antigen.
Difco Laboratories Limited, P.O . Box. 14B, Central Avenue, W es t Molesey, Surrey KT8 
2S E , U.K.
Middlebrook 7H9: PC= 0 713-17 -9 ; Middlebrook O A D C  enrichment: PC= 0722-64 -0 .
Dynatech Laboratories Limited, Daux Road, Billingshurst, Sussex, M A 781, U.K.
Immulon 4: PC= 01 1-01 0 -3 8 5 5 , ELISA microtiter immunoassay plate flat bottom.
European Collection of Animal Cell Cultures (ECACC), Division of Biologies, PHLS  
Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, S P 4  0JG, 
U.K.
B95-8 cell line; TH P -1.
Fisons pic, FDA Laboratory Supplies, Bishop M eadow Road, Loughborough,
Leicestershire, LE11 0RI, U.K.
Absolute methanol: PC= M /4000/17; Acetone, (C H 3C O C H 3), Analytical grade: PC= 
A /0600/17; M.wt. 58.08; Glycerol (C H 2O H .C H O H .C H 2OH): PC= G /0650 /17; M.wt. 92 .10 .
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Hayman Limited 70 Eastways Industrial Park, W itham , Essex, C M 8 3YE, and U.K. 
Absolute alcohol 100, (C 2H5O H ) (ethyl alcohol).
ICN (Flow) Biomedicals Limited, Eagle House, Peregrine Business Park, Gom m  Road, 
High W ycom be, Bucks, H P 13  7DL, U.K,
Hepes buffer: PC= 16-884-46; 1 Molar solution; M. wt. 238.5m g/m L; RPMI 1640 medium, 
phenol red-free: PC= 7 3 -128 -54 , with sodium bicarbonate and without L-glutamine, sterile 
filtered, endotoxin tested.
ILACON Ltd, Gilbert House, River W alk, Tonbridge, K e n tT N 9  1DT, U.K,
ILACON cell harvester.
Immunotech, The Binding Site Limited, Birmingham Research Park, 97  Vincent Drive 
Edgbaston, B15 2S Q , Birmingham, U.K.
Anti-hum an C D 28  FITC conjugated: PC= 1236.
Leo Laboratories Limited, Prince Risborough, Bucks, U.K.
Heparin (Mucous): P C = 0043 /0086 ; 5 ,00 0  units/mL, endotoxin free.
L .I.P . (Equipm ent and Services) Ltd, 111 Dockfield Road, Shipley, W est Yorkshire, BD17
7AS, U.K.
Micropipette Tips (1mL).
Life Sciences International (UK) Ltd, Unit 5, The Ringway Centre, Edison Road, 
Basingstoke, Hants, RG21 2YH , UK.
Labsystems, Spectrophotometer; Luckham, Plate shaker, Model R100; Pyrongen/ 
endotoxin frees 2-200|il: PC= TP 62; Pyrongen/ endotoxin frees 2 0 0 -1 000pJ: PC= TP 65.
Kartell Spa (Agent Kartell Plastics (U.K.) Ltd), Via Della 20082 , Novigiio, 1 -20082  Milan, 
Italy.
UV G rade Cuvettes: PC= D 01939.
163
M arathon  L abora to ry  S upplies, Unit 6, 55 -57  Park Royal Road, London, N W 10  7JJ, 
FACScan tubes: P C =  2054; 96-microwell plates: PC = F3077;
Cell Scrapers: P C = F3086; Tissue culture flasks (25 cm2): PC = F3108; Tissue culture flasks 
(75 cm2): PC = F3111.
M C R  A ID S  D irected  P rogram m e, National Institute for Biological Standards & Control, 
Blanche Lane, South Mimms, Potters Bar, Herts EN6 3Q G , U.K.
Rabbit anti-serum to rHIV-1 MN gp120; Sheep anti-serum to rHIV-1 IIIB gp120 (C HO ). 
A G M E D  INC, rHIV-1 IIIB gp120 (CHO); rHIV-1 MN gp120 (Baculovirus).
M iltenyi B io tec Inc, 1250 O akm ead Park, Suite 210, Sunnyvale. CA 94088 -3599 , USA, 
Magnetic cell sorter (M ACS); Monoclonal anti human C D 3 (Leu™ -4): PC = 456-01 .
N algene  C om pany, A/Subsidiary of sybron corporation, Rochester, New  York, 1460 2 -0 3 65  
USA.
Cryovia! (1.8m L).
Harris  S c ientific , 618  W estern Avenue, Park Royal, London, W 3  0TE , U.K.
New  Improved N eubauer haem ocytom eter slide: PC = H 12-144.
N ycom ed (U K) Lim ited, 2111 Coventry Road, Sheldon, B IRM ING HAM , B26 1BR, UK. 
Lymphoprep (Bouyant density 1 .077 + /- 0.001 g/mL (20°C): Osmolarity 280  + /- 15 mOsm).
O rganon  T ekn ika  C o rp ora tion , C appel Research Products, 100 Akzo Avenue, DURHAM , 
NC 27704 , USA.
Rabbit anti-serum to Keyhole Limpet Hemocyanin: P C = 55966.
Phillips
T 400  transmission electron microscope.
R & D  S ystem s E urope  Lim ited, 4 -1 0  The Quadrant, Barton Lane, Abingdon, O X 14  3YS, 
U.K.
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interleukin 2 (rlL-2): PC= 202-IL -010: specific activity > 2 .0 -4 .0  x  106 units/mg.
Roche Products Limited, Diagnostic Departm ent, P.O. Box. 8, W elw yn Garden City, 
Hertfordshire, AL7 3AY, U.K.
1,a, 25-dihydroxycholecalciferol (V itD3), a gift: M. wt. 416.65 .
Unipath Limited (Oxoid), Basingstoke, Hants, U.K.
Phosphate buffered saline (Dulbecco ‘A ’) tablets: PC= Br14a, pH7.3.
Sartorius, Longmead Business Centre, Blenheim Road, Epsom, Epsom, Surrey KT19  
9Q N.
Filtered 0.20-pm , 16534K.
Serotec Limited, 22  Bankside, Station approach, Kidlington, Oxford 0 X 5  1JE, U.K.
G oat anti-human IL-6: PC= AB 206NA; Interleukin 6  (rlL-6, 100ng/pL): PC= P H P045; 
Interleukin 6 (rlL-6): PC= M AB206; Interleukin 10 (rlL-10, 0,1m g/m L): PC= PHP047;
Mouse anti-human interleukin 10 (IL-10): PC= M CA926; Mouse anti-human tumour necrosis 
factor alpha (TNF-a): PC= AB 210NA; Mouse anti-human TNF-a: M C A 747M .
Shimadzu Corpoation, Howe, V.A, & Co Ltd, U.K.
Spectrophotometer, U V -1201.
Sigma Chemical Company Limited, Fancy Road, Poole, Dorest, BH 17 7BR, U.K.
Adjuvant peptide, (PPD ) N-Acetylmuramyl-L-D-isoglutamine: PC= A -9519, M. wt. 492.5 ; 
Anti-hum an C D 3 PE conjugated: PC= P5810; Anti-human C D 8 PE  conjugated: PC= P5560; 
Anti-hum an C D 11c  FITC  conjugated: PC= F5773; Anti-human C D 45 /C D 14  DUAL-TAG  
F ITC /P E  conjugated: PC= F-8527; Anti-hum an IgG (Fc specific) developed in goat: PC= I- 
8885; Anti-hum an IgG (Fc specific) developed in rabbit: PC= 1-9135; Anti-goat IgG alkaline 
phosphatase conjugate: PC= A -2168; Anti-mouse IgG alkaline phosphatase conjugate:
PC= A -4312, gelatine and 0 .1%  azide; Anti-Rabbit IgG: PC= R2004; developed in goat; 
Centrifugation 2-15; Centrifugation 3K-10; Dimethyl sulphoxide (DM SO ): PC= D-5879; M. 
wt. 78.13; Ethylenediamine tetraacetic acid (EDTA) (dipotassium salt): PC= ED2P,
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M .w t.368.4; Etoxate Kit: P O  210-A 1; L-glutamine, 200m M  solution: P C =  G 7513; sterile 
filtered and endotoxin tested; G lutaraldehyde, (Pentane-1, -dial) G ra d e l: 25%  aqueous  
solution: P O  G 582; G oat anti-hum an IL-10: P O  I-5020; G oat Serum: P O  G -9023; 
Granulocyte macrophage colony stimulation factor (rGM -CSF): P O  G -0532; Guinea pig 
com plem ent serum: P O  S -1639; Hem ocyanin from Keyhole Limpet: P O  H-7017; Heparin, 
sodium salt, and G rade 1-a from porcine intestinal mucosa: P O  H -3149; Hum an serum  
from male AB plasma: P O  H -4522; Kanamycin Solution: P O  K0129; L-a- Lysophosphatidyl 
choline: P O  L-4129; M acrophage colony stimulation factor (rM -CSF): P O  M -9667; 
Mitomycin C: P O  M -0503; Monoclonal anti-human C D 14  PE conjugate: P O  P-5435; 
Monoclonal anti-goat IgG -F ITC  conjugate: P O  F-4891; Monoclonal anti-rabbit-IgG (y-chain 
specific) F ITC conjugate: P O  F-4151; M ouselgG 1/M ouselgG 2a DU AL-TAG  F ITC /P E  
conjugated: P O  F0528; M ouselgG I/M ouselgM  DUAL-TAG F ITC /P E  conjugated: P C =  
F0653; Nonidet P -40 (N P-40): P O  N -3516; M TT (C i8H 16N5SBr) (3-[4,5-dimethylthiazol-2-yl3- 
2,5-diphenyltetrazolium  bromide: P O  M -2128; M. wt. 414.3; Osmium tetroxide (O s 0 4, 
O sm icacid): P O  05500; M. wt. 254.2 ; Paraformaldehyde: P O  P6148; Penicillin- 
streptomycin solution: P C =  P0781; Phorbol 12-myristate 13-acetate (PMA): P C =  P-8139; M. 
wt. 616.8 ; pN PP Substrate tablet set: PC= N -1891; Pyruvic acid (C 3 H 4 0 3 ), 
(a-ketopropionic acid): P O  P-1656; M. wt. 88.06; Rabbit Serum: P O  R-9133; RPMI 1640  
medium: P O  R0883; with sodium bicarbonate and without L-glutamine, sterile filtered, 
endotoxin tested; Trypan Blue (C 34H24N6O i4S 4N a4): P C =  T8154; 0 .4%  solution prepared in 
0 .81%  sodium chloride + 0 .06%  potassium phoshate dibasic, M. wt. 960.8 .
Taab Laboratories Equipment Ltd, 3 Minerva House, Caileva Park, Aldermaston, Berks, 
R G 7 8NA, UK.
Dodecenyl succinic anhydride (DDSA): P O  D027; M.wt. 266.38; Epon /Taab  812  resin:
P O  T026; M.wt. 306; 2,4,6-tri (dimethylaminomethyl) phenol, (D M P-30): P O  D032, M. wt. 
265.40 .
TCS Biologicals Limited, BOTOLPH CLA YD O N , Buckingham, M K 18 2LR, U.K.
Foetal calf serum: P O  C F006.
Wallac Scintillation products, Milton Keynes, W allac  UK.
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Optiphase ‘safe ’: S C /1025 /21 , scintillation fluid; W allac 1410 Liquid Scintillation counters; 
Scintillation vials: P C = 10200.
W h atm an  In ternational Ltd, M aidstone.
Fibreglass filter mats: P C = 1827842; G rade 934-A H .
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